Bodies change. Find the peptides relevant to where yours is now.

The transition years before menopause — hormones fluctuating, cycle irregular, sleep and mood shifting. Typically late 30s to mid-50s.

Postmenopausal years — sustained low estrogen, accelerated bone and muscle loss, altered metabolism. Typically 50+.

Age-related testosterone decline and HPG-axis softening in men, typically 40+. Symptoms span libido, mood, body composition, recovery.

Whole-system aging — declining mitochondrial function, telomere shortening, sarcopenia, slowed recovery, gradual cognitive shifts.

Tissue healing after acute injury — joints, tendons, ligaments, muscle tears, post-surgical recovery, chronic non-healing wounds.

Persistent low energy, motivation collapse, post-stress exhaustion — not explained by anemia or thyroid dysfunction.

Optimizing reproductive health ahead of conception attempts — applies to both partners.

Recovery from pregnancy and childbirth — mood, energy, body composition, sleep deprivation, lactation considerations.

Subjective cognitive shifts — slower processing, word retrieval issues, memory lapses — typically age-related but sometimes post-illness or post-stress.

Reduced libido or arousal, independent of testosterone levels — applies to both sexes.

Difficulty falling or staying asleep most nights for ≥3 months — distinct from occasional sleep disruption. Affects 10–15% of adults.

Clinical depression, anxiety disorders, or PTSD — distinct from situational low mood or stress. Affects ~20% of adults at some point.

Persistent symptoms ≥12 weeks after acute COVID-19 — fatigue, brain fog, GI disruption, exercise intolerance, autonomic dysregulation. Affects ~10% of infected adults.

Hormonal and metabolic disorder affecting ~10% of women of reproductive age — irregular cycles, hyperandrogenism, insulin resistance, infertility, endometrial cancer risk.

Endometrial-like tissue growing outside the uterus — pelvic pain, dysmenorrhea, infertility, fatigue. Affects ~10% of women of reproductive age; average diagnostic delay 7–10 years.

Already on hormone replacement (testosterone or estrogen) and considering layering peptides on top. Coordination with your prescriber is the precondition.

Adjunct considerations during gender-affirming care — surgical recovery, skin/hair effects of HRT, sexual function. Peptides are adjuncts, never alternatives to gender-affirming medical care.

Tested athletes (WADA, USADA, NCAA, IPC, national federations) considering peptides ahead of competitive cycles. The decisive variable is regulatory, not clinical.

eGFR-staged considerations across the peptide library — renal clearance, dose adjustment, dialysis-specific monitoring. Affects ~14% of US adults.

MASLD/MASH (formerly NAFLD/NASH), viral hepatitis B and C, alcoholic liver disease, cirrhosis — the GLP-1 trials reshaping MASH medicine and thymosin alpha-1's approved use abroad for hepatitis B/C.

Cognitive optimization in healthy adults — the 'nootropic stack' framing for biohackers, founders, knowledge workers, and students. Distinct from age-related cognitive decline.

The clinically frail subset of older adults — sarcopenia, falls, slow recovery from acute illness or surgery, reduced reserve — where the body's structural decline outpaces chronological aging.

Peptide considerations around elective major orthopedic surgery — pre-op optimization, anticoagulant protocols, infection surveillance, post-op rehabilitation. ~1M US arthroplasties annually.

Episodic multi-system mast-cell-mediator-release symptoms — flushing, urticaria, GI, cardiovascular, neuropsychiatric — under the umbrella of MCAS, systemic mastocytosis, and hereditary alpha-tryptasemia.

The most common cause of hypothyroidism in iodine-sufficient populations — autoimmune destruction of thyroid follicular cells driven by TPO and thyroglobulin antibodies. Affects ~5% of adults, women 7-10× more than men.

Post-Treatment Lyme Disease Syndrome and the contested 'chronic Lyme' framing — persistent fatigue, cognitive, musculoskeletal, neuropsychiatric, and GI symptoms after acute Lyme treatment. The most clinically contested axis in this library.

Confirmed remission from prior cancer — considering peptides for recovery, body composition, or general aging. Active oncology is a separate, hard-refusal situation.

Active IVF or other ART cycle — REI-managed stimulation, monitoring, retrieval, and transfer. Distinct from preconception fertility-planning. Tight protocol timing leaves minimal room for adjuncts.

Postural orthostatic tachycardia syndrome and the broader dysautonomia umbrella — affects ~1-3M US adults, predominantly young women (5:1), average 4-5 year diagnostic delay. Strong overlap with MCAS, EDS/hypermobility, ME/CFS, and post-COVID dysautonomia.

Ehlers-Danlos syndromes and hypermobility spectrum disorders — heritable connective-tissue disorders with joint instability, chronic pain, skin/tissue fragility, and frequent autonomic + mast-cell overlap.

Myalgic encephalomyelitis / chronic fatigue syndrome — a complex multi-system illness defined by post-exertional malaise (PEM), unrefreshing sleep, cognitive impairment, and orthostatic intolerance.

Migraine — a primary headache disorder with neurovascular and trigeminal-autonomic pathophysiology. Standard-of-care has been completely reshaped by CGRP-targeting biologics, gepants, and lasmiditan.

Post-stroke rehabilitation and secondary prevention — the population where neurotrophic peptides have their strongest source-jurisdiction registered evidence, with cross-jurisdictional replication as the load-bearing methodological gap.

Adjunct considerations for users navigating mild TBI, persistent post-concussion symptoms, or moderate-severe TBI recovery alongside a neurology and rehabilitation team.

Adjunct considerations for users navigating post-traumatic stress disorder alongside a trauma-focused therapist and psychiatrist — where evidence-based psychotherapy and first-line medication are the dominant interventions and peptide adjuncts are at best supporting characters in a clinician-led plan.

Honest framing for users navigating AGA, telogen effluvium, and the gap between peptide community claims and the well-established dermatology standard-of-care.

Where peptides — especially semaglutide — now sit inside the standard-of-care stack for preventing major adverse cardiovascular events.

Where peptides fit (and don't fit) in the prevention and treatment of osteopenia, osteoporosis, and fragility fracture risk.

Primary DSM-5 anxiety diagnoses — generalized anxiety disorder, panic disorder, social anxiety disorder, specific phobias, agoraphobia — distinct from PTSD trauma biology and from depression-spectrum mood disorders, with peptide adjuncts that sit underneath a CBT-plus-SSRI standard of care.

Rome IV symptom-based functional gastrointestinal disorders — IBS (D/C/M subtypes), functional dyspepsia, functional bloating, functional constipation/diarrhea, SIBO/IMO, post-infectious IBS — without the inflammatory pathology that defines IBD.

The clinical disease entity of progressive loss of muscle mass, strength, and physical function (EWGSOP2 / AWGS consensus criteria) — distinct from the broader frail-elderly phenotype and from training-context muscle concerns.

Nerve damage in the peripheral nervous system — diabetic, chemotherapy-induced, idiopathic small-fiber, alcoholic, or post-infectious — covering what standard-of-care looks like and where peptide-adjacent molecules genuinely have a clinical case versus where the case is community framing without evidence.

Non-healing wounds — diabetic foot ulcers, venous stasis ulcers, pressure ulcers, arterial and mixed-etiology ulcers, chronic surgical dehiscence — covering what wound-care standard-of-care looks like and where peptides with actual wound-healing primary research domain (BPC-157, TB-500, GHK-Cu, LL-37) fit relative to interventions with effect sizes that drive outcomes.

Obstructive sleep apnea — the disease of upper-airway collapse during sleep diagnosed by polysomnography — where standard-of-care has been reshaped in June 2025 by the first-ever FDA approval of a pharmacological treatment.

Standard-of-care first for clinical dementia and MCI — biomarker diagnosis, the MAb era (lecanemab, donanemab), the ChEI + memantine ladder, reversible-cause workup, and the narrow peptide adjunct case.

Male erectile dysfunction — failure to achieve or maintain an erection sufficient for satisfactory sexual performance — is a distinct clinical entity from female HSDD (covered separately under sexual-dysfunction) and from broader andropause, with PDE5 inhibitors as standard-of-care first-line.

Standard-of-care first for clinical T2D — ADA 2026 diagnosis at HbA1c ≥6.5%, the pharmacotherapy ladder reshaped by GLP-1 RA and dual-incretin promotion to first-line in ASCVD, CKD, HF, and obesity phenotypes, and the complications-screening calendar that does most of the long-term work.

Gastroesophageal reflux disease, peptic ulcer disease, erosive esophagitis, eosinophilic esophagitis, and the long-term considerations of chronic acid suppression — covering what ACG 2022 standard-of-care looks like and where peptides with actual upper-GI primary research domain (BPC-157) fit relative to interventions with effect sizes that drive outcomes.

Atherogenic lipid profiles — elevated LDL-C, ApoB, lipoprotein(a), elevated triglycerides, low HDL — where statins, ezetimibe, PCSK9 inhibitors, bempedoic acid, and the icosapent-ethyl-class TG interventions drive outcomes, and where the peptide library's narrow role is the GLP-1 / GIP+GLP-1 indirect signal from SUSTAIN / SELECT / SURPASS / SURMOUNT rather than any peptide that modifies lipids directly.

Central-sensitization disorder defined by ACR 2010 / 2016 criteria — widespread pain >3 months plus symptom-severity overlay (sleep disruption, fatigue, cognitive symptoms) — where the FDA-approved trio (duloxetine, milnacipran, pregabalin) plus CBT and graded aerobic exercise carry the dominant evidence, and the peptide library's narrow role addresses the anxiety overlay and the B12-deficiency rule-out.

GOLD-2024-defined progressive airflow obstruction from chronic exposure (smoking, biomass fuel, occupational dust) — where standard-of-care is well-established, the dupilumab and ensifentrine 2024 approvals have reshaped the refractory-disease conversation, and the honest answer about peptides is that they don't fit well here.

DEWS II-classified ocular surface disease — aqueous-deficient, evaporative, or MGD-dominant subtypes — plus neurotrophic keratitis as the closest peptide-to-FDA-approval indication in the library (Tβ4 / RGN-259 Phase 3).

Primary open-angle, normal-tension, and angle-closure glaucoma — IOP-lowering through the prostaglandin / SLT (LiGHT 2019) / iDose TR (FDA December 2023) ladder is the only intervention with hard visual-field preservation evidence, and the editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Chronic subjective tinnitus — the perception of sound (ringing, buzzing, hissing) without external source — where CBT-T (AAO-HNS 2014 Tier 1) plus bimodal stimulation (Lenire, FDA De Novo March 2023) carry the actual standard-of-care, no FDA-approved tinnitus drug exists, and the library's narrow role is B12 rule-out and the Cerebrolysin SSNHL acute-window adjacency.

Autoimmune depigmentation driven by CD8+ T-cell-mediated melanocyte destruction via the IFN-γ / CXCL9 / CXCL10 / JAK-STAT axis — where ruxolitinib cream (Opzelura, FDA July 2022) reshapes the topical repigmentation conversation, narrow-band UVB carries the moderate-to-extensive disease backbone, and the library's narrow surfaced case is afamelanotide (Scenesse) + nbUVB combination from the Lim 2015 JAMA Dermatology trial.

Dry AMD (including geographic atrophy as the advanced form) and wet (neovascular) AMD — where AREDS2 supplementation (2013) is the Tier 1 risk-modification intervention for intermediate disease, intravitreal anti-VEGF therapy is the Tier 1 wet-AMD intervention with hard visual-acuity preservation evidence, the 2023 FDA approvals of pegcetacoplan (Syfovre, complement C3) and avacincaptad pegol (Izervay, complement C5) reshaped the geographic-atrophy conversation, and the editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

CASPAR-criteria-defined autoimmune inflammatory arthritis with peripheral synovitis, enthesitis, dactylitis, axial inflammation, and concurrent skin and nail psoriasis — where biologics-dominated standard-of-care (TNF inhibitors Tier 1, IL-17A inhibitors including bimekizumab / Bimzelx FDA September 2024, IL-23 inhibitors, JAK inhibitors with black-box warnings, apremilast, abatacept) and GRAPPA 2021 / EULAR 2023 treat-to-target guidelines drive outcomes, and the editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Idiopathic Parkinson's disease — levodopa-ladder refinements (Crexont ER August 2024, foslevodopa/foscarbidopa Vyalev October 2024) anchor standard-of-care; the GLP-1 class signal from LIXIPARK lixisenatide (Meissner 2024 NEJM) and Foltynie 2017 exenatide does NOT propagate to semaglutide without molecule-specific evidence; the atypical-parkinsonism rule-out matters editorially; the MDS-endorsed exercise prescription is Tier 1 non-pharmacologic.

Rapidly-progressing terminal motor-neuron disease — sporadic and familial (SOD1, C9orf72, TARDBP, FUS), bulbar-onset vs limb-onset, 2-5 year median survival from symptom onset — where Awaji-Shima diagnostic criteria, riluzole + edaravone standard-of-care, tofersen (Qalsody, FDA April 2023) for the SOD1-ALS ~2% subset, multidisciplinary clinic care, time-sensitive NIV and PEG and AAC communication device planning, advance care planning, and HEALEY ALS Platform Trial enrollment drive outcomes — and the editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Inherited monogenic retinal dystrophies driven by photoreceptor (rod-then-cone) degeneration — Luxturna (voretigene neparvovec, FDA December 2017) for biallelic RPE65, sepofarsen Phase 3 for CEP290 LCA10, the AAV gene-therapy pipeline (cross-jurisdictional) targeting RPGR / USH2A / RHO and others, Foundation Fighting Blindness trial registries, and low-vision rehabilitation drive standard-of-care. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case — RP is gene-therapy-paradigm and inherited-disease territory.

Autosomal-dominant CAG trinucleotide repeat expansion in the HTT gene (chromosome 4p16.3, mean adult onset ~40) — chorea, cognitive decline, and psychiatric features in a defined progressive trajectory — where genetic counseling is the load-bearing precondition, VMAT2 inhibitors (tetrabenazine 2008, deutetrabenazine 2017, valbenazine / Ingrezza FDA August 2023 for HD-associated chorea) anchor symptomatic chorea management, SSRI / SNRI and antipsychotic layers manage psychiatric features, the HTT-lowering trial program (tominersen GENERATION HD1 paused 2021 then restarted in lower-dose / younger-patient cohorts, branaplam discontinued 2022, pridopidine PROOF-HD missed primary endpoint 2023, AMT-130 AAV5-miRNA Phase 1/2 ongoing) drives the disease-modifying conversation, and the editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Autosomal recessive hemoglobinopathy — HbSS, HbSC, HbS-β⁰-thalassemia, HbS-β⁺-thalassemia — driving vaso-occlusive crises, chronic hemolytic anemia, splenic dysfunction, stroke risk, acute chest syndrome, organ damage cascade, and shortened life expectancy. Hydroxyurea since 1998, L-glutamine (Endari, FDA 2017), Casgevy and Lyfgenia gene therapies (both FDA December 2023), allogeneic HSCT in matched-sibling-donor candidates, chronic transfusion programs for stroke prevention, opioid-stewardship pain management, penicillin prophylaxis through age 5, pneumococcal / meningococcal / Hib vaccination, and annual TCD screening drive standard-of-care. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Chronic neurological sleep disorder defined by ICSD-3 polysomnography + Multiple Sleep Latency Test (MSLT) — Type 1 with cataplexy + HLA-DQB1*06:02 + CSF hypocretin-1 ≤110 pg/mL reflecting destruction of orexin-producing neurons in the lateral hypothalamus, and Type 2 without cataplexy or the hypocretin finding. Modafinil / armodafinil first-line + solriamfetol (Sunosi 2019 DNRI) + pitolisant (Wakix 2019 H3 inverse agonist) wake-promoting ladder, low-sodium oxybate (Xywav 2020) for cataplexy + nocturnal sleep consolidation, SSRI / SNRI / TCA for cataplexy, and the TAK-861 (Takeda) orexin-2 receptor agonist Phase 3 program plus the broader orexin-agonist pipeline (ALKS 2680, Centessa ORX750) drive standard-of-care. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

HLA-B27-associated axial spondyloarthritis — inflammatory back pain, sacroiliitis, syndesmophyte formation, eventual ankylosis. The modern axSpA umbrella covers radiographic AS (classic) and non-radiographic axSpA (nr-axSpA); peripheral SpA spectrum overlap exists. Standard-of-care is one of the most aggressive in rheumatology: continuous NSAIDs first-line, then TNF inhibitors, then IL-17A inhibitors (secukinumab, ixekizumab, bimekizumab / Bimzelx FDA-approved August 2024 for AS and nr-axSpA), then JAK inhibitors (tofacitinib FDA 2021, upadacitinib FDA 2022) with ORAL Surveillance black-box warnings. Comorbidity drives biologic selection — uveitis (anti-TNF preferred), IBD (IL-17 carries IBD-exacerbation signal), psoriasis. ACR/SAA/SPARTAN 2019 + ASAS-EULAR 2023 guidelines drive sequencing. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Monosodium urate (MSU) crystal arthropathy driven by hyperuricemia (serum urate above ~6.8 mg/dL physiological saturation threshold). Acute flares are NLRP3-inflammasome-driven inflammatory arthritis (classically first metatarsophalangeal joint — podagra — but any joint); chronic tophaceous disease is structural MSU deposition over years of inadequately controlled hyperuricemia. Standard-of-care is well-mapped: acute flare runs NSAIDs / colchicine / corticosteroids first-line, IL-1 inhibitors (anakinra, canakinumab) refractory. ULT treat-to-target serum urate <6.0 mg/dL (<5.0 in tophaceous) per ACR 2020 + EULAR 2016: allopurinol first-line with HLA-B*5801 screening in Han Chinese, Korean, Thai, and African ancestry given SCAR risk; febuxostat alternative restricted to allopurinol-intolerant given the CARES 2018 CV-mortality signal; probenecid uricosuric where renal function preserved; pegloticase (Krystexxa, FDA 2010) for refractory tophaceous disease with methotrexate co-treatment per the MIRROR trial. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Rome IV functional bowel disorder of brain-gut interaction — IBS-D (diarrhea predominant), IBS-C (constipation), IBS-M (mixed), IBS-U (unsubtyped) — distinct from IBD, microscopic colitis, and celiac disease. Diagnosis of exclusion: rule out organic disease (celiac serology, fecal calprotectin to distinguish from IBD, TSH, CBC, CRP, age-appropriate colonoscopy). ACG 2021 + AGA 2022 evidence-graded ladder: low-FODMAP elimination (Monash University protocol), subtype-targeted pharmacotherapy (rifaximin / Xifaxan FDA 2015 IBS-D, eluxadoline / Viberzi 2015 with pancreatitis warning in cholecystectomy patients, alosetron / Lotronex REMS-restricted; linaclotide / Linzess, plecanatide / Trulance, lubiprostone, tegaserod re-approved 2019 for women <65 for IBS-C), neuromodulator-dose TCAs/SSRIs, CBT-GI, gut-directed hypnotherapy, peppermint oil (BSG-recommended). The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case — BPC-157 'leaky gut' community framing applies a mucosal-injury-repair mechanism to a functional brain-gut-axis disorder where the lesion isn't mucosal injury.

Bradykinin-mediated angioedema from C1-INH deficiency (type I quantitative, type II functional) or HAE with normal C1-INH (factor XII, plasminogen, kininogen, ANGPT1, myoferlin, heparan sulfate variants). Distinct from mast-cell / histamine-mediated angioedema — antihistamines, corticosteroids, and epinephrine do not work. Diagnosis requires C1q + C4 + C1-INH antigenic + C1-INH functional testing, with genetic testing for HAE-nC1INH variants when C1-INH is normal. On-demand attack treatment: icatibant (Firazyr B2 receptor antagonist), ecallantide (Kalbitor kallikrein inhibitor), plasma-derived C1-INH (Berinert IV, Cinryze IV), recombinant C1-INH (Ruconest). Long-term prophylaxis: lanadelumab (Takhzyro, FDA 2018), berotralstat (Orladeyo, FDA 2020), donidalorsen (Wainzua, FDA 2024), SC C1-INH (Haegarda); NTLA-2002 (Intellia) single-dose CRISPR/Cas9 KLKB1 knockout with Phase 2 >90% attack reduction. ACE inhibitors absolute contraindication. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case — bradykinin biology is engaged by very specific contact-system therapeutics.

Autosomal codominant SERPINA1 mutations (PiZZ severe, PiSZ intermediate, PiMZ carriers) producing misfolded Z polymer that fails to leave hepatocytes (causing liver disease from polymer accumulation) AND fails to reach the lung in sufficient quantity to inhibit neutrophil elastase (causing panacinar emphysema, classically lower-lobe). Extrapulmonary manifestations: panniculitis, ANCA-associated vasculitis. Standard-of-care: smoking cessation as only intervention modifying pulmonary disease course (COPD-parallel framing); augmentation therapy (Prolastin-C, Zemaira, Aralast NP, Glassia; RAPID + RAPID-OLE supporting CT-density preservation); fazirsiran (Takeda/Arrowhead Phase 3 SEQUOIA) for hepatic disease via hepatocyte-targeted siRNA; Beam Therapeutics' BEAM-302 base-editing Phase 1/2 correcting E342K mutation. Liver and lung transplant for end-stage disease. AlphaNet patient-services organization. ATS/ERS 2003 + 2024 update guidelines: genetic testing every COPD patient + every first-degree relative of an index case. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

JAK2-mutation-driven clonal myeloproliferative neoplasm — JAK2 V617F in ~95% of cases, exon 12 mutations in most of the remainder. Hematology-managed disease; risk-stratified per ELN 2018 / NCCN MPN guidelines (high-risk = age >60 or prior thrombosis history). Standard-of-care: phlebotomy to hematocrit <45% (since 1960s), low-dose aspirin, hydroxyurea (Droxia, Siklos) for high-risk; ruxolitinib (Jakafi JAK1/2 inhibitor) for HU-resistant/intolerant per RESPONSE trials. Paradigm shifts: ropeginterferon alfa-2b (Besremi, FDA November 2021) — first PV-specific disease-modifying agent with documented JAK2 V617F allele burden reduction (molecular response per PROUD-PV / CONTINUATION-PV); rusfertide (PTG-300 hepcidin mimetic) per Phase 3 VERIFY 2024 readouts (iron-restrictive paradigm without phlebotomy iron deficiency). WHO 2022 + ICC 2022 diagnostic criteria. MPN-SAF symptom tracking (pruritus especially aquagenic, fatigue, splenomegaly). The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case — and several have theoretical reasons to AVOID (angiogenic mechanism vs thrombosis-driven morbidity; immune stimulation in clonal myeloid disease).

Autoimmune cholestatic liver disease — chronic non-suppurative destructive cholangitis of intralobular bile ducts. AMA (anti-mitochondrial antibody) positive ~95%, anti-sp100 / anti-gp210 in AMA-negative ~5%. Female predominance ~10:1. UDCA first-line since the 1990s with treat-to-target ALP <1.67x ULN per POISE / Paris II at 12 months. 2024 PPAR-agonist paradigm: elafibranor (Iqirvo PPAR α/δ FDA June 2024) and seladelpar (Livdelzi PPAR δ FDA August 2024). Obeticholic acid (Ocaliva FXR agonist FDA 2016) restricted to non-cirrhotic patients after September 2024 FDA boxed-warning action. Bezafibrate off-label per BEZURSO + EASL 2017 endorsement. Pruritus ladder (cholestyramine → rifampin → naltrexone → sertraline; plasmapheresis refractory). DEXA + bisphosphonates for cholestasis-osteoporosis. Fat-soluble vitamin replacement. HCC surveillance every 6 months once cirrhotic. Liver transplant for end-stage. EASL 2017 + AASLD 2018 guidelines. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Systemic autoimmune exocrinopathy with lymphocytic infiltration of salivary and lacrimal glands — dryness is the most visible symptom, but the disease is B-cell-driven and systemic. Primary SjD (pSjD) and secondary (with RA, SLE, scleroderma overlap). Female predominance ~9:1. ACR/EULAR 2016 classification criteria; anti-Ro/SSA + anti-La/SSB diagnostic anchor. ~5% lifetime MALT lymphoma risk requires surveillance. Standard-of-care is rheumatology-led: cyclosporine (Restasis/Cequa), lifitegrast (Xiidra), perfluorohexyloctane (Miebo, FDA August 2023) for ocular surface; pilocarpine and cevimeline for sicca; hydroxychloroquine for fatigue/arthralgia per EULAR 2019; methotrexate/leflunomide for articular involvement; rituximab off-label for severe extraglandular. Paradigm shift: ianalumab anti-BAFF Phase 3 NEPTUNUS positive readouts 2024 — first plausible disease-modifying therapy. Counter-paradigm: iscalimab anti-CD40 Phase 3 failed 2024. Dazodalibep anti-CD40L Phase 3 continues. CD19 CAR-T in compassionate use for refractory severe disease. EULAR 2019 + ACR 2020 guidelines + Sjögren's Foundation. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Idiopathic inflammatory myopathy with cutaneous manifestations — Gottron's papules over MCP/PIP joints, heliotrope rash over the eyelids, shawl sign, V-sign, mechanic's hands, and proximal symmetric muscle weakness. Myositis-specific antibodies define phenotype: anti-Mi-2 (classic skin + muscle, steroid-responsive), anti-MDA5 (clinically amyopathic DM + rapidly progressive ILD — life-threatening), anti-TIF1γ (cancer-associated DM in adults — 50%+ adenocarcinoma association within 3 years), anti-NXP2 (calcinosis + dysphagia, JDM + adult), anti-SAE (cutaneous-dominant). Juvenile DM (JDM) is a distinct entity with characteristic vasculopathy and calcinosis burden. ACR/EULAR 2017 criteria. Standard-of-care: high-dose corticosteroids first-line (prednisone 1 mg/kg or pulse methylprednisolone); steroid-sparing agents (methotrexate, azathioprine, mycophenolate mofetil); IVIG (Octagam 10%, FDA-approved 2021 via ProDERM — first DM-specific FDA approval); rituximab (RIM trial) off-label refractory; JAK inhibitors (tofacitinib for MDA5-ILD); cyclophosphamide + plasmapheresis for anti-MDA5 RPI-LD; hydroxychloroquine for cutaneous disease. Cancer screening per anti-TIF1γ / anti-NXP2 status. ILD surveillance with HRCT + PFTs. ACR 2024 + AAD 2024 guidelines + Myositis Association (TMA). The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Transmural inflammatory bowel disease — distinct from ulcerative colitis in pattern (skip lesions, ileal predominance per Montreal L1 ~40% / L3 ~30% / L2 ~20% / L4 upper GI), depth (full-thickness through bowel wall), and complications (Montreal B1 inflammatory / B2 stricturing / B3 penetrating-fistulizing + perianal modifier). Genetic risk: NOD2/CARD15 (defective bacterial sensing), ATG16L1 (Paneth-cell autophagy defect), IRGM. Standard-of-care: corticosteroids for induction (budesonide for ileal/right-colon); thiopurines (AZA, 6-MP) and methotrexate maintenance — TPMT + NUDT15 testing before thiopurines load-bearing; anti-TNF biologics (infliximab, adalimumab, certolizumab pegol); vedolizumab (Entyvio gut-selective α4β7); ustekinumab (Stelara anti-IL-12/23); risankizumab (Skyrizi anti-IL-23p19 FDA June 2022 via ADVANCE/MOTIVATE/FORTIFY); guselkumab (Tremfya anti-IL-23p19 FDA April 2024 via GRAVITI/GALAXI); upadacitinib (Rinvoq JAK1 FDA May 2023 via U-EXCEL/U-EXCEED/U-ENDURE — ORAL Surveillance black-box). 5-ASAs NOT effective in CD (UC-CD distinction). Pediatric induction: exclusive enteral nutrition (EEN) per ECCO/ESPGHAN evidence-based first-line with mucosal-healing rates comparable to corticosteroids. Perianal fistulizing subset: anti-TNF + surgical setons + Cx601 (darvadstrocel/Alofisel allogeneic adipose MSC — EU approved post-ADMIRE-CD Phase 3, NOT US approved). STRIDE-II treat-to-target (mucosal + transmural healing). ECCO 2024 + ACG 2018 + AGA 2021 + Crohn's & Colitis Foundation. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Continuous mucosal inflammation of the colon extending proximally from the rectum — bloody diarrhea, urgency, tenesmus; Montreal extent E1 proctitis / E2 left-sided / E3 pancolitis. PSC association ~3-7%. Toxic megacolon is a medical emergency. Colorectal cancer surveillance from 8 years post-diagnosis (earlier for PSC or extensive disease) via chromoendoscopy or HD-WLE with targeted biopsies. The 2018-2024 drug-development cycle reshaped management: 5-ASA optimization (mesalamine, sulfasalazine, balsalazide, olsalazine) remains Tier 1 mild-moderate and is consistently under-optimized before escalation; corticosteroids for induction; thiopurines (AZA, 6-MP) maintenance; anti-TNF (infliximab, adalimumab, golimumab/Simponi); vedolizumab (Entyvio gut-selective); ustekinumab (FDA Oct 2019 UNIFI); tofacitinib (Xeljanz JAK FDA 2018 OCTAVE + ORAL Surveillance black-box); ozanimod (Zeposia S1P modulator FDA May 2021 True North); upadacitinib (Rinvoq JAK1 FDA March 2022 U-ACHIEVE/U-ACCOMPLISH); etrasimod (Velsipity S1P FDA Oct 2023 ELEVATE UC); mirikizumab (Omvoh IL-23p19 FDA Oct 2023 LUCENT-1/2); guselkumab (Tremfya IL-23p19 FDA Sep 2024 QUASAR). Colectomy with IPAA definitive for medically-refractory disease, dysplasia, cancer, or toxic megacolon. STRIDE-II treat-to-target: clinical + biomarker (CRP, fecal calprotectin) + endoscopic (Mayo endoscopic subscore 0-1) + histologic remission. ACG 2019 + AGA 2020 + ECCO 2022 + Crohn's & Colitis Foundation. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case.

Chronic immune-mediated hepatocyte destruction — Type 1 (~90%, ANA + ASMA + anti-actin) and Type 2 (~10%, anti-LKM1 + anti-LC1, pediatric/young adult skew); occasional anti-SLA/LP positive (relapse-risk marker). Female predominance ~3-4:1. Distinct from PBC (cholestatic AMA-positive) and PSC (biliary strictures). IAIHG simplified criteria + liver biopsy gold standard. Standard-of-care: prednisone/prednisolone 30-60 mg taper induction OR budesonide (Entocort/Uceris) for non-cirrhotic ONLY (first-pass hepatic metabolism lost in cirrhosis due to portosystemic shunting); azathioprine maintenance with TPMT genotype or activity testing BEFORE start (catastrophic myelosuppression risk in deficient patients); mycophenolate mofetil second-line maintenance; tacrolimus/cyclosporine refractory; rituximab/infliximab rare refractory. Treat-to-target: ALT/AST normalization + IgG <1.1x ULN + histologic remission for sustained complete biochemical remission per AASLD 2019, EASL 2015, BSG 2011. HCC surveillance once cirrhotic. Liver transplant for end-stage with 10-20% post-transplant recurrence. Autoimmune Hepatitis Association (AIHA). The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case — and thymosin alpha-1's hepatitis-B Tier 1 evidence propagates with the OPPOSITE SIGN (Rule 6 non-propagation in the strongest form in the library).

Chronic cholestatic autoimmune liver disease with intrahepatic + extrahepatic bile duct strictures and beaded MRCP appearance. ~70-80% have concurrent IBD (mostly UC pancolitis with right-sided predominance). 10-15% lifetime cholangiocarcinoma (CCA) risk. Male predominance ~2:1 (opposite of PBC's ~9:1 female). NO DISEASE-MODIFYING THERAPY EXISTS. UDCA at moderate doses (15-20 mg/kg) is contested — may improve biochemistry without progression benefit; high-dose UDCA (28-30 mg/kg) FAILED Lindor 2009 NEJM and STOPPED EARLY for INCREASED serious adverse events + transplant need — the PSC-specific anti-supplement-stacking precedent (analog to Berson 1993 RP vitamin E). Annual MRCP + CA 19-9 for CCA surveillance. Annual colonoscopy when IBD overlap is present (PSC-IBD CRC risk exceeds IBD alone). ERCP for dominant strictures with brushings for CCA. Liver transplant for end-stage (5-year survival 80-85%); ~25% post-transplant recurrence. Trial-enrollment paths: norUDCA Phase 3 (most active DMT candidate); cilofexor FXR agonist failed Phase 2; vancomycin off-label small pediatric studies; vedolizumab for IBD overlap with emerging liver signal; bezafibrate off-label per BEZURSO extrapolation. Pruritus ladder (rifampin → cholestyramine → naltrexone → sertraline). AASLD 2022 + EASL 2022. PSC Partners Seeking a Cure + PSC Support. The editorial honest answer for this trigger is that no peptide in the Juno library has a defensible discovery-card case — trial enrollment is the actionable conversation.

Primary progressive (PPMS) and non-active secondary progressive (SPMS) multiple sclerosis — the smoldering inflammation + chronic neurodegeneration phenotype that defines disability accrual in MS. Ocrelizumab (Ocrevus FDA 2017 PPMS via ORATORIO) and siponimod (Mayzent FDA 2019 active SPMS via EXPAND) anchor the DMT landscape; tolebrutinib's HERCULES 2024 positive Phase 3 readout in non-relapsing SPMS marks the field's first paradigm shift for the historically under-treated non-active SPMS population. Evobrutinib + fenebrutinib + remibrutinib BTK pipeline and frexalimab anti-CD40L Phase 2/3 follow. Symptomatic ladder: dalfampridine for walking, baclofen + tizanidine for spasticity, gabapentin for neuropathic pain, modafinil/armodafinil off-label for fatigue. AHSCT remains experimental and is limited mainly to highly active relapsing disease. AAN 2018 + ECTRIMS-EAN 2018 + AAN 2024 guidelines + NMSS anchor management. No peptide in the Juno library has a defensible discovery-card case here — Cerebrolysin and Semax are source-jurisdiction-registered for stroke / dementia / TBI (Russia + EU member states), not MS; Selank is anxiolytic and doesn't touch disease; NMN's NAD+ biology is mechanistically adjacent but not trial-supported in human progressive MS; LL-37 carries the autoimmune-contraindication thread from psoriasis and lupus literature and should not be approached in a CNS autoimmune disease without specialist input. Twenty-third deliberate non-elevation.

Sex chromosome monosomy in females (~1 in 2,500 female births) producing ovarian dysgenesis with primary ovarian insufficiency, short stature, and a lifelong cardiovascular surveillance burden. ~50% classic 45,X; ~30% mosaic 45,X/46,XX; ~5% 45,X/46,XY mosaic (gonadoblastoma risk → gonadectomy); rest structural X variants (Xq isochromosome, ring X, Xp deletion). Universal short stature (untreated ~143 cm); gonadal dysgenesis → infertility 95-99%; cardiovascular — bicuspid aortic valve ~30% + coarctation aorta ~10% + AORTIC DISSECTION RISK LIFELONG; renal anomalies; hearing loss; AUTOIMMUNE (Hashimoto's, celiac, T1DM) elevated; nonverbal learning disability + visuospatial deficits (verbal IQ preserved); metabolic risk elevated. Diagnostics: karyotype gold standard. Standard of care: GROWTH HORMONE somatropin (FDA + EMA approved Turner indication; start age 4-6; final height +5-10 cm), oxandrolone adjunct age 8-13, estrogen replacement from age 12-13 (transdermal estradiol + progestin if uterus, continue until natural menopause); CARDIOVASCULAR SURVEILLANCE echo + cardiac MRI baseline + every 5-10 years (aortic root tracking); REPRODUCTIVE oocyte donation IVF; PREGNANCY HIGH-RISK (aortic dissection + maternal mortality) — pre-pregnancy cardiology mandatory + MFM coordination; autoimmune screening annual; audiology + neuropsychology support. 2016 Cincinnati international consensus + 2017 Endocrine Society + 2024 ESPE. Turner Syndrome Society of US + Turner Syndrome Foundation + Living with Turner Syndrome. **Editorial point**: somatropin pediatric protocol distinct from community adult GH-axis peptide use; epiphyseal closure makes CJC/ipamorelin/MK-677 useless for height. Fifty-first deliberate non-elevation.

ACTH-secreting pituitary corticotroph adenoma driving endogenous cortisol excess. Distinct from Cushing's syndrome (the umbrella term for any cause of hypercortisolism), ectopic ACTH syndrome, adrenal Cushing, and exogenous (iatrogenic) Cushing — the most common cause overall, from prescribed glucocorticoids. The pituitary subtype accounts for roughly 70% of endogenous Cushing. Features: central obesity + moon facies + buffalo hump + violaceous striae >1cm + thin skin + easy bruising + hirsutism + acne + hypertension + severe insulin resistance/T2D + osteoporosis with often-silent vertebral fractures + proximal muscle weakness + psychiatric (depression to psychosis to cognitive impairment). MORTALITY 4-5x general population if untreated. Diagnostics: screening triad (24h UFC + late-night salivary cortisol + 1 mg overnight DEX suppression — 2 of 3 abnormal); pseudo-Cushing's exclusion (chronic alcohol + severe depression + obesity + exogenous steroid); confirmation localization (plasma ACTH + high-dose DEX suppression + pituitary MRI + IPSS when MRI negative/ambiguous + CT for ectopic). Standard of care: TRANSSPHENOIDAL PITUITARY SURGERY first-line at high-volume centers (cure 65-90% microadenoma, 30-65% macroadenoma); stereotactic radiosurgery (Gamma Knife) for residual/refractory; steroidogenesis inhibitors — OSILODROSTAT (Isturisa) FDA Mar 2020 via LINC-2/3/4; LEVOKETOCONAZOLE (Recorlev) FDA Dec 2021; metyrapone; ketoconazole; mitotane; GR antagonist MIFEPRISTONE (Korlym) FDA 2012 hyperglycemia; SSA PASIREOTIDE (Signifor) FDA 2012 SSTR5 (hyperglycemia risk); cabergoline off-label; bilateral adrenalectomy definitive refractory → lifelong AI replacement. EMERGING: RELACORILANT (Corcept) selective GR antagonist Phase 3 GRACE positive 2024 FDA submission. Post-cure: cortisol-withdrawal syndrome + adrenal insufficiency months. Cushing's Support and Research Foundation + Pituitary Network Association + AANS. **Editorial**: GH-axis peptides in known corticotroph adenoma = sustained pituitary stimulation in tumor-bearing gland (uncharacterized population); tesamorelin FDA label contraindicates pituitary tumor history. Fifty-second deliberate non-elevation.

Pituitary somatotroph adenoma producing pathologic GH/IGF-1 excess — adult acromegaly 95%+ adenoma cases (gigantism = pediatric/adolescent equivalent before epiphyseal closure); rare GH-RH-producing tumors (pancreatic, lung). Features (insidious years): acral overgrowth + jaw prognathism + macroglossia + skin thickening + carpal tunnel + insulin resistance/T2D + hypertension + CARDIOMYOPATHY (major mortality driver) + arrhythmias + OSA + arthropathy + osteoporosis + hypogonadism + cancer surveillance (colorectal + thyroid + breast). Diagnostics: IGF-1 elevated + OGTT-suppressed GH + MRI pituitary + visual field testing. Standard of care: TRANSSPHENOIDAL SURGERY first-line; SSAs (octreotide LAR + lanreotide + pasireotide + oral octreotide Mycapssa FDA Jun 2020); GH receptor antagonist PEGVISOMANT (Somavert FDA 2003); dopamine agonists; stereotactic radiosurgery. EMERGING: PALTUSOTINE (CRN00808) oral non-peptide SSA Phase 3 PATHFNDR-1/2 positive 2023/2024 FDA submission pending. AACE 2024 + Endocrine Society + Acromegaly Community + AANS. **CRITICAL**: GH-stimulating peptides (sermorelin, CJC-1295, ipamorelin, MK-677, tesamorelin) ACTIVELY CONTRAINDICATED in active acromegaly; 2-5 year post-cure caution; tesamorelin FDA label contraindicates pituitary tumor history. Forty-ninth deliberate non-elevation.

The most common sex chromosome aneuploidy in males — 47,XXY karyotype (variants: 48,XXYY; 48,XXXY; 49,XXXXY; mosaic 46,XY/47,XXY) causing primary hypogonadism, near-universal infertility, and a cluster of metabolic, skeletal, and psychosocial comorbidities. ~1 in 660 male births. VASTLY UNDERDIAGNOSED: only ~25-50% of cases identified in a lifetime. Pathology: progressive seminiferous tubule fibrosis from puberty → primary hypogonadism + infertility. Features: small firm testes + azoospermia + INFERTILITY ~99% + gynecomastia + eunuchoid proportions; LOW T + ELEVATED LH/FSH (primary hypogonadism signature); tall stature; reduced muscle mass + bone density; central adiposity; language-based learning difficulties + ADHD + autism spectrum overlap + anxiety/depression; T2D + metabolic syndrome + CV + osteoporosis + BREAST CANCER 20-50x normal male risk + germ cell tumors + autoimmune (SLE, RA, T1DM). Diagnostics: karyotype gold standard. Standard of care: TESTOSTERONE REPLACEMENT THERAPY (TRT) load-bearing starting adolescence ~12-14; FERTILITY — micro-TESE + ICSI TIME-SENSITIVE (sperm recovery 30-60% before tubular sclerosis complete; offer BEFORE or with TRT pause); DEXA every 2 years; mental health + learning support; breast cancer screening. AAKSIS + Living with XXY + Klinefelter Syndrome Foundation. 2024 international expert consensus + Endocrine Society. **Kisspeptin + gonadorelin mechanistically INAPPROPRIATE — primary not secondary hypogonadism.** Fiftieth deliberate non-elevation (editorial milestone).

Loss of ovarian function before age 40 — amenorrhea with elevated FSH (>25-40 IU/L on 2 occasions 4 weeks apart) and low estradiol. Terminology shifted from 'premature ovarian failure' to POI reflects intermittent ovarian function possible (~5-10% spontaneous conception). Etiologies divide into GENETIC ~10-15% (Turner syndrome including mosaic 45,X, FMR1 premutation 55-200 CGG repeats, BRCA1/2, autosomal genes), AUTOIMMUNE ~5-30% (APS-1 with AIRE mutations, APS-2, isolated ovarian antibodies often clustering with thyroid and adrenal autoimmunity), IATROGENIC (alkylating chemotherapy, pelvic radiation, surgical), and IDIOPATHIC majority. ~1% of women under 40; ~0.1% under 30. Symptoms: hot flashes + night sweats + vaginal dryness + dyspareunia + fatigue + mood changes + low libido + INFERTILITY. Long-term sequelae: osteoporosis + cardiovascular disease + cognitive decline + depression + premature mortality from decades of estrogen deficiency. Standard of care: HRT NON-NEGOTIABLE until natural menopause age (~51) — PHYSIOLOGIC replacement (HIGHER doses than menopausal HRT); transdermal estradiol preferred; progestin if uterus intact; DEXA every 1-2 years for bone density; cardiovascular risk screening; calcium + vitamin D optimization; mental health attention. Fertility: oocyte donation IVF main realistic pathway; ovarian tissue cryopreservation before known iatrogenic exposure; PRP/IVA (Kawamura PI3K-PTEN) experimental no high-quality evidence. 2016 ESHRE POI guideline + 2024 NAMS update + Endocrine Society. Daisy Network (UK) + Rachel's Well + International Premature Ovarian Insufficiency Association. Forty-seventh deliberate non-elevation.

Group of autosomal recessive disorders of adrenal steroidogenesis — most commonly 21-hydroxylase deficiency (CYP21A2, ~95% of cases) — requiring lifelong hormone replacement and now reshaped by the December 2024 FDA approval of crinecerfont, the first non-steroid therapy in this space. 21-OHD spectrum: classic salt-wasting (~75% classic — neonatal salt-wasting crisis + ambiguous genitalia 46,XX); classic simple virilizing (~25% — cortisol deficiency + androgen excess + ambiguous genitalia 46,XX + precocious puberty); non-classic late-onset hyperandrogenism mimicking PCOS. Other forms: 11β-OHD (CYP11B1 with hypertension), 17α-OHD, 3β-HSD, StAR/lipoid CAH, P450 oxidoreductase. US newborn screening 17-OHP since 1990s converted catastrophic-presentation disease to first-week diagnosis. Standard of care: glucocorticoid replacement (hydrocortisone preferred in children — shortest half-life, least growth suppression; prednisone/dexamethasone adults; goal — replace cortisol AND suppress excess ACTH-driven androgen production); fludrocortisone for salt-wasters + salt supplementation infants; stress dosing + emergency injection kit like Addison; CHRONOCORT/EFMODY (modified-release hydrocortisone) FDA Dec 2021 CAH adults — first novel CAH approval in decades; CRINECERFONT (Crenessity) FDA DEC 2024 — CRF1 receptor antagonist reduces hydrocortisone ~30% — FIRST NON-STEROID approval for classic CAH paradigm shift; TILDACERFONT CRF1 antagonist Phase 3 SPARK-T + SPARK-A. Surgical: feminizing genitoplasty CONTROVERSIAL — DELAYED with child input considered per intersex advocacy + specialty society consensus. Long-term burden mostly glucocorticoid exposure trade-offs. Transition to adult care + fertility planning + mental health + gender identity considerations all load-bearing. CARES Foundation + CAH Quality Care Initiative. Forty-eighth deliberate non-elevation.

Progressive irreversible inflammatory disease of the pancreas — fibrosis and glandular destruction lead to exocrine insufficiency (malabsorption), endocrine insufficiency (type 3c pancreatogenic diabetes), and chronic pain. TIGAR-O classification anchors etiology: Toxic-metabolic (alcohol 60-70%, smoking, hypertriglyceridemia, hypercalcemia), Idiopathic, Genetic (PRSS1 hereditary, SPINK1, CFTR, CTRC, CASR), Autoimmune (type 1 IgG4-RD, type 2), Recurrent acute, Obstructive (pancreas divisum, sphincter of Oddi, tumors). Diagnostics: cross-sectional imaging (CT, MRCP, EUS — secretin-enhanced MRCP for early-stage), fecal elastase-1 <200 µg/g flagging exocrine insufficiency, Cambridge + Rosemont criteria, genetic testing. Standard of care: ALCOHOL CESSATION load-bearing; smoking cessation; pancreatic enzyme replacement therapy (PERT — pancrelipase Creon, Zenpep, Pancreaze, Pertzye, Viokace) dosed with meals; fat-soluble vitamin replacement (A, D, E, K); insulin for type 3c diabetes (brittle — alpha-cell glucagon loss impairs counter-regulation); pain management WHO ladder + tricyclics + gabapentinoids + celiac plexus block + thoracoscopic splanchnicectomy; endoscopic (ERCP for ductal stones/strictures, stenting, lithotripsy); surgical (Puestow lateral pancreaticojejunostomy, Frey, Beger, Whipple, TPIAT total pancreatectomy with islet auto-transplant). AIP type 1 IgG4-RD: corticosteroid induction + rituximab + INEBILIZUMAB MITIGATE 2024 FDA approval. PDAC SURVEILLANCE mandatory in hereditary PRSS1 + long-standing disease (CAPS consortium guidance — annual MRI/MRCP + EUS). National Pancreas Foundation + Mission: Cure + PanCAN. Forty-fifth deliberate non-elevation.

Adrenal cortex destruction causing cortisol and aldosterone deficiency — autoimmune adrenalitis (21-hydroxylase antibodies) accounts for ~80% of cases in developed countries; tuberculosis was historically dominant; CMV/HIV, metastatic disease, bilateral adrenalectomy, congenital adrenal hyperplasia, adrenoleukodystrophy (X-linked males), drugs, and polyendocrine syndromes (APS-1 via AIRE, APS-2 via HLA-DR3) round out the differential. Distinguished from SECONDARY adrenal insufficiency (pituitary ACTH deficiency — aldosterone preserved, no hyperpigmentation). Symptoms: fatigue + weight loss + anorexia + nausea + abdominal pain + salt craving + postural dizziness + HYPERPIGMENTATION (palmar creases + scars + buccal mucosa via ACTH/MSH cross-reactivity) + vitiligo + autoimmune comorbidity. ADRENAL CRISIS = LIFE-THREATENING EMERGENCY: hypotension + shock + hyperkalemia + hyponatremia + hypoglycemia + altered mental status; precipitated by infection + surgery + trauma + dehydration; significant mortality without rapid IV hydrocortisone. Diagnostics: ACTH stimulation test (cosyntropin 250 mcg with cortisol <18 µg/dL diagnostic); plasma ACTH elevated primary; 21-hydroxylase antibodies; VLCFAs for ALD males. Standard of care: hydrocortisone 15-25 mg/day divided BID-TID (Plenadren modified-release; Chronocort/Efmody FDA Dec 2021 21-OHD CAH dual-release); fludrocortisone 0.05-0.2 mg/day; DHEA replacement controversial; STRESS-DOSE STEROIDS (2-3x maintenance for febrile illness; IV hydrocortisone surgery/trauma); EMERGENCY INJECTION KIT (Solu-Cortef 100 mg) MANDATORY; MEDICAL ALERT IDENTIFIER MANDATORY. EMERGING: crinecerfont (Crenessity FDA Dec 2024 for 21-OHD CAH — CRF1 receptor antagonist reduces hydrocortisone need). Endocrine Society 2016 + ESE 2024. NADF + AIM-HI + Pituitary Foundation. Forty-sixth deliberate non-elevation.

The most common identifiable cause of secondary hypertension — and the most underdiagnosed. Affects 5-10% of all hypertension and ~20% of resistant hypertension, yet screening rate is in low single digits. Autonomous aldosterone secretion drives sodium retention, potassium wasting (normokalemic PA is majority phenotype), and end-organ damage that exceeds essential hypertension at matched BP (atrial fibrillation 3x, stroke 2x, MI 2x). Subtypes: unilateral aldosterone-producing adenoma (APA, Conn syndrome — surgically curable) vs bilateral adrenal hyperplasia (BAH — medically managed). Diagnostics: aldosterone-to-renin ratio (ARR) screening → confirmatory testing (saline suppression, salt loading, captopril, fludrocortisone) → adrenal CT → ADRENAL VEIN SAMPLING (AVS) gold standard for lateralization in patients >35. Standard of care: laparoscopic adrenalectomy for unilateral APA (cure ~50%, improvement most); mineralocorticoid receptor antagonists for bilateral — spironolactone first-line (anti-androgen side effects), eplerenone selective, finerenone (Kerendia) non-steroidal FDA Jul 2021 via FIDELIO-DKD + FIGARO-DKD diabetic CKD with emerging PA application, esaxerenone Japan 2019. Emerging aldosterone synthase inhibitors — baxdrostat (CIN-107, BrigHTN Phase 2 positive 2022) + lorundrostat (Target-HTN Phase 2 positive 2024) — paradigm shift blocking hormone at source. Endocrine Society 2016 + ESH 2024 + PA Foundation. Forty-third deliberate non-elevation.

Chronic, severe inflammatory skin disease with barrier dysfunction (filaggrin loss-of-function), Th2 immune dysregulation (IL-4, IL-13, IL-31, TSLP), and intractable pruritus — recalcitrant to topical therapy and managed by dermatology with biologics, JAK inhibitors, and structured skincare. EASI >21, IGA 4, BSA >30%. Pediatric onset common (~60% by age 1); ~30% persist into adulthood. Atopic march into asthma + allergic rhinitis + food allergy. Comorbidities: depression + elevated suicide risk + sleep disturbance. Hanifin-Rajka criteria + UK Working Party. Standard-of-care escalation: foundation emollients + gentle skincare + trigger avoidance + dilute bleach baths for S. aureus colonization → topical corticosteroids + topical calcineurin inhibitors (tacrolimus + pimecrolimus) + topical PDE4 (crisaborole + roflumilast) + topical JAK (ruxolitinib cream FDA Sept 2021) → phototherapy (NB-UVB) → oral immunosuppressants (cyclosporine + methotrexate + MMF + AZA) → BIOLOGICS PARADIGM SHIFT: DUPILUMAB (Dupixent) anti-IL-4Rα FDA March 2017 (pediatric down to 6 months); TRALOKINUMAB (Adbry) anti-IL-13 FDA Dec 2021 via ECZTRA; LEBRIKIZUMAB (Ebglyss) anti-IL-13 FDA Sept 2024 via ADvocate + ADhere; NEMOLIZUMAB (Nemluvio) anti-IL-31RA FDA Dec 2024 AD via ARCADIA. ORAL JAK INHIBITORS: UPADACITINIB (Rinvoq) JAK1 FDA Jan 2022; ABROCITINIB (Cibinqo) JAK1 FDA Jan 2022. JAK BOXED WARNING — VTE + MACE + malignancy. Emerging: rocatinlimab + amlitelimab anti-OX40/OX40L Phase 3. National Eczema Association + International Eczema Council + ETFAD. Forty-fourth deliberate non-elevation.

Episodic, multisystem mast cell mediator release — flushing, urticaria, GI cramping, cardiovascular instability (presyncope, tachycardia, hypotension), neuropsychiatric (brain fog, anxiety) — managed by allergy/immunology specialists with a layered pharmacotherapy ladder and trigger avoidance. Diagnostic framework contested between Valent et al. 2007/2012 Consensus-1 (STRICT — tryptase >20% baseline + 2 ng/mL within 4 hours) and Akin/Castells/Afrin Consensus-2 (BROADER — includes 24-hour urinary mediators). Hereditary alpha-tryptasemia (HαT, TPSAB1 copy number elevated baseline tryptase, ~5-7% of population) is load-bearing confounder. Distinguished from systemic mastocytosis (KIT D816V clonal proliferation; avapritinib FDA June 2021 advanced SM + January 2023 indolent SM via PIONEER + HARBOR; bezuclastinib Phase 3 SUMMIT). Mast cell triad with POTS + hEDS. Standard of care: trigger avoidance + H1/H2 antihistamines + cromolyn + leukotriene antagonists + aspirin (carefully) + omalizumab off-label emerging + IVIG refractory + epinephrine auto-injector load-bearing. LL-37 known MRGPRX2 agonist — DIRECTIONAL CONTRAINDICATION. Mastocytosis Society + The Mast Cell Disease Society + MCAS Support Group. Forty-first deliberate non-elevation.

A chronic, recurrent, autoinflammatory follicular skin disease causing painful nodules, abscesses, sinus tracts, and scarring in apocrine-bearing areas (axillae, inguinal, perianal, inframammary) — historically underdiagnosed by 7-10 years and now treated with a modern biologic ladder that has reshaped the field three times in nine years: adalimumab (Humira, FDA Sept 2015 via PIONEER I/II) — first biologic; secukinumab (Cosentyx, FDA Oct 2023 via SUNSHINE + SUNRISE) — anti-IL-17A; bimekizumab (Bimzelx, FDA July 2024 via BE HEARD I+II) — dual anti-IL-17A/F. Hurley I-III staging. Female predominance 3:1. Comorbidities: obesity + metabolic syndrome + diabetes + cardiovascular + IBD overlap ~25% + spondyloarthropathy + depression + ELEVATED SUICIDE RISK. SMOKING CESSATION #1 LIFESTYLE INTERVENTION (smokers 4x risk). Antibiotics (tetracyclines, clindamycin+rifampin, dapsone), hormonal (spironolactone, OCPs, finasteride, metformin), procedural (deroofing, CO2 laser, surgical excision), and mental health screening with suicide-risk PHQ-9 part of standard care. Povorcitinib JAK1 Phase 3 STOP-HS + sonelokimab anti-IL-17A/F nanobody Phase 3 VELA + avacopan C5aR1 Phase 2/3 ASTRA pipeline. LL-37 directly contraindicated — cathelicidin upregulated in HS lesional skin per published immunology. 2022 European S1 + 2019 US HS Foundation + Hope for HS + HS Awareness Month. Forty-second deliberate non-elevation.

Daily or near-daily hives (with or without angioedema) lasting more than six weeks — chronic spontaneous urticaria (CSU) when no consistent trigger is identifiable, and chronic inducible urticaria (CIndU) when physical stimuli (cold, heat, pressure, vibration, cholinergic exertion, water, sunlight, dermographism) reliably provoke the wheals. Around 30-50% of CSU is autoimmune (type IIb IgG anti-FcεRI or anti-IgE; type I IgE autoantibodies against thyroid peroxidase or IL-24). Hashimoto's thyroiditis overlap ~25%. 2021 EAACI/GA²LEN/EuroGuiDerm/APAAACI international guideline + AAAAI/ACAAI 2014 US update. Standard-of-care stepwise ladder: Step 1 second-generation H1-antihistamines at standard dose; Step 2 up-titrate to 4x standard; Step 3 OMALIZUMAB (Xolair, FDA 2014 via ASTERIA I/II + GLACIAL) anti-IgE 300 mg SC q4w paradigm shift; Step 4 cyclosporine off-label + add-on biologics. Emerging: DUPILUMAB FDA April 2025 CSU via LIBERTY-CUPID; BARZOLVOLIMAB anti-KIT mast-cell depletion Phase 3; REMIBRUTINIB + FENEBRUTINIB BTK inhibitors Phase 3. Angioedema without urticaria suspicious for HAE (bradykinin-mediated). UAS7 + DLQI tracking. Thirty-ninth deliberate non-elevation.

Chronic inflammatory dermatosis of the anogenital region — vulvar in women, foreskin/glans in men (balanitis xerotica obliterans, BXO), with pediatric (~7-15% of vulvar LS) and postmenopausal peaks — managed lifelong with ultrapotent topical corticosteroids and annual surveillance for squamous cell carcinoma. Features: porcelain-white atrophic plaques + pruritus + soreness + dyspareunia + architectural changes (labial fusion, clitoral hood phimosis, introital stenosis, foreskin phimosis); 'figure-8' or 'hourglass' perianal-vulvar pattern; subepithelial hemorrhage and ecchymosis-like lesions. CRITICAL SAFETY: 4-5% lifetime VULVAR squamous cell carcinoma (SCC) risk in untreated LS; 2-12% in inadequately treated; ANNUAL EXAM SURVEILLANCE LOAD-BEARING; differentiated VIN (dVIN) precursor lesion. Standard of care: ULTRAPOTENT TOPICAL CORTICOSTEROIDS — clobetasol propionate 0.05% ointment — nightly induction 4-12 weeks then maintenance 2-3x/week LIFELONG; reduces SCC risk. Pimecrolimus + tacrolimus calcineurin inhibitors steroid-sparing. Topical estrogen if coexisting menopausal atrophy (GSM). Surgery (adhesion lysis, circumcision for severe phimosis) for established architectural change. British Association of Dermatologists 2018 + AAD + ISSVD. Pediatric LS overlaps visually with sexual abuse findings — pediatric dermatology + child-protective evaluation pathways navigated simultaneously. Fortieth deliberate non-elevation.

Systemic sclerosis (scleroderma) is a multisystem connective tissue disease defined by the triad of autoimmunity, vasculopathy, and fibrosis. It splits clinically into limited cutaneous SSc (skin involvement distal to elbows and knees plus the CREST features — calcinosis, Raynaud's, esophageal dysmotility, sclerodactyly, telangiectasia — with anti-centromere antibodies and a late pulmonary arterial hypertension risk) and diffuse cutaneous SSc (proximal skin involvement, anti-Scl-70 or anti-RNA polymerase III antibodies, and early severe interstitial lung disease plus scleroderma renal crisis risk). Other subsets include SSc sine scleroderma and juvenile SSc. The treatment landscape has shifted dramatically in the past decade — tocilizumab gained FDA approval for SSc-ILD in September 2021 via the focuSSced trial as the first IL-6 receptor antagonist in the indication; nintedanib gained FDA approval for SSc-ILD in September 2019 via the SENSCIS trial as a multi-kinase anti-fibrotic; autologous stem cell transplantation (ASTIS and SCOT trials) demonstrated mortality benefit for severe rapidly progressive dcSSc. STEROID AVOIDANCE in dcSSc is load-bearing (renal crisis risk). 2013 ACR/EULAR classification criteria + 2024 EULAR/ACR + 2023 World Scleroderma Foundation. Scleroderma Foundation + Scleroderma Research Foundation + International Scleroderma Network. Thirty-seventh deliberate non-elevation.

Complex regional pain syndrome (CRPS) is a chronic disorder of dysregulated pain processing that typically follows an injury — a wrist fracture, a sprain, a surgical procedure, sometimes a frank nerve injury — and produces pain wildly out of proportion to the inciting event, plus sensory disturbances (hyperalgesia, allodynia), vasomotor changes (skin color, temperature asymmetry), sudomotor changes (sweating, edema), and over time motor and trophic changes (atrophy, contracture, abnormal nail and hair growth). It's classified as Type I when there's no major nerve injury (the older 'reflex sympathetic dystrophy' / RSD label) and Type II when a major nerve injury is identifiable (the older 'causalgia' label). Diagnosis is clinical, based on the Budapest Criteria; there's no specific biomarker. Treatment is anchored by early mobilization and structured PT — immobilization makes outcomes worse — supplemented by pain neuroscience education, mirror therapy and graded motor imagery, neuropathic analgesics, sympathetic blocks, ketamine infusions in selected cases, and neuromodulation (dorsal root ganglion stimulation, spinal cord stimulation) for refractory disease. The peptide community is unusually active on CRPS, which is the reason this page exists — not to recommend peptides, but to be honest about why they don't address what CRPS actually is. RSDSA + IASP + American Academy of Pain Medicine. Thirty-eighth deliberate non-elevation.

Hereditary hemochromatosis is a Mendelian disorder of iron regulation — most often HFE-related (C282Y homozygous, or compound heterozygous C282Y/H63D), with rarer non-HFE forms involving TFR2, HJV, HAMP, or SLC40A1 (ferroportin). The shared substrate defect is hepcidin insufficiency — relative or absolute — which removes the normal brake on intestinal iron absorption. Iron progressively accumulates in the liver, heart, pancreas, joints, anterior pituitary, and skin over years to decades, driving the classic late presentations: cirrhosis with hepatocellular carcinoma risk, restrictive then dilated cardiomyopathy with arrhythmia, 'bronze diabetes,' arthralgia in the second and third metacarpophalangeal joints, hypogonadotropic hypogonadism, hypothyroidism, and skin hyperpigmentation. Therapeutic phlebotomy is the gold-standard treatment — first-line, weekly during induction until ferritin <50 ng/mL, then maintenance every 2-4 months — and has been since the 1950s. AASLD 2018 + 2024 + EASL + ACG guidelines. Iron in supplements explicitly contraindicated. Raw seafood avoidance (Vibrio vulnificus sepsis >50% mortality in iron overload) load-bearing. Family screening mandatory for first-degree relatives. Rusfertide (PTG-300) hepcidin mimetic + mini-hepcidins emerging therapeutic class targeting upstream defect. Iron Disorders Institute + American Hemochromatosis Society + Canadian Hemochromatosis Society. Thirty-fifth deliberate non-elevation.

Autoimmune encephalitis is the umbrella term for a heterogeneous family of antibody-mediated inflammatory diseases of the brain — anti-NMDA receptor encephalitis (most common, Dalmau et al. 2007, ovarian teratoma association ~50% adult women), LGI1 encephalitis (faciobrachial dystonic seizures, hyponatremia, older men), CASPR2 encephalitis (Morvan syndrome, thymoma), GABA-B receptor encephalitis (refractory seizures, small-cell lung cancer), AMPA receptor encephalitis (limbic encephalitis, thymoma/lung/breast), IgLON5 disease (sleep-disordered breathing, parasomnia, bulbar), GAD65 encephalitis (stiff person syndrome, cerebellar ataxia, limbic encephalitis), and paraneoplastic limbic encephalitis (anti-Hu, anti-Ma2, anti-CV2/CRMP5, anti-amphiphysin — intracellular antigens, cancer-driven, worse prognosis). Diagnosis follows the 2016 international consensus criteria (Graus et al. Lancet Neurology) using paired serum + CSF antibody panels, MRI, CSF analysis, EEG (extreme delta brush pathognomonic for NMDAR), and rigorous cancer screening. Treatment is first-line high-dose IV methylprednisolone + IVIG + plasma exchange, second-line rituximab + cyclophosphamide, maintenance with rituximab + mycophenolate + azathioprine, and tumor removal where paraneoplastic. Emerging: inebilizumab (anti-CD19) ExTINGUISH Phase 3 NMDAR ongoing; bortezomib for refractory plasma-cell-driven; daratumumab anti-CD38. AAN 2024 + IAES + Autoimmune Encephalitis Alliance + Anti-NMDA Receptor Encephalitis Foundation. Thirty-sixth deliberate non-elevation.

MOG antibody-associated disease is an antibody-mediated CNS demyelinating disorder driven by IgG against myelin oligodendrocyte glycoprotein, the surface glycoprotein on oligodendrocyte processes that the antibody targets to drive complement-fixing and effector-mediated injury. The 2023 international consensus criteria (Banwell, Bennett, Marignier and colleagues) reclassified MOGAD as a distinct entity — separate from AQP4-positive neuromyelitis optica spectrum disorder, separate from multiple sclerosis, with its own diagnostic algorithm anchored on a reliable cell-based assay for MOG-IgG (live or fixed, NOT ELISA), characteristic MRI pattern, and clinical phenotype. Clinical phenotypes span optic neuritis (often bilateral, often with disc swelling, anterior and longitudinally extensive on orbits MRI), transverse myelitis, acute disseminated encephalomyelitis (ADEM, particularly in children), brainstem encephalitis, and cortical encephalitis with seizures. Roughly half of cases are monophasic; the other half relapse and require maintenance immunotherapy. There is no FDA-approved MOGAD-specific therapy as of 2026 — acute attacks are managed with high-dose IV methylprednisolone pulses plus IVIG plus plasma exchange for severe presentations, and relapsing disease is managed with rituximab, mycophenolate, azathioprine, tocilizumab, or monthly maintenance IVIG depending on the clinical pattern and the treating neuroimmunologist's read. Thirty-third deliberate non-elevation.

IgG4-related disease is a multisystem fibroinflammatory condition characterized by a distinctive histopathology (dense lymphoplasmacytic infiltrate enriched in IgG4+ plasma cells, storiform fibrosis, obliterative phlebitis) and frequently — but not always — elevated serum IgG4. It was characterized relatively recently: Japanese rheumatology and gastroenterology first described the unifying syndrome in the 2003–2010s, with international consensus on the entity emerging in 2012–2015, the ACR/EULAR classification criteria published in 2019, and international management consensus in 2020. Presentations are heterogeneous and historically were diagnosed under organ-specific labels — Mikulicz disease (lacrimal + salivary), type 1 (lymphoplasmacytic) autoimmune pancreatitis, IgG4-related sclerosing cholangitis, retroperitoneal fibrosis (Ormond disease), Riedel thyroiditis, IgG4-related orbital and ophthalmic disease, tubulointerstitial nephritis, aortitis and periaortitis, hypertrophic pachymeningitis, sclerosing mediastinitis, and pulmonary involvement. The 2024 MITIGATE Phase 3 trial of inebilizumab (anti-CD19 B-cell depletion) met its primary endpoint for relapse prevention, with FDA approval expected/recent for IgG4-RD — a landmark moment for the field. Thirty-fourth deliberate non-elevation.

Neuromyelitis optica spectrum disorder is a rare antibody-mediated autoimmune disease of the central nervous system, distinct from multiple sclerosis. Roughly 75-80% of cases are driven by AQP4-IgG, autoantibodies against the aquaporin-4 water channel on astrocytes; antibody binding recruits complement and produces astrocytic injury with secondary demyelination. MOG antibody-associated disease (MOGAD) was formerly grouped with NMOSD and was re-classified under 2023 international consensus criteria. Classic clinical syndromes: severe optic neuritis (often bilateral), longitudinally extensive transverse myelitis (≥3 vertebral segments on MRI), area postrema syndrome (intractable hiccups, nausea, vomiting). 2015 IPND diagnostic criteria + 2023 NMOSD/MOGAD international consensus. Acute relapse: IV methylprednisolone pulses ± plasma exchange (early PLEX improves outcomes). Maintenance has been transformed since 2019 by four FDA approvals for AQP4+ disease: eculizumab (PREVENT 2019, C5 complement inhibitor), inebilizumab (N-MOmentum 2020, anti-CD19), satralizumab (SAkuraStar + SAkuraSky 2020, anti-IL-6R, SC monthly), and ravulizumab (CHAMPION-NMOSD 2024, longer-acting C5). Rituximab off-label widely used. MS DMTs (interferon-beta, natalizumab, fingolimod) WORSEN NMOSD — load-bearing safety thread. Guthy-Jackson Charitable Foundation + Sumaira Foundation patient organizations. Thirty-first deliberate non-elevation.

Sarcoidosis is a multisystem granulomatous inflammatory disease of unknown etiology characterized by non-caseating granulomas, most commonly in the lungs (>90%) but with capacity to involve essentially any organ — skin, eyes, heart, nervous system, liver, kidneys, joints. Presentations range from asymptomatic incidental hilar lymphadenopathy through the classic acute Löfgren's syndrome (erythema nodosum + bilateral hilar lymphadenopathy + arthralgia/fever, generally self-resolving with good prognosis) to chronic progressive multisystem disease with organ-threatening complications. Diagnosis: tissue biopsy showing non-caseating granulomas + exclusion of TB, fungal infection, beryllium exposure, hypersensitivity pneumonitis. Standard-of-care: observation in asymptomatic disease; glucocorticoids (prednisone 20-40 mg/day pulmonary, higher for neurosarcoidosis or cardiac); methotrexate first-line steroid-sparing; azathioprine + mycophenolate + leflunomide additional steroid-sparing options; hydroxychloroquine for cutaneous and hypercalcemia; TNF inhibitors (infliximab + adalimumab) for refractory or severe organ-threatening disease; emerging NRP2-targeting candidate efzofitimod (aTyr Pharma, EFZO-FIT Phase 3 readout 2025) — first novel sarcoidosis-specific Phase 3 in decades. VITAMIN D AVOIDANCE LOAD-BEARING — sarcoid macrophages constitutively activate vitamin D outside renal regulation; supplementation can precipitate hypercalcemia. Cardiac sarcoidosis carries sudden cardiac death risk. ATS/ERS/WASOG joint statement + AAN neurosarcoidosis + Foundation for Sarcoidosis Research. Thirty-second deliberate non-elevation.

Stargardt disease is the most common form of inherited juvenile macular degeneration — a bilateral, progressive central vision loss most often caused by biallelic mutations in the ABCA4 gene (autosomal recessive), with rarer dominant forms via ELOVL4 and PROM1. Onset typically falls between ages 6 and 20, though presentation can extend later. Trajectory: gradual loss of central vision, color vision changes, photophobia, characteristic pisciform yellow flecks at the posterior pole on funduscopy progressing to bull's-eye macular atrophy. Diagnostics: dilated funduscopy, OCT, fundus autofluorescence (the 'dark choroid sign' on fluorescein angiography is a recognized hallmark), full-field ERG, EOG, genetic testing across ABCA4 + ELOVL4 + PROM1. No FDA-approved disease-modifying therapy exists as of 2026. VITAMIN A AVOIDANCE is the load-bearing safety thread — vitamin A is the substrate that becomes toxic A2E in ABCA4-related Stargardt, and supplementation can accelerate disease progression. UV protection + sun avoidance + low vision rehabilitation are standard. Emixustat SeaSTAR Phase 3 FAILED 2022. Gildeuretinol (ALK-001 deuterated vitamin A) Phase 3 TEASE positive 2024 — leading DMT candidate. AAV-ABCA4 gene therapy (StarGen + OCU410 + dual-vector approaches; ABCA4 too large for single AAV) and hESC-RPE transplant (Astellas/Ocata ASTRO-01-Stargardt + UCL/King's + jCyte) in earlier-phase trials. Foundation Fighting Blindness principal US patient organization. Genetic counseling required. No peptide has a defensible Stargardt discovery-card case. Twenty-ninth deliberate non-elevation.

Wilson disease is an autosomal recessive inherited disorder of copper metabolism caused by biallelic mutations in ATP7B on chromosome 13 — over 700 known pathogenic variants encode a defective copper-transporting ATPase in hepatocytes that cannot excrete copper into bile or load it onto ceruloplasmin. Progressive hepatic copper accumulation with spillover into CNS (basal ganglia + brainstem), cornea (Kayser-Fleischer rings on Descemet's membrane), kidney, and red cell line. Presentations span hepatic (steatohepatitis to cirrhosis to acute liver failure, sometimes as fulminant hepatic failure with Coombs-negative hemolysis), neurologic (tremor, dystonia, parkinsonism, dysarthria, cerebellar signs), psychiatric (depression, personality change, psychosis), and mixed. Diagnostics anchor on serum ceruloplasmin (low <20 mg/dL in ~95%), 24-hour urinary copper (>100 µg, or >40 µg pre-symptomatic), Kayser-Fleischer rings on slit-lamp (~95% of neurologic Wilson, ~50% hepatic), liver biopsy with hepatic copper quantification (>250 µg/g dry weight diagnostic), ATP7B genetic testing, and the Leipzig score. Standard of care: chelation — D-penicillamine, trientine tetrahydrochloride (Cuvrior FDA 2022), zinc salts (zinc acetate Galzin FDA 1997 maintenance gold standard) — plus strict low-copper diet, mandatory family screening of first-degree relatives, and liver transplant for acute liver failure or refractory decompensated disease. AASLD 2023 + EASL 2012 + APASL. No peptide has Wilson-disease evidence. Thirtieth deliberate non-elevation.

CIDP is an acquired chronic immune-mediated demyelinating polyneuropathy of the peripheral nerves — symmetric proximal and distal weakness, sensory loss, areflexia, and characteristic cytoalbuminologic dissociation on CSF testing. Nerve conduction studies show demyelinating features (conduction block, temporal dispersion, prolonged distal latencies, reduced conduction velocities). Diagnostic frameworks: EFNS/PNS 2010 and 2021 + EAN/PNS 2021 revised criteria + INCAT and ONLS scores for disability tracking. Standard of care multi-tiered: IVIG (intravenous immunoglobulin, ICE trial 2008 Lancet Neurology), SCIg (subcutaneous immunoglobulin, PATH trial 2018 Lancet Neurology, Hizentra FDA-approved for CIDP maintenance 2018), corticosteroids, and plasmapheresis remain first-line; efgartigimod (Vyvgart Hytrulo for CIDP, FDA-approved June 2024 via ADHERE Phase 3 trial) is the first FcRn antagonist approved for CIDP and is changing the maintenance landscape, with nipocalimab and rozanolixizumab in trials. Rituximab off-label for refractory CIDP and nodal/paranodal antibody subtypes (anti-NF155, anti-NF186, anti-Contactin-1, anti-CASPR1 — these subtypes often respond preferentially to rituximab over IVIG). AAN 2024 + EFNS/PNS 2021 + EAN/PNS 2021 + GBS/CIDP Foundation International. No peptide in the Juno library has a defensible CIDP discovery-card case. Twenty-seventh deliberate non-elevation.

Myasthenia gravis (MG) is an antibody-mediated autoimmune disease of the neuromuscular junction. Circulating IgG against the acetylcholine receptor (~85% of cases), against muscle-specific kinase (~5-10%), against LRP4 (~1-3%), or in the seronegative subset blocks neuromuscular transmission and accelerates receptor turnover, producing the disease's signature fluctuating weakness with fatigability — ocular onset with ptosis and diplopia, bulbar involvement with dysphagia and dysarthria, proximal limb weakness, and in serious cases respiratory compromise requiring intubation (myasthenic crisis). The modern MG arsenal is one of neurology's most dynamic — pyridostigmine for symptomatic management, corticosteroids and steroid-sparing immunosuppressants for disease modification, thymectomy for non-thymomatous AChR-positive generalized MG (MGTX 2016 NEJM), rituximab particularly transformative for MuSK-positive disease, complement inhibitors eculizumab (REGAIN FDA Oct 2017) and ravulizumab (FDA Apr 2022) and zilucoplan (RAISE FDA Oct 2023), FcRn antagonists efgartigimod (ADAPT FDA Dec 2021) and rozanolixizumab (MycarinG FDA Jun 2023), with IVIG and plasmapheresis as bridging tools. MGFA classification + AAN 2020 + International Consensus Guidance 2021 update. Twenty-eighth deliberate non-elevation.

Behçet's disease is a systemic variable-vessel vasculitis with a classic triad of recurrent oral aphthous ulcers, genital ulcers, and uveitis — frequently accompanied by skin lesions (erythema nodosum, papulopustular eruption), arthritis, gastrointestinal involvement (terminal ileum ulceration that can mimic Crohn's), neurological involvement (neuro-Behçet's), and vascular involvement (deep vein thrombosis, pulmonary artery aneurysms, arterial vasculitis). Prevalence is highest along the historic Silk Road — Turkey, Iran, Israel, Japan, Korea — with strong HLA-B51 association. Disease typically presents in the 20s to 40s. Diagnosis follows ISGBD 1990 or ICBD 2014 criteria. Management is rheumatology-anchored per EULAR 2018: colchicine first-line, apremilast (Otezla, FDA 2019 via RELIEF Phase 3) for oral ulcers, adalimumab (FDA via VISUAL trials) for non-infectious uveitis, infliximab for severe uveitis + neuro-Behçet's + GI Behçet's, interferon-alpha for refractory ocular disease, azathioprine + cyclosporine + cyclophosphamide for severe disease. American Behçet's Disease Association is the principal patient organization. No peptide in the Juno library has a defensible Behçet's discovery-card case. Twenty-fifth deliberate non-elevation.

ANCA-associated vasculitis (AAV) is a family of necrotizing small-vessel vasculitides — granulomatosis with polyangiitis (GPA, formerly Wegener's), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA, formerly Churg-Strauss) — defined by anti-neutrophil cytoplasmic antibodies (ANCA) against proteinase-3 (PR3) or myeloperoxidase (MPO). The disease attacks small vessels in kidney (crescentic glomerulonephritis), lung (alveolar hemorrhage, granulomas, asthma in EGPA), upper airway (sinus disease in GPA), peripheral nerve, and skin. Standard of care has been reshaped by rituximab (RAVE 2010, MAINRITSAN 2014/2018), avacopan (FDA-approved October 2021 via ADVOCATE), mepolizumab for EGPA (FDA-approved December 2017 via MIRRA), benralizumab non-inferior to mepolizumab (MANDARA 2024), and the PEXIVAS 2020 NEJM trial which moved the field away from routine plasma exchange and toward reduced-dose glucocorticoid regimens. Mortality has dropped from ~90% at 2 years pre-cyclophosphamide era to <20% at 5 years modern era; 30-50% 5-year relapse rate. KDIGO 2024 + EULAR 2023 + ACR/EULAR 2022 + Vasculitis Foundation. Peptides do not have a defined role in AAV. Twenty-sixth deliberate non-elevation.

Giant cell arteritis (GCA) is a granulomatous large-vessel vasculitis of the aorta and its branches — classically the temporal artery — presenting with new headache, jaw claudication, scalp tenderness, polymyalgic symptoms, and most dangerously vision loss from anterior ischemic optic neuropathy. GCA vision symptoms are a minutes-to-hours emergency: untreated, the affected eye can blind permanently, and the contralateral eye follows in 25-50% of cases within days. Acute management is high-dose prednisone (40-60 mg, or 60-80 mg with visual involvement) started on clinical suspicion before biopsy confirmation, with IV methylprednisolone pulses for vision-threat. Polymyalgia rheumatica (PMR) shares the spectrum — bilateral shoulder + hip stiffness, age >50, elevated ESR + CRP, often morning-predominant; 15-20% of PMR patients develop GCA. The steroid-sparing landscape has been transformed: tocilizumab (Actemra) FDA 2017 for GCA via GiACTA — the first non-steroid agent with replicated efficacy in vasculitis. Sarilumab (Kevzara) FDA February 2023 for PMR via SAPHYR — the first FDA-approved DMT for PMR after sixty years of prednisone-only management. Upadacitinib (Rinvoq) JAK1 inhibitor SELECT-GCA Phase 3 positive readout 2024-2025, FDA submission expected. Methotrexate older steroid-sparing alternative. ACR/EULAR 2022 GCA criteria + ACR/EULAR 2012 PMR criteria + EULAR 2015 + ACR 2024 vasculitis guidelines + Vasculitis Foundation. No peptide in the Juno library has GCA or PMR evidence. Twenty-fourth deliberate non-elevation.

Catecholamine-secreting neuroendocrine tumors arising from chromaffin cells of the adrenal medulla (pheochromocytoma) or extra-adrenal sympathetic/parasympathetic paraganglia (paraganglioma). Classic triad — episodic headache + palpitations + diaphoresis on a backdrop of sustained or paroxysmal hypertension — but ~10% are normotensive and ~10% are incidentalomas. Hereditary fraction ~40% per modern genetic testing studies: MEN2A and MEN2B (RET; medullary thyroid carcinoma + hyperparathyroidism / mucosal neuromas + Marfanoid habitus), VHL (hemangioblastomas + retinal angiomas + clear-cell RCC + pancreatic NETs), NF1 (neurofibromas + CNS tumors), and the SDHx hereditary paraganglioma syndromes (SDHA / SDHB / SDHC / SDHD; SDHB carries the highest malignant potential ~30-50%), plus MAX, TMEM127, FH, EPAS1 / HIF-2α, MDH2, and the 3PA association (pituitary adenoma with PPGL). Diagnostics: plasma free metanephrines or 24-hour urine metanephrines (>95% sensitivity); CT or MRI abdomen for localization; 68Ga-DOTATATE PET (modern preferred imaging, including for metastatic disease) supplanting 123I-MIBG for most contexts; germline genetic testing recommended for ALL PPGL patients per Endocrine Society 2014 / 2024 + ESE 2020 (decision is based not on family history alone but on the high hereditary fraction). Standard of care: alpha-blockade (phenoxybenzamine or doxazosin) for ≥10-14 days pre-operatively → adrenal-sparing laparoscopic adrenalectomy (or open for large or extra-adrenal tumors); peri-op fluid loading; beta-blocker only AFTER alpha-blockade established (alone causes unopposed alpha-vasoconstrictive crisis); metastatic / unresectable disease — 177Lu-DOTATATE Lutathera peptide receptor radionuclide therapy (PRRT) for somatostatin-receptor-positive tumors, belzutifan for VHL / SDHB pseudohypoxia HIF-2α pathway, sunitinib or cabozantinib multi-kinase, 131I-MIBG. 177Lu-DOTATATE Lutathera is the one TRUE peptide therapy with a PPGL indication — distinct from community peptide framing. Endocrine Society 2014 / 2024 + ESE 2020 + Pheo Para Alliance + NIH-Karel Pacak group. **Editorial**: BPC-157 pro-angiogenic counter-directional to anti-angiogenic PPGL therapy (VHL / SDHB pseudohypoxia subset); GH-axis peptides contraindicated by 3PA pituitary-adenoma overlap + IGF-1 mitogenic tumor-bearing concern; SEMAGLUTIDE FDA BOXED WARNING contraindicates personal or family history of MEDULLARY THYROID CARCINOMA or MEN2 — relevant to the ~5-10% PPGL hereditary syndrome subset; perioperative GLP-1 hold for aspiration risk before elective adrenalectomy. Fifty-third deliberate non-elevation.

Prolactin-secreting pituitary adenoma — the MOST COMMON pituitary tumor, accounting for ~40-50% of functional pituitary adenomas. The clinical syndrome diverges sharply by sex and tumor size. Premenopausal women predominate as microadenomas (<10mm; ~90% of female prolactinomas; F:M ratio ~10:1 in microadenomas) — menstrual irregularity, galactorrhea, infertility, decreased libido, hypogonadism. Men and postmenopausal women more often present with macroadenomas (>10mm) — bitemporal hemianopsia from optic chiasm compression, headache, hypopituitarism from compression of normal pituitary tissue, ED, libido changes. Pituitary apoplexy (sudden hemorrhage / infarction) is a neurosurgical emergency with severe headache + visual loss + ophthalmoplegia + potential adrenal crisis. Mechanism of hypogonadism: PRL acts at the hypothalamus to suppress GnRH pulsatility → downstream LH / FSH collapse → secondary hypogonadism with low or inappropriately-normal gonadotropins. KEY EDITORIAL POINT: when PRL normalizes on dopamine agonist therapy, the HPG axis recovers SPONTANEOUSLY in most patients — the hypogonadism is driven by upstream PRL excess, not by primary gonadotropin-axis defect. Diagnostics: morning fasting PRL (>200 ng/mL strongly suggests; 25-200 ng/mL warrants differential workup); pituitary MRI with and without contrast; differential exclusion is non-negotiable — pregnancy (beta-hCG), medications (antipsychotics especially risperidone, also haloperidol, metoclopramide, verapamil, opioids, estrogen, SSRIs to a lesser degree), primary hypothyroidism (TSH; elevated TRH cross-stimulates lactotrophs), macroprolactin assay (biologically inactive PRL-IgG complex inflates the number without causing the syndrome), stalk effect (large non-functioning adenomas disrupting dopamine inhibition); macroadenomas additionally require visual field testing (Humphrey or Goldmann perimetry) + full anterior pituitary hormone panel (cortisol, IGF-1, free T4 + TSH, gonadal axis). **UNIQUE PARADIGM**: DOPAMINE AGONIST FIRST-LINE — vs. surgery-first for every other pituitary adenoma (acromegaly, Cushing's disease, non-functioning macroadenomas). Cabergoline preferred (twice-weekly oral; longer half-life; better tolerated; 80-90% macroadenoma shrinkage rate); bromocriptine alternative (older agent; multiple-daily dosing; longest pregnancy safety record); quinagolide / Norprolac non-ergot DA available EU but not FDA-approved US; surgery / radiation reserved for DA-resistant (~10-20%) or DA-intolerant cases. Pregnancy management: microprolactinomas often discontinue DA at conception; macroprolactinomas may continue DA or pre-conception debulking surgery — co-managed endocrinology + REI. Long-term cabergoline cardiac valve evaluation: baseline + periodic echocardiogram past 2 years (historical cumulative-dose valvulopathy concern from Parkinson's-dose cabergoline; lower endocrine doses appear lower risk but not zero). Endocrine Society 2011 + 2024 update + Pituitary Network Association + AANS. **Editorial**: kisspeptin + gonadorelin push GnRH against an actively-PRL-suppressed hypothalamus — wrong direction; load-bearing lever is PRL suppression at lactotroph source (cabergoline), not upstream GnRH stimulation. GH-axis peptides (CJC-1295 + ipamorelin) stimulate same pituitary that bears the tumor — uncharacterized in adenoma-bearing gland. BPC-157 + NMN no pituitary-adenoma characterization. Fifty-fourth deliberate non-elevation.

Rare autosomal dominant tumor predisposition syndrome (germline MEN1 mutation 11q13 encoding menin) with >95% lifetime penetrance by age 50. The 'three Ps' define the clinical syndrome: parathyroid (~95% primary hyperparathyroidism — usually first manifestation in 20s-30s), pituitary (~30-40% anterior pituitary adenomas — prolactinoma most common; also GH-secreting causing acromegaly, ACTH-secreting causing Cushing's disease, and non-functioning), and pancreatic/duodenal NETs (gastrinomas driving Zollinger-Ellison; insulinomas; glucagonomas; VIPomas; non-functioning pNETs — ~50% lifetime pancreatic NET risk). Additional manifestations: foregut carcinoids (thymic NETs especially aggressive in male smokers, bronchial, gastric), adrenocortical tumors (~40% usually non-functioning), facial angiofibromas + collagenomas + lipomas (cutaneous), meningiomas + ependymomas (CNS). Diagnostic criteria: ≥2 of 3 main tumor types, or 1 main tumor in first-degree relative of MEN1 patient, or pathogenic germline MEN1 variant. Cascade genetic testing of first-degree relatives is part of the care model. Surveillance per Thakker 2012 Clinical Practice Guidelines + Endocrine Society + ESE: annual calcium + PTH from age 8; gastrin from age 20; glucose/insulin/proinsulin from age 5; prolactin + IGF-1 from age 5; pancreatic imaging (MRI + EUS) every 1-3 years from age 10; pituitary MRI every 3-5 years from age 5; thymic/bronchial imaging every 1-2 years from age 15-20. Management: subtotal vs total parathyroidectomy for primary HPT (recurrence high — subtotal preferred; cinacalcet adjunct); high-dose PPIs (omeprazole, lansoprazole) for ZES gastrinomas; surgical resection for insulinomas + selected NETs; SSAs (octreotide, lanreotide) for symptomatic functioning NETs; DA therapy for prolactinoma; standard pituitary management for GH-secreting or ACTH-secreting adenomas. 177Lu-DOTATATE Lutathera PRRT (NETTER-1 + NETTER-2) for somatostatin-receptor-positive metastatic NETs from pancreatic/duodenal primaries = one TRUE peptide therapy with MEN1-relevant indication. AMEN (Association for Multiple Endocrine Neoplasia Disorders) is patient advocacy. **Editorial**: GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) functionally contraindicated by 30-40% pituitary adenoma risk + tesamorelin FDA label contraindicates pituitary tumor history; SEMAGLUTIDE coordinated-care decision given ~50% lifetime pancreatic NET risk + chart-clarity issue (GLP-1 boxed warning names MEN2 specifically, not MEN1 — must be explicit in chart); BPC-157 angiogenesis profile uncharacterized in multi-organ tumor surveillance population; NMN does not engage menin biology. Fifty-fifth deliberate non-elevation.

Von Hippel-Lindau syndrome is an autosomal dominant tumor predisposition syndrome caused by germline pathogenic variants in the VHL tumor suppressor gene on chromosome 3p25, with >90% lifetime penetrance by age 65. Molecular pathology = HIF-2α pseudohypoxia: the VHL protein normally targets HIF-α subunits for proteasomal degradation under normoxic conditions; loss-of-function variants produce constitutive HIF-2α activity and downstream VEGF / EPO / GLUT1 overdrive, driving the tumor spectrum. Manifestations: CNS hemangioblastomas (cerebellum + brainstem + spinal cord — multiple tumors across lifespan); retinal angiomas (often first manifestation in childhood; vision-loss risk from exudation and hemorrhage); clear cell renal cell carcinoma (cumulative lifetime risk ~70%; bilateral and multifocal; LEADING CAUSE OF VHL MORTALITY); pheochromocytoma and paraganglioma (~20%, concentrated in Type 2 genotypes); pancreatic NETs and serous cystadenomas (~15-20%); endolymphatic sac tumors (cause hearing loss); epididymal or broad-ligament cystadenomas. Genotype-phenotype: Type 1 (truncating variants and large deletions — low pheo risk); Type 2 (missense — high pheo risk) subdividing into 2A (low ccRCC), 2B (high ccRCC), and 2C (pheo-only); Chuvash polycythemia is the autosomal recessive variant. Diagnostic criteria: clinical (≥1 hemangioblastoma + ≥1 visceral tumor OR ≥2 hemangioblastomas) OR pathogenic germline VHL variant. Surveillance per VHL Alliance / Stewart 2014 / NIH-Linehan-group: annual ophthalmologic + neurologic exam from infancy; annual urine catecholamines/metanephrines from age 5; annual abdominal MRI from age 16; brain/spine MRI every 2 years from age 16; audiometry every 2-3 years from age 5. Management: nephron-sparing partial nephrectomy / cryoablation / RFA / surveillance for ccRCC (3cm rule); microsurgical / Gamma Knife / observation for CNS hemangioblastomas; laser photocoagulation / cryotherapy / anti-VEGF for retinal angiomas; pheochromocytoma surgery per PPGL guidelines. **BELZUTIFAN (Welireg, Merck) FDA-approved August 2021** = first-in-class HIF-2α inhibitor for VHL-associated RCC + CNS hemangioblastoma + pancreatic NET (LITESPARK-004); FDA expanded indication December 2023 to advanced ccRCC (LITESPARK-005). Sunitinib, cabozantinib, pazopanib as multi-kinase TKI options. 177Lu-DOTATATE Lutathera PRRT for SSTR-positive pancreatic NETs = one TRUE peptide therapy in VHL portfolio. **EDITORIAL**: BPC-157 PRO-ANGIOGENIC VEGF / NO / eNOS modulation is mechanistically OPPOSITE to belzutifan's HIF-2α inhibition — the sharpest peptide contradiction in the library (Tier 2, not the usual Tier 3 contraindication ceiling). GH-axis peptides (CJC-1295, tesamorelin, ipamorelin): IGF-1 mitogenicity in multi-organ tumor-surveillance population; tesamorelin label contraindicates active malignancy (VHL routinely manages indolent tumors under surveillance). Semaglutide: coordinated-care decision given pancreatic NET surveillance overlap. NMN: no engagement with VHL HIF biology. VHL Alliance patient advocacy. Fifty-sixth deliberate non-elevation.

Autosomal dominant multi-organ tumor syndrome (historically LAMB / NAME syndrome): ~70% germline PRKAR1A on 17q24 encoding PKA regulatory subunit 1α; ~30% PRKACA or other causes; rare familial PRKAR1B. Loss of PKA-R1α function dysregulates cAMP-PKA signaling and produces a characteristic constellation of endocrine and non-endocrine neoplasia plus pigmentary lesions. Stratakis criteria 2001/2021: 2 of 12 major features, OR 1 major + germline PRKAR1A, OR 1 major + first-degree CNC relative. The 12 major features: SPOTTY SKIN PIGMENTATION (lentigines + blue nevi, characteristically on face + lips + conjunctiva + sclera); PRIMARY PIGMENTED NODULAR ADRENOCORTICAL DISEASE (PPNAD) causing ACTH-INDEPENDENT CUSHING'S SYNDROME in ~25-50% of patients (atypical presentation often cyclical or paradoxically increasing on Liddle's test rather than dexamethasone-suppressed); CARDIAC MYXOMAS in ~30-60% (ANY chamber + ANY age + often multiple + recurrent — MAJOR MORTALITY DRIVER from embolic stroke + intracardiac obstruction + sudden death); cutaneous myxomas (eyelids + ears + nipple + extremities); mammary myxoid fibroadenomas; LARGE CELL CALCIFYING SERTOLI CELL TUMORS (LCCSCT) in ~30-40% of males (bilateral, mostly benign, estrogen-secreting → gynecomastia + precocious puberty); GH-SECRETING PITUITARY ADENOMA in ~10-15% → acromegaly; thyroid nodules + thyroid carcinoma (papillary, follicular); psammomatous melanotic schwannoma (characteristic CNC tumor); osteochondromyxoma (rare). Surveillance per Stratakis + Carney Complex Foundation, LIFELONG and multi-organ: annual ECHOCARDIOGRAM (atrial AND ventricular AND multiple foci — aggressive resection at detection given recurrence risk); urinary free cortisol + LDDST every 6-12 months from childhood; testicular ultrasound annually from age 5; thyroid ultrasound annually; IGF-1 + GH annually from puberty; neurologic-complaint imaging (melanotic schwannoma); cutaneous exam. Management: aggressive cardiac myxoma resection at detection (single most important intervention); bilateral adrenalectomy for PPNAD-driven Cushing's (cortisol replacement lifelong); orchiectomy / testicular-sparing surgery for LCCSCT; transsphenoidal surgery + SSAs + GH receptor antagonists for acromegaly; thyroid surgery. Mortality dominated by cardiac myxoma complications. Carney Complex Foundation patient advocacy; Stratakis NIH group reference center; Endocrine Society + ESE. **Editorial**: GH-axis peptides (CJC-1295, tesamorelin, ipamorelin) TIER 2 MECHANISTICALLY CONTRAINDICATED — GHRH-receptor signaling activates Gs / cAMP / PKA, the EXACT pathway PRKAR1A loss-of-function constitutively dysregulates. Three independent vectors stack: (1) tesamorelin FDA label contraindicates pituitary tumor history; (2) ~10-15% CNC baseline GH-secreting adenoma risk; (3) upstream stimulus on already-dysregulated pathway. BPC-157 pro-angiogenic overlaps cardiac myxoma surveillance. NMN general-aging doesn't engage PRKAR1A. Fifty-ninth deliberate non-elevation.

Autoimmune-mediated inflammation of the pituitary gland and/or pituitary stalk causing pituitary dysfunction. Subtypes by anatomic involvement: LYMPHOCYTIC ADENOHYPOPHYSITIS (anterior pituitary only — classic primary form; female predominance ~6:1; presents in late pregnancy or postpartum); LYMPHOCYTIC INFUNDIBULONEUROHYPOPHYSITIS (stalk + posterior pituitary — presents primarily with AVP-D); LYMPHOCYTIC PANHYPOPHYSITIS (both compartments). Pathology: dense lymphocytic + plasma cell infiltrate of the pituitary; eventual fibrosis and atrophy. Etiologies: PRIMARY AUTOIMMUNE (classic non-ICI form; pregnancy/postpartum predilection; associated with Hashimoto's + T1DM + Addison's + autoimmune polyglandular syndromes); **IMMUNE CHECKPOINT INHIBITOR (ICI)-INDUCED = MODERN EPIDEMIC** — ipilimumab (anti-CTLA-4) most strongly associated; nivolumab + pembrolizumab (anti-PD-1) also cause it; combination ipilimumab + nivolumab highest incidence ~10-17%; presents weeks to months after ICI initiation; IgG4-RELATED HYPOPHYSITIS (overlapping with IgG4-RD spectrum); GRANULOMATOUS HYPOPHYSITIS (sarcoidosis, TB, syphilis, Langerhans cell histiocytosis); XANTHOMATOUS HYPOPHYSITIS (rare). Clinical features: headache (mass-effect from inflammatory swelling — sella enlargement); visual disturbances (chiasmal compression — visual field defects, decreased acuity); adenohypophyseal dysfunction (ACTH deficiency = adrenal crisis risk; central hypothyroidism; central hypogonadism; GH deficiency; hyperprolactinemia from stalk effect or hypoprolactinemia from lactotroph destruction); infundibuloneurohypophysitis = AVP-D. Diagnostics: pituitary MRI with gadolinium = thickened pituitary stalk + symmetric pituitary enlargement + diffuse gadolinium enhancement + loss of posterior bright spot (if posterior involved); biochemical workup (full anterior pituitary axis screen + cortisol axis priority; serum sodium + osmolality for AVP-D); anti-pituitary antibodies (limited clinical utility); biopsy (reserved for atypical cases). Differential: pituitary adenoma, craniopharyngioma, metastasis, sarcoidosis, IgG4-RD. For ICI-induced: ICI exposure history with appropriate timing makes diagnosis clinical. Management: HORMONE REPLACEMENT BY DEFICIENT AXIS — hydrocortisone (CORTISOL REPLACEMENT IS LOAD-BEARING + STRESS-DOSE PROTOCOLS); levothyroxine; sex hormones; desmopressin if AVP-D involved; somatropin if confirmed adult GHD. Corticosteroids for active inflammation in primary autoimmune disease (historically high-dose prednisone 0.5-1 mg/kg tapered over months; mixed efficacy data); azathioprine + methotrexate + rituximab as steroid-sparing options. **ICI-induced consensus shift (last 5 years)**: HIGH-DOSE CORTICOSTEROIDS NO LONGER ROUTINELY RECOMMENDED for ICI hypophysitis (does NOT improve recovery of pituitary function); replacement-only approach for most cases; HOLD ICI for moderate-severe; restart ICI typically possible after adrenal axis stable on replacement. Endocrine Society + ESE 2018 + EAU Pituitary Working Group + Society for Immunotherapy of Cancer (SITC) toxicity guidelines + Pituitary Network Association. **Editorial**: GH-axis peptides (CJC + tesa + ipa) Tier 2 — pituitary IS the failed organ from inflammation/destruction; same archetypal wrong-direction as hypopituitarism + tesa label contraindicates pituitary tumor history (hypophysitis presents AS sellar mass on imaging). TA-1 Rule 6 wrong-direction (T-cell activation in T-cell-mediated autoimmune destruction; compounded for ICI-induced — disease IS downstream of T-cell checkpoint release). LL-37 autoimmune-contraindication thread (documented autoantigen behavior). BPC-157 pro-angiogenic in actively inflamed pituitary. NMN no autoimmune-pituitary engagement. Sixtieth deliberate non-elevation.

Autosomal dominant vascular dysplasia driven by germline mutations in TGF-β/BMP signaling genes — ENG (HHT1 ~50%; endoglin), ACVRL1/ALK1 (HHT2 ~40%; activin receptor-like kinase 1), SMAD4 (HHT3 ~2%; juvenile polyposis-HHT overlap syndrome), GDF2/BMP9 (HHT4 rare). Disease driver = endothelial dysfunction producing fragile dilated vessels lacking proper intervening capillaries → telangiectasias (small mucocutaneous + visceral) and arteriovenous malformations (AVMs — large pulmonary, hepatic, cerebral, spinal). Curaçao Criteria 2020: 3+ definite, 2+ possible. Clinical features: recurrent spontaneous EPISTAXIS (universal; mean onset ~12 years; near-100% by 21); multiple telangiectasias (lips + oral cavity + face + fingers + tongue); visceral AVMs — pulmonary 30-50%, hepatic 30-70%, cerebral 10-20%, spinal rare, GI 50%+; family history. **PULMONARY AVMs (PAVMs)** = right-to-left shunt → STROKE + brain abscess (paradoxical embolism — even small PAVMs ≥3mm feeding artery require IR embolization), migraine, hypoxia, hemoptysis, spontaneous hemothorax. Cerebral AVMs: ~10-20%; hemorrhagic stroke risk. Hepatic AVMs: high-output cardiac failure + portal hypertension + biliary cholangiopathy. GI telangiectasias: chronic occult bleeding → iron deficiency anemia. ESS (Epistaxis Severity Score) 0-10 scale; severe nosebleeds dominate quality of life. **2024 PARADIGM SHIFT — BEVACIZUMAB (Avastin, anti-VEGF mAb) FDA-APPROVED JUNE 2024** as the FIRST DISEASE-MODIFYING THERAPY FOR HHT (via international expert consensus + ATAC trial data) — transformative for severe epistaxis + transfusion-dependent GI bleeding + high-output cardiac failure from hepatic AVMs. Anti-VEGF mechanism = blocks the angiogenic signaling that maintains and worsens HHT vasculature. Other management: PAVM embolization (IR gold standard); contrast bubble echocardiography every 5-10 years; cerebral MRI/MRA screening; epistaxis ladder (humidification → topical → laser → embolization → septodermoplasty → Young's procedure → systemic bevacizumab); iron supplementation + transfusions; antifibrinolytics (tranexamic acid). Pazopanib + other TKIs studied. Pregnancy: PAVMs can rupture and cause maternal death — screening + treatment before pregnancy is high-priority; estrogen-driven worsening; high-risk obstetrics. Genetic testing + family cascade screening. International HHT Foundation + Cure HHT patient advocacy; 2020 international guidelines update (Faughnan et al.); Curaçao Criteria 2020. **Editorial**: BPC-157 + TB-500 TIER 2 SHARP MECHANISTIC CONTRADICTION with bevacizumab — both community-marketed as pro-angiogenic via VEGF + endothelial sprouting; bevacizumab is anti-VEGF; this is the CLEANEST peptide × disease contradiction in the Juno library (cleaner than VHL because HHT IS vascular dysplasia, not a tumor syndrome with vascular involvement). GH-axis trio (CJC + tesa + ipa) Tier 3 (IGF-1 effects on endothelial biology + VEGF expression uncharacterized in HHT genetically-dysregulated vasculature; bevacizumab interaction). NMN no engagement. Sixty-first deliberate non-elevation.

Sporadic post-zygotic mosaic disorder caused by activating mutations in GNAS (GNAS1 gene encoding the α-subunit of the stimulatory G protein Gsα) — NOT inherited; arises from somatic mutations occurring post-fertilization, distributing variably across tissues (GNAS sequencing on peripheral blood often negative because of mosaicism; diagnostic test requires affected-tissue sampling). Classic triad: (1) FIBROUS DYSPLASIA OF BONE (FD) — monostotic, polyostotic, or panostotic; bone pain + fractures + deformities + cranial nerve compression in skull-base disease + scoliosis; (2) CAFÉ-AU-LAIT MACULES — 'coast of Maine' irregular borders, midline-respecting, often on side of FD involvement; (3) HYPERFUNCTIONING ENDOCRINOPATHIES driven by constitutive Gsα-cAMP-PKA signaling — gonadotropin-independent peripheral PRECOCIOUS PUBERTY (most common endocrine manifestation; girls present with vaginal bleeding + breast development at very young ages, sometimes infancy; boys testicular enlargement + autonomous androgen production; ovarian cysts + autonomous estrogen); HYPERTHYROIDISM (~30-50%, multinodular hyperfunctioning); GH-SECRETING PITUITARY ADENOMA → ACROMEGALY or PEDIATRIC GIGANTISM (~10-20%); CUSHING'S syndrome from adrenal hyperplasia (NEONATAL usually fatal if untreated); HYPOPHOSPHATEMIC RICKETS / OSTEOMALACIA from FGF23 produced by FD tissue. Other: hepatobiliary disease (cholestasis); cardiac abnormalities (arrhythmias, sudden death); pancreatic disease; intestinal polyps. Diagnosis: clinical + radiologic (bone 'ground glass' appearance + skeletal survey + bone scintigraphy) + endocrine workup + GNAS sequencing on AFFECTED TISSUE (not blood). Standard of care: NO CURE for FD itself; supportive bone management (orthopedic surgery for deformity + fracture; IV bisphosphonates pamidronate / zoledronate reduce bone turnover but don't reverse FD; denosumab selected; pain management); endocrine management of each hyperfunctioning axis specifically — letrozole or tamoxifen (anti-estrogen) + GnRH analog (after central puberty engages) for precocious puberty; methimazole + radioiodine or thyroidectomy for hyperthyroidism; transsphenoidal surgery + SSAs + GHRA pegvisomant for acromegaly; surgical adrenalectomy for Cushing's; phosphorus + activated vitamin D + **BUROSUMAB (Crysvita, anti-FGF23 antibody)** FDA-approved for tumor-induced osteomalacia in selected cases. Surveillance: annual endocrine panel (TSH + IGF-1 + cortisol + sex hormones + phosphate + 25-OH vitamin D + bone markers); annual eye exam if skull-base FD (optic nerve compression); periodic dental (mandibular FD); audiology if temporal bone FD; baseline + interval skeletal imaging; CT/MRI for skull-base symptoms. PEDIATRIC ONSET typical age 2-5 years; some patients diagnosed in infancy with neonatal Cushing's. FD Foundation + McCune-Albright Network patient advocacy; Pediatric Endocrine Society + Endocrine Society guidelines. **Editorial**: This is the THIRD substrate in the cAMP-PKA-driver family (after Carney complex's PRKAR1A loss-of-function and Cushing's disease at the corticotroph) and the MOST DIRECT — the GNAS activating mutation IS the pathway driver, constitutively activating Gsα → cAMP → PKA in any mutation-carrying tissue. **GH-axis trio (CJC + tesa + ipa) TIER 2 MECHANISTICALLY CONTRAINDICATED** — GHRH-receptor signaling at the somatotroph runs through Gsα-cAMP-PKA, the EXACT pathway MAS constitutively dysregulates. Three converging vectors: (1) tesamorelin FDA label contraindicates pituitary tumor history; (2) ~10-20% MAS baseline GH-secreting adenoma rate (HIGHER than CNC); (3) direct pathway overlap. BPC-157 pro-angiogenic in multi-hyperfunctioning-tumor body. NMN no GNAS engagement + general-aging framing-mismatch for pediatric-onset syndrome. Sixty-second deliberate non-elevation.

Complex multi-system genetic disorder caused by loss of expression of paternally-inherited genes on chromosome 15q11-q13 (PWS critical region containing SNRPN + necdin + MAGEL2 + MKRN3 + others). Three molecular mechanisms: paternal deletion (~70%, most common), maternal uniparental disomy (~25%), imprinting defect (~3-5%). Methylation testing of SNRPN locus is diagnostic gold standard (detects all 3 mechanisms). Developmental phases: NEONATAL = severe hypotonia + poor feeding + failure to thrive + cryptorchidism in males + characteristic facies (NG feeding required; universal hypogonadotropic hypogonadism). EARLY CHILDHOOD = gradual tone improvement followed by DEFINING TRANSITION TO HYPERPHAGIA age 2-5 (insatiable food seeking + hoarding + extreme food-related behaviors). ADOLESCENCE/ADULTHOOD = continued hyperphagia → morbid obesity if uncontrolled + short stature from GHD + incomplete puberty + learning disabilities (IQ typically 60-70) + behavioral/psychiatric (OCD-like + skin picking + rigidity + outbursts + depression + psychosis especially mUPD subtype) + OSA + scoliosis + osteoporosis. Universal GH deficiency; ~10-15% central adrenal insufficiency; ~25% central hypothyroidism. **STANDARD-OF-CARE PEPTIDE THERAPY = SOMATROPIN (recombinant human GH) — FDA-APPROVED FOR PWS 2000**; administered from infancy / early childhood; established benefits on growth + body composition + motor function + cognition. **This is itself a peptide therapy — the load-bearing one in PWS, distinct from community peptide framing.** Juno covers somatropin as standard-of-care framing; community peptides are not adjuncts or substitutes. Other management: NG feeding neonatal; **STRICT FOOD SECURITY ENVIRONMENT (locked food access + supervised meals + structured routine)** is the load-bearing non-pharmacologic intervention; sex hormone replacement (testosterone or estrogen + progesterone); hydrocortisone if adrenal insufficiency; levothyroxine if hypothyroidism; sleep study + CPAP for OSA; behavioral / cognitive support; speech/OT/PT; calcium + vitamin D + DEXA. **Hyperphagia-targeting landscape (NO FDA-approved hyperphagia-specific therapy)**: setmelanotide DAYBREAK Phase 3 MISSED primary endpoint 2022; DCCR / dicamba DESTINY-PWS missed primary endpoint 2022 + resubmitted via subgroup analysis 2024; intranasal oxytocin + carbetocin (PWS-specific oxytocin analog) mixed trial data; semaglutide / GLP-1 agonists used off-label in PWS clinics. FPWR + IPWSO + PWS-USA + Foundation for Prader-Willi Research patient advocacy + patient assistance. Endocrine Society + Pediatric Endocrine Society guidelines + 2013 GH consensus statement. **Editorial**: GH-axis trio (CJC + tesa + ipa) Tier 2 — SAME ARCHETYPAL WRONG-DIRECTION ERROR AS HYPOPITUITARISM. PWS somatotrophs are not normally responsive to upstream stimulation because hypothalamic dysfunction is the root defect; somatropin bypasses; GHRH analogs cannot. Semaglutide / GLP-1: emerging off-label use; coordination-of-care decision; FDA boxed warning for MTC + MEN2; food security environment stays in place regardless. BPC-157 + NMN no engagement with PWS biology. Sixty-third deliberate non-elevation of community peptides.

Autosomal recessive ciliopathy — a disorder of primary cilia (antenna-like organelles on most cells). Caused by biallelic mutations in 25+ BBS genes encoding BBSome components (BBS1 + BBS2 + BBS4 + BBS5 + BBS7 + BBS8/TTC8 + BBS9 + BBS18/BBIP10), chaperonin-related proteins (MKKS + BBS6 + BBS10 + BBS12), and other primary-cilium components. Disease driver = primary cilium dysfunction affecting tissues where cilia perform critical signaling — hypothalamic neurons (energy balance via MC4R pathway), photoreceptors (vision), renal tubules (kidney function), heart, limbs. Primary clinical criteria (≥4 OR ≥3 primary + 2 secondary for diagnosis): RETINAL DEGENERATION / retinitis pigmentosa → progressive vision loss (universal; rod-cone dystrophy; often blindness by 3rd-4th decade); POLYDACTYLY (post-axial, ~70%); OBESITY with EARLY-ONSET CHILDHOOD HYPERPHAGIA (hypothalamic MC4R pathway dysfunction from BBSome involvement); LEARNING DISABILITIES / intellectual impairment (variable); HYPOGONADISM / hypogenitalism + delayed/incomplete puberty; RENAL ABNORMALITIES — cystic kidney disease + tubular dysfunction + progressive renal failure (LEADING MORTALITY DRIVER — many patients require dialysis or kidney transplant). Secondary features: speech delay + developmental delay + behavioral problems + eye anomalies (nystagmus, strabismus, cataracts) + brachydactyly/syndactyly + dental anomalies + ataxia/poor coordination + anosmia/hyposmia + mild facial dysmorphism + cardiac (~10%) + hepatic + GI + BBS-specific insulin resistance + metabolic syndrome + hypertension. Diagnosis: clinical criteria + genetic testing (NGS panel for 25+ BBS genes; ~80% identified by genetic testing in modern cohorts). Standard of care: NO CURE; supportive management — ophthalmology surveillance + low-vision rehabilitation + cataract management; nephrology for renal disease (dialysis + transplant when ESRD); endocrinology for hypogonadism + diabetes; orthopedic management for polydactyly (early surgical correction common); speech/OT/PT; behavioral + learning support; cardiac evaluation. **OBESITY MANAGEMENT — MAJOR LANDMARK**: **SETMELANOTIDE (Imcivree, Rhythm Pharmaceuticals — MC4R AGONIST PEPTIDE) FDA-APPROVED JUNE 2022** for BBS-associated obesity in patients ≥6 years (and ≥2 years per 2024 expansion) — the **FIRST FDA-APPROVED THERAPY SPECIFICALLY FOR BBS-RELATED OBESITY, AND A PEPTIDE THERAPY**. Phase 3 trial: ~7% weight loss + significant hyperphagia reduction. SQ daily injection. AEs = hyperpigmentation + injection site reactions + nausea. **Access through specialty pharmacy + REMS program + Rhythm Pharmaceuticals patient assistance — NOT through peptide clinics.** Juno covers setmelanotide as standard-of-care framing rather than community-peptide-elevated. Other obesity management: comprehensive lifestyle; semaglutide / tirzepatide off-label adolescents/adults; bariatric surgery rarely. Vision: ongoing gene therapy research for ciliopathies (no approved gene therapy for BBS yet). Foundation Fighting Blindness + Bardet-Biedl Syndrome Foundation (BBSFoundation.org) patient advocacy. **Editorial**: SETMELANOTIDE is THE peptide therapy in BBS-obesity context — FDA-approved, BBS-specific, MC4R mechanism directly addresses the hypothalamic dysfunction at the root of BBS hyperphagia. Named explicitly in browse but access pathway distinguished from community peptide channels. BPC-157 angiogenic + ocular VEGF concern in retinal dystrophy population. NMN no ciliopathy engagement. GH-axis trio IGF-1 / renal cyst progression concern given BBS renal trajectory (closest cousin = ADPKD IGF-1 / mTOR / cystogenesis literature). Semaglutide off-label — coordinate setmelanotide eligibility first. Sixty-fourth deliberate non-elevation of community peptides.

Autosomal dominant tumor-predisposition syndrome caused by germline loss-of-function in TSC1 (9q34, hamartin) or TSC2 (16p13, tuberin). TSC2 mutations ~75% + generally more severe; ~2/3 sporadic + ~1/3 familial. Molecular consequence = loss of TSC1-TSC2 complex GAP activity on Rheb-GTP → CONSTITUTIVE mTORC1 HYPERACTIVATION → unregulated cell growth + protein synthesis + proliferation + autophagy suppression. Multi-organ manifestations: CNS = cortical tubers + subependymal nodules + SEGAs (~10-15%, hydrocephalus + obstructive risk); EPILEPSY in ~80-90% (INFANTILE SPASMS common in infancy — vigabatrin first-line, aggressive treatment essential); intellectual disability + autism + TAND (TSC-associated neuropsychiatric disorder). Skin: HYPOMELANOTIC MACULES (ash-leaf — earliest finding) + facial angiofibromas + shagreen patches + ungual fibromas + confetti + café-au-lait. Kidney: ANGIOMYOLIPOMAS (~80% adults, bilateral + multiple; >4cm hemorrhage risk = WUNDERLICH SYNDROME life-threatening retroperitoneal bleed); renal cysts; RCC at ~2-3%. Lung: LYMPHANGIOLEIOMYOMATOSIS (LAM) ~30-40% adult women — progressive cystic lung disease + dyspnea + pneumothorax + chyle; ESTROGEN-DRIVEN reproductive-age females; respiratory failure mortality endpoint. Heart: cardiac rhabdomyomas ~50% pediatric (often regress; arrhythmias + obstruction in neonates). Eye: retinal hamartomas. Other: enamel pits + gingival fibromas + bone cysts + GI polyps + rare pancreatic NETs. 2012/2021 International TSC Consensus diagnostic criteria: definite = 2 major OR 1 major + 2 minor OR pathogenic TSC1/TSC2 variant. Surveillance per Krueger-Northrup 2013/2021: brain MRI every 1-3y through age 25 then per clinical; EEG (infantile spasms screening); annual renal MRI from age 12 for AML surveillance; dermatologic + ophthalmologic + dental review; cardiac infancy; PFT + HRCT chest in adult women for LAM screening; annual neuropsychological/TAND assessment. **STANDARD-OF-CARE = mTOR INHIBITORS (LOAD-BEARING)**: **EVEROLIMUS (Afinitor) FDA-APPROVED** for SEGA (2010, EXIST-1) + renal AML (2012, EXIST-2) + TSC-associated focal-onset seizures (2018, EXIST-3); **SIROLIMUS (Rapamune)** expanded access + topical for facial angiofibromas; first-line for moderate-severe LAM (MILES trial). **CANNABIDIOL (Epidiolex) FDA-APPROVED 2018** for TSC-associated seizures. Vigabatrin for infantile spasms. Surgical: epilepsy surgery for refractory seizures; SEGA resection for hydrocephalus/obstruction; selective renal artery embolization or partial nephrectomy for symptomatic/large AMLs; lung transplant for end-stage LAM. TSC Alliance (tscalliance.org) + ITSCA patient advocacy. **Editorial**: ARCHETYPAL mTOR-PATHWAY DISEASE. **GH-axis trio (CJC + tesa + ipa) TIER 2 SHARP MECHANISTIC CONTRADICTION** — IGF-1 → PI3K → Akt → mTORC1 is the EXACT pathway TSC1/TSC2 loss-of-function constitutively hyperactivates and everolimus/sirolimus inhibit as standard-of-care. Joins HHT (bevacizumab/BPC-157) + MAS/Carney complex (GHRH/PKA) as third archetypal substrate where community peptide product line directly opposes standard-of-care pharmacology. Tesamorelin FDA label contraindicates active malignancy (TSC multi-organ tumor surveillance editorial extension). BPC-157 pro-angiogenic + dissonant with mTOR-inhibitor anti-angiogenic effects in multi-organ tumor population. NMN theoretical sirtuin/mTOR cross-talk uncharacterized in TSC1/TSC2-deficient organs. Sixty-fifth deliberate non-elevation.

Heterogeneous family of disorders defined by partial or near-total loss of adipose tissue and the cardiometabolic chaos that follows: severe insulin resistance, extreme hypertriglyceridemia (often >1000 mg/dL in generalized forms), recurrent pancreatitis, hepatic steatosis/NASH, difficult-to-control diabetes (often requiring 1000+ U/day of insulin in CGL/AGL), premature atherosclerotic CVD, and in some subtypes hypertrophic cardiomyopathy + arrhythmias driving mortality. **CONGENITAL GENERALIZED LIPODYSTROPHY (CGL, Berardinelli-Seip syndrome) — autosomal recessive**: near-total adipose absence from birth. CGL1 (AGPAT2 — adipogenesis defect), CGL2 (BSCL2/seipin — adipocyte differentiation; sometimes intellectual disability), CGL3 (CAV1/caveolin-1), CGL4 (PTRF/CAVIN1 — muscular dystrophy + HCM + arrhythmias). **ACQUIRED GENERALIZED LIPODYSTROPHY (AGL, Lawrence syndrome)** = autoimmune-spectrum acquired form. **FAMILIAL PARTIAL LIPODYSTROPHY (FPLD) — autosomal dominant**: partial fat loss (peripheral) + central accumulation. FPLD1 (Köbberling), FPLD2 (Dunnigan-Köhler — LMNA mutations; most common; often females presenting at puberty), FPLD3 (PPARG), FPLD4 (PLIN1), FPLD5 (CIDEC), FPLD6 (LIPE), FPLD7+. LMNA mutations also cause progeria + cardiomyopathy syndromes. **ACQUIRED PARTIAL LIPODYSTROPHY (APL, Barraquer-Simons syndrome)** = cephalothoracic lipoatrophy + lower-body sparing + complement C3 nephritic factor + membranoproliferative GN. **HIV-ASSOCIATED LIPODYSTROPHY** = older antiretroviral regimens; specifically the tesamorelin FDA-approved indication. Diagnostics: clinical phenotype + DEXA/MRI fat quantification + targeted genetic testing + autoantibody + complement studies + skin biopsy + metabolic panel (glucose + HbA1c + insulin + C-peptide + TG + lipids + LFTs + LEPTIN + adiponectin) + cardiovascular workup (echo + EKG + ambulatory monitor). Management: aggressive dietary fat restriction (CRITICAL for TG control + pancreatitis prevention); insulin sensitizers (metformin + thiazolidinediones with pioglitazone caution in HF); often extreme insulin doses; GLP-1 agonists off-label for FPLD metabolic management; fibrates (fenofibrate) for hypertriglyceridemia; statins; ACE/ARB for albuminuria; cardiomyopathy management. **TWO FDA-APPROVED PEPTIDE THERAPIES**: **METRELEPTIN (Myalept, Aegerion/Amryt) = recombinant leptin analog FDA-APPROVED FEBRUARY 2014 for GENERALIZED LIPODYSTROPHY (CGL + AGL)** — first FDA-approved leptin therapy; replaces deficient leptin signaling driving hyperphagia + insulin resistance; SC daily injection; **REMS PROGRAM** (lymphoma risk + severe infection risk + neutralizing antibody risk); not approved for partial lipodystrophy (FPLD); responders see dramatic improvements in HbA1c + TG + hepatic steatosis + ovarian function. **TESAMORELIN (Egrifta, Theratechnologies) = GHRH analog FDA-APPROVED 2010 specifically for HIV-ASSOCIATED LIPODYSTROPHY** (truncal/visceral adiposity reduction; ~15% VAT reduction over 26 weeks). **HIV-LD approval does NOT propagate to non-HIV lipodystrophy syndromes — Rule 6 non-propagation**; off-label use in CGL/AGL/FPLD/APL thin evidence base; label contraindicates active malignancy + pituitary tumor history. Patient advocacy: International Society for Lipodystrophy + Lipodystrophy United + The Lipodystrophy Foundation. Endocrine Society 2016 + 2024 update. **Editorial**: METRELEPTIN + TESAMORELIN are TRUE peptide therapies named explicitly as standard-of-care. **CJC-1295 + ipamorelin TIER 2 WRONG-DIRECTION** — marketed for 'LIPOLYSIS' in a disease where ADIPOSE DEFICIENCY IS THE DISEASE (conceptually opposed); GH-axis stimulation worsens insulin resistance in population on extreme insulin doses. Semaglutide off-label coordination-of-care for FPLD metabolic syndrome. BPC-157 + NMN no engagement with adipose biology or leptin signaling. Sixty-sixth deliberate non-elevation of community peptides.

Most common autosomal dominant tumor predisposition syndrome in humans — incidence ~1 in 3000 worldwide (same prevalence as cystic fibrosis). Caused by germline mutations in NF1 (17q11.2) encoding neurofibromin, a GTPase-activating protein for RAS. Loss of neurofibromin → constitutive RAS-MAPK pathway activation with downstream PI3K-AKT-mTOR crosstalk. ~50% sporadic, ~50% familial; fully penetrant by age 5 but expression highly variable. 2021 NIH/Legius criteria: ≥2 of café-au-lait macules (≥6, >5mm prepubertal / >15mm postpubertal), ≥2 neurofibromas (or 1 plexiform), axillary/inguinal freckling (Crowe sign), optic pathway glioma, ≥2 Lisch nodules (iris hamartomas) or choroidal abnormalities, distinctive osseous lesion (sphenoid dysplasia / tibial pseudoarthrosis), first-degree NF1 relative, OR pathogenic NF1 variant. Clinical: cutaneous neurofibromas (~95% by adulthood); PLEXIFORM neurofibromas (~30-50%; often congenital/early; ~8-13% lifetime risk MALIGNANT TRANSFORMATION TO MPNST = malignant peripheral nerve sheath tumor; LEADING CAUSE OF NF1-ADULT MORTALITY); optic pathway gliomas (~15-20% pediatric); learning disabilities + ADHD + autism spectrum + seizures (~5%); cerebrovascular dysplasia (Moyamoya-like); sphenoid wing dysplasia + tibial pseudoarthrosis + scoliosis + short stature + osteopenia; precocious puberty (especially with OPG); rare PHEOCHROMOCYTOMA ~0.1-5.7% (PPGL syndrome overlap); GIST; pediatric JMML; HYPERTENSION ~25% (renal artery stenosis + pheo workup indicated). Cancer beyond MPNST: BREAST CANCER women <50 (2-5x elevated), GIST, JMML, optic pathway gliomas. Surveillance per Stewart 2018/2021 + Children's Tumor Foundation: annual clinical exam + dermatologic + ophthalmologic + neurologic + BP + growth/puberty; whole-body MRI for plexiform burden in high-risk; brain MRI if visual/neurologic symptoms; HTN workup (renal artery US/MRA + metanephrines); developmental/educational assessment. **MEK INHIBITOR ERA**: **SELUMETINIB (Koselugo) FDA-APPROVED APRIL 2020** for pediatric NF1 with inoperable plexiform neurofibromas — FIRST FDA-approved targeted therapy for NF1; ~70% objective response. **MIRDAMETINIB (Gomekli) FDA-APPROVED FEBRUARY 2025** for adults + pediatric ≥2 years with NF1-PN (broader indication than Koselugo). Other MEK inhibitors (trametinib, binimetinib) in trial. Imatinib selected GIST/plexiform; bevacizumab for OPG selected cases; MPNST surgical + radiation. CBD emerging in NF1 trials. Children's Tumor Foundation + NF Network + International Federation of Neurofibromatosis Foundations patient advocacy. **Editorial**: NF1 is constitutive RAS-MAPK pathway disease. **GH-axis trio (CJC + tesa + ipa) TIER 2** — IGF-1 → IGF-1R → PI3K-AKT-mTOR is downstream crosstalk partner of RAS-MAPK; preclinical NF1-deficient tumor models document IGF-1/RAS synergy in proliferation; layered on lifetime tumor burden (plexiform + OPG + ~8-13% MPNST + breast cancer + pheo + GIST); tesamorelin FDA label contraindicates active malignancy. BPC-157 pro-angiogenic in tumor-predisposition population with vascularized plexiform/MPNST lesions. NMN general-aging category-mismatch with NF1 RAS-MAPK biology. Sixty-seventh deliberate non-elevation.

Deficient PTH production → impaired calcium homeostasis → HYPOCALCEMIA + hyperphosphatemia + low/inappropriately-normal PTH + decreased 1,25(OH)2 vitamin D + renal calcium wasting. PTH normally: stimulates osteoclast bone resorption → Ca release; increases renal Ca reabsorption + PO4 excretion; stimulates renal 1α-hydroxylase → activates vitamin D → GI Ca absorption. **ETIOLOGIES**: POST-SURGICAL ~75% (most common; post-thyroidectomy + parathyroidectomy + neck surgery for malignancy; transient most common; permanent ~1-3% of total thyroidectomies; higher after re-operative surgery or cancer). AUTOIMMUNE (isolated OR APS-1/APECED — AIRE mutation; chronic mucocutaneous candidiasis + hypoPTH + Addison's). GENETIC: DiGeorge syndrome (22q11.2 deletion → thymic + parathyroid agenesis); CASR activating mutations → ADH (autosomal dominant hypocalcemia); GNA11 + GCM2; familial isolated. INFILTRATIVE: hemochromatosis + Wilson disease + metastatic + radiation. SEVERE HYPOMAGNESEMIA: impairs PTH secretion + action (reversible with Mg correction). HUNGRY BONE SYNDROME: post-parathyroidectomy for primary HPT. **PSEUDOHYPOPARATHYROIDISM (PHP) is distinct entity, NOT actually hypoparathyroidism** — PTH RESISTANCE from GNAS mutations (PHP1A/1B/1C); PTH is HIGH + low Ca + Albright hereditary osteodystrophy phenotype. Vitamin D deficiency distinguished by HIGH compensatory PTH. CLINICAL: chronic hypocalcemia → neuromuscular irritability (paresthesias + carpopedal spasm + Chvostek/Trousseau + TETANY + LARYNGOSPASM + SEIZURES); cardiac (PROLONGED QT → arrhythmias); cognitive (anxiety + depression + cognitive impairment); cataracts; basal ganglia calcifications + extrapyramidal; renal stones + nephrocalcinosis + CKD (paradoxical hypercalciuria on conventional therapy); enamel/dental hypoplasia (childhood-onset); dry skin + brittle nails + alopecia. Dx: serum Ca (corrected/ionized) + PTH (low/inappropriately-normal) + PO4 (high) + Mg + 25-OH + 1,25(OH)2 vitamin D + 24h urine Ca + ECG (QTc). **CONVENTIONAL THERAPY**: oral Ca supplements (1-3g elemental/day divided) + ACTIVATED VITAMIN D (CALCITRIOL = 1,25(OH)2 vitamin D = drug of choice; alfacalcidol alternative; NOT ergo/cholecalciferol — require 1α-hydroxylase which is PTH-dependent); thiazides may reduce urinary Ca losses; PO4 restriction; Mg replacement. CHALLENGES: difficulty achieving normocalcemia without hypercalciuria → nephrolithiasis + nephrocalcinosis + CKD; QoL impaired by symptoms + therapy burden. **PTH-REPLACEMENT THERAPY — PEPTIDE STANDARD-OF-CARE**: **TERIPARATIDE (Forteo) = recombinant human PTH(1-34)**: FDA-approved for OSTEOPOROSIS (not hypoparathyroidism); OFF-LABEL for hypoparathyroidism (~50% Ca + vit D dose reduction); short half-life ~1h requires multiple daily injections. **PTH(1-84) (NATPARA, Shire/Takeda)**: full-length recombinant PTH; FDA-approved Jan 2015; **WITHDRAWN 2019** (silicone particles in cartridges manufacturing issue); compassionate use continued. **PALOPEGTERIPARATIDE (YORVIPATH, Ascendis Pharma) = recombinant PTH(1-34) prodrug via TransCon technology** = **FDA-APPROVED AUGUST 2024 for ADULT CHRONIC HYPOPARATHYROIDISM** as adjunct to Ca + vit D — **FIRST PERMANENT FDA-APPROVED THERAPY FOR HYPOPARATHYROIDISM** (PaTHway Phase 3 trial); once-daily SC; sustained PTH effect; QoL improvements + reduced Ca/active vit D needs + addresses hypercalciuria; REPLACES Natpara modern practice. **Editorial**: PALOPEGTERIPARATIDE + TERIPARATIDE are TRUE peptide therapies named explicitly. Community peptides Tier 3: BPC-157 pro-angiogenic in nephrocalcinosis-affected kidney uncharacterized; NMN no engagement with PTH/Ca biology; GH-axis trio IGF-1 bone-turnover effects + uncharacterized interaction in tightly-managed Ca balance. WADA: PTH analogs prohibited (anabolic agents). Hypoparathyroidism Association + NEXT + Endocrine Society 2016 + APS-1 patient resources. Sixty-eighth deliberate non-elevation of community peptides.

Heritable connective tissue disorder. Marfan = autosomal dominant FBN1 mutations (15q21.1) encoding fibrillin-1, a structural microfibril protein. Loss of normal fibrillin-1 disrupts microfibril assembly AND dysregulates TGF-β signaling. ~1/5000 incidence; ~75% autosomal dominant familial + ~25% sporadic. Revised Ghent nosology 2010: aortic root dilation + ectopia lentis = major criteria + FBN1 mutation + family history. Manifestations: SKELETAL (tall stature + long limbs + arachnodactyly + pectus deformity + scoliosis + arm span > height + reduced upper:lower segment ratio + joint hypermobility + thumb/wrist signs + high-arched palate); CARDIOVASCULAR (AORTIC ROOT DILATION + AORTIC DISSECTION — LEADING MORTALITY DRIVER; mitral valve prolapse + tricuspid valve prolapse + arrhythmias); OCULAR (ECTOPIA LENTIS = diagnostic hallmark + severe myopia + retinal detachment); SKIN (striae atrae); DURAL ECTASIA (lumbosacral); PULMONARY (pneumothorax + emphysematous bullae). DIFFERENTIAL: **LOEYS-DIETZ SYNDROME** (TGFBR1/TGFBR2/SMAD3/TGFB2/TGFB3; MORE AGGRESSIVE aortic disease + skin translucency + arterial tortuosity + bifid uvula + cleft palate; EARLIER DISSECTION at SMALLER diameters; surgical thresholds shift lower). **VASCULAR EHLERS-DANLOS** (COL3A1; arterial + intestinal + uterine rupture risk beyond aorta). Homocystinuria mimics Marfan ophthalmologically. Standard of care: NO CURE; multidisciplinary lifelong (cardiology — load-bearing; ophthalmology; orthopedic; cardiothoracic surgery; medical genetics). **AORTIC DISSECTION PREVENTION**: BETA-BLOCKERS (atenolol, metoprolol, propranolol) historical first-line; **LOSARTAN (ARB) — Pediatric Heart Network 2014 trial = equivalent to atenolol** for aortic root growth in pediatric Marfan (TGF-β-related pathway blockade). ACE inhibitors + ARBs expanded use. CALCIUM CHANNEL BLOCKERS AVOIDED (some evidence of harm). STIMULANTS (incl. ADHD medications) WARNED AGAINST. Lifestyle: NO isometric/heavy resistance training; NO contact sports; aerobic limits per individual cardiology recommendations. **PROPHYLACTIC AORTIC ROOT REPLACEMENT** at root diameter ~5.0 cm (smaller in family history early dissection / Loeys-Dietz): VALVE-SPARING ROOT REPLACEMENT (David procedure) preferred over Bentall composite when feasible. Annual echocardiogram + CT/MRI surveillance lifelong. Endocarditis prophylaxis for high-risk dental procedures. Ophthalmologic surveillance for ectopia lentis + retinal detachment risk from high myopia. **PREGNANCY = HIGH-RISK**: aortic dissection risk PEAKS during pregnancy + postpartum; pre-pregnancy aortic root assessment mandatory; root <4.0 cm typically safe; >4.5 cm relative contraindication; cesarean often recommended; MFM + cardiology + CT surgery coordination non-negotiable. **GENETIC COUNSELING + 50% cascade FBN1 testing** of family members. The Marfan Foundation + Loeys-Dietz Syndrome Foundation patient advocacy; 2014 PHN-Marfan trial + 2010 revised Ghent nosology + ACC/AHA 2022 aortic disease guidelines reference standards. **Editorial**: **GH-axis trio (CJC + tesa + ipa) TIER 2 SHARP DIRECTION-OF-EFFECT CONCERN** — IGF-1 acts directly on VASCULAR SMOOTH MUSCLE CELLS + FIBROBLASTS + AORTIC MEDIA (the EXACT tissue compartment whose fibrillin-1 microfibril architecture is compromised); Marfan standard-of-care moving toward MORE TGF-β-pathway blockade (losartan, ARBs); community GH-axis peptides push GROWTH-AXIS signaling in the OPPOSITE direction; pregnancy dissection window compounds IGF-1 elevation concern. BPC-157 ECM remodeling in already-compromised connective tissue + pro-angiogenic effects; community 'tendon/ligament healing' framing lands on CTD hypermobility population but ECM concerns dominate. NMN orthogonal to Marfan biology. Sixty-ninth deliberate non-elevation.

Autosomal recessive disorder caused by biallelic mutations in CFTR (7q31.2) encoding cAMP-regulated chloride/bicarbonate channel. Defective epithelial Cl-/HCO3- transport → thick viscous mucus in lung + pancreas + intestine + biliary tract + sweat glands + reproductive tract. ~30,000 US patients; ~1/2500-3500 incidence Northern European populations (founder effect); >2,000 CFTR mutations grouped into 6 functional classes (F508del most common). **HISTORICAL TRANSFORMATION**: childhood-fatal disease through 20th century → median survival <10 years (1960s) to 50+ years (modern era). Multi-organ manifestations: PULMONARY (chronic + recurrent infections — Pseudomonas + Burkholderia + Staphylococcus + Mycobacterium abscessus + Aspergillus; chronic inflammation; bronchiectasis; progressive FEV1 decline → respiratory failure; HISTORICALLY LEADING MORTALITY); PANCREATIC (exocrine insufficiency → malabsorption + steatorrhea + failure to thrive; ~85% of CF patients; PERT [pancreatic enzyme replacement therapy] required; **CFRD = CYSTIC FIBROSIS-RELATED DIABETES = leading endocrinopathy in CF**, distinct from T1DM + T2DM, affects ~50% adults, insulin therapy); HEPATOBILIARY (cirrhosis + portal hypertension + gallstones); GI (DIOS = distal intestinal obstruction syndrome; constipation; meconium ileus in newborns); NUTRITIONAL (failure to thrive historically; high-calorie/high-fat diet; **POST-TRIKAFTA shifting toward weight management as new concern**); SINUS (chronic rhinosinusitis + polyps); MUSCULOSKELETAL (osteoporosis); REPRODUCTIVE (**CBAVD = CONGENITAL BILATERAL ABSENCE OF VAS DEFERENS in nearly all males with CF → obstructive infertility navigable through ICSI**; reduced but possible female fertility; pregnancy planning + management important especially post-Trikafta); SWEAT (elevated Cl- diagnostic). Diagnostics: NEWBORN SCREENING universal in US; sweat chloride test (>60 mmol/L positive; 30-59 intermediate); CFTR mutation analysis. CF Foundation registry + comprehensive multidisciplinary CF centers. **STANDARD OF CARE TRANSFORMED BY CFTR MODULATORS**: **IVACAFTOR (Kalydeco, Vertex Pharmaceuticals) FDA 2012** — potentiator for G551D + 10 gating mutations + R117H — opened CFTR modulator era. **LUMACAFTOR/IVACAFTOR (Orkambi) FDA 2015** F508del homozygous. **TEZACAFTOR/IVACAFTOR (Symdeko) FDA 2018** improved corrector. **ELEXACAFTOR/TEZACAFTOR/IVACAFTOR (TRIKAFTA, Vertex Pharmaceuticals) FDA OCTOBER 2019 = TRIPLE COMBINATION 'highly effective modulator therapy' for F508del heterozygous + homozygous (~90% CF population eligible)**. **PARADIGM SHIFT — TRIKAFTA HAS TRANSFORMED CF**. Phase 3: dramatic FEV1 improvement (+14 percentage points); sweat chloride dramatic reduction; pulmonary exacerbation rate fall; QoL improvements; many patients delisted from lung transplant; pregnancy increasing (fertility + health improvements). Other foundational: AIRWAY CLEARANCE THERAPIES (chest physiotherapy + Vest + flutter + autogenic drainage); INHALED — **DORNASE ALPHA / PULMOZYME = RECOMBINANT DNase, PEPTIDE-RELATED THERAPY, FDA-approved 1993** (cleaves DNA from neutrophil burden in viscous CF mucus; canonical peptide-related CF therapy + first FDA-approved CF-specific drug); hypertonic saline 7%; inhaled antibiotics (tobramycin / aztreonam / colistin); oral antibiotics for exacerbations; PERT (lipase + protease + amylase with meals); fat-soluble vitamin supplementation (A + D + E + K); insulin for CFRD; lung transplant for end-stage (decreasing need post-Trikafta). CFRD: ADA-CFF joint guidelines; insulin not oral agents; complications profile distinct from T1/T2 DM. Cystic Fibrosis Foundation (cff.org) + CF Network international + CF transplant centers. **Editorial**: **DORNASE ALPHA named explicitly as canonical FDA-approved peptide-related CF therapy** (1993). Community peptides Tier 3: BPC-157 channelopathy not 'healing'; NMN general-aging post-Trikafta relevant but Trikafta CYP3A interaction + CFRD complexity; GH-axis trio at intersection of historical somatropin pediatric CF use + post-Trikafta body composition inversion + CFRD diabetogenic concern; semaglutide genuinely novel post-Trikafta body composition emerging issue + CFRD coordination + PERT timing interaction + pancreatitis surveillance in pancreatic-disease population. Seventieth deliberate non-elevation of community peptides.

Most common form of disproportionate short stature. Gain-of-function mutations in FGFR3 (fibroblast growth factor receptor 3, chromosome 4p16.3); ~98% cases same single G380R transmembrane mutation. ~80% de novo (sporadic); ~20% inherited autosomal dominant. FGFR3 normally INHIBITS chondrocyte proliferation in growth plates — gain-of-function means EXAGGERATED INHIBITION → markedly reduced endochondral bone growth → short stature with characteristic disproportionate features. Incidence ~1/15,000-40,000 live births. Clinical: short stature (adult height ~131 cm males / 124 cm females); RHIZOMELIC LIMB SHORTENING (proximal segments more affected); MACROCEPHALY + FRONTAL BOSSING + midface hypoplasia; LUMBAR LORDOSIS + thoracolumbar kyphosis in infancy; TRIDENT HAND; brachydactyly. **CRITICAL COMPLICATIONS**: FORAMEN MAGNUM STENOSIS in infancy + childhood — NEUROSURGICAL EMERGENCY if compression → sudden infant death + sleep apnea + hydrocephalus + brainstem compression; MRI surveillance; decompression surgery if symptomatic. Cervicomedullary junction compression; OBSTRUCTIVE SLEEP APNEA (universal, especially infancy/childhood); recurrent otitis media (75-90%) → conductive hearing loss + speech delay; SPINAL STENOSIS (childhood + adult — claudication + neurogenic bladder + paraparesis if untreated); genu varum; restrictive pulmonary disease + sleep apnea; cardiovascular issues + HTN + cardiovascular mortality elevated; psychosocial/educational; obesity tendencies. **INTELLIGENCE IS NORMAL**. Diagnosis: clinical + radiologic features (skeletal survey) + genetic testing FGFR3; PRENATAL diagnosis possible via ultrasound (2nd trimester) + genetic testing. Standard of care: NO CURE for FGFR3 mutation itself; multidisciplinary management — orthopedic + neurosurgical + pulmonology + ENT + endocrinology + genetics + dental + psychology. **GROWTH HORMONE (SOMATROPIN)**: variable height improvement; some clinical use but not standard-of-care; less effective than in GH-deficient populations because lesion is FGFR3 over-inhibition, not GH insufficiency. **LIMB-LENGTHENING SURGERY** (Ilizarov technique; controversial within community; multi-stage; psychological burden). Foramen magnum decompression if compression; tympanostomy tubes; orthodontic; speech therapy; nutrition + obesity prevention; mental health. **VOSORITIDE (VOXZOGO, BioMarin Pharmaceutical) — C-TYPE NATRIURETIC PEPTIDE (CNP) ANALOG = PEPTIDE THERAPY**: **FDA-APPROVED NOVEMBER 2021** for achondroplasia patients ≥5 years with open epiphyses; **EXPANDED MAY 2024 to ≥4 months of age**. **EMA-approved August 2021**. Mechanism: CNP binds NPR-B (natriuretic peptide receptor B) on chondrocytes → inhibits FGFR3 downstream MAPK signaling → restores chondrocyte proliferation + differentiation in growth plates. Phase 3 trial: ~1.6 cm/year increased growth velocity; daily subcutaneous injection. AEs: injection site reactions + transient hypotension. **FIRST PRECISION FDA-APPROVED THERAPY FOR ACHONDROPLASIA AND IS A PEPTIDE THERAPY**. Other emerging: INFIGRATINIB (FGFR1-3 inhibitor) in Phase 2/3 trials; TRANSCON CNP (Ascendis) — long-acting CNP prodrug. Related FGFR3 dysplasias: HYPOCHONDROPLASIA (mild); THANATOPHORIC DYSPLASIA (typically lethal at birth). Distinct disorders: PSEUDOACHONDROPLASIA (COMP mutation); DIASTROPHIC DYSPLASIA; SPONDYLOEPIPHYSEAL DYSPLASIAS. Little People of America (LPA) + Little People Worldwide (LPWW) + Restricted Growth Association (UK) + Médecins Achondroplasie international patient advocacy. International Achondroplasia Workgroup recommendations + 2020 international consensus statement. **Editorial**: VOSORITIDE = FDA-approved CNP analog peptide standard-of-care named explicitly. Community peptides Tier 3: BPC-157 no FGFR3 engagement + pediatric safety unknowns; NMN general-aging adult framing doesn't translate; GH-axis trio (CJC + tesa + ipa) ≠ CNP/FGFR3 mechanism (IGF-1 stimulation doesn't act on FGFR3-MAPK pathway vosoritide targets); somatropin historical limited efficacy. **IDENTITY-COMMUNITY SENSITIVITY**: vosoritide controversial within LPA/LPWW/RGA communities (some embrace; others view as harmful 'fixing' of natural variation); substrate respects both perspectives without taking sides. Seventy-first deliberate non-elevation of community peptides.

Inherited hemoglobinopathy. HBB gene mutations (chromosome 11p15.4) reduce or eliminate beta-globin chain synthesis → unpaired alpha-globin chains accumulate → INEFFECTIVE ERYTHROPOIESIS (precursors destroyed in marrow) + EXTRAMEDULLARY HEMATOPOIESIS + chronic hemolytic anemia. ~200+ HBB mutations identified. **CLINICAL SPECTRUM**: BETA-THAL MINOR / TRAIT (heterozygous; mild microcytic anemia); BETA-THAL INTERMEDIA / NON-TRANSFUSION-DEPENDENT THALASSEMIA (NTDT) (β+/β+ or β0/β+; mild-moderate disease; intermittent transfusions; ineffective erythropoiesis + gut iron hyperabsorption + pulmonary HTN + thromboembolism + leg ulcers + paraspinal masses); **BETA-THAL MAJOR / COOLEY'S ANEMIA / TRANSFUSION-DEPENDENT THALASSEMIA (TDT)** (β0/β0 or β0/β+; requires regular transfusions for survival from age 6mo-2y; severe anemia + failure to thrive without transfusion; pre-transfusion Hb target 9-10.5 g/dL). **MULTI-JURISDICTIONAL DISEASE**: global carrier ~1.5%; high frequency Mediterranean + Middle East + South Asia + Southeast Asia + parts of Africa (malaria selective pressure); ~60,000 severe cases born annually worldwide. **IRON OVERLOAD = LEADING MORTALITY DRIVER**: ~200 mg iron per unit transfused blood; cumulative deposits HEART (cardiomyopathy + arrhythmias + heart failure — historical leading mortality); LIVER (fibrosis + cirrhosis + HCC); ENDOCRINE (HYPOGONADOTROPIC HYPOGONADISM + **GROWTH HORMONE DEFICIENCY** ~25-30% TDT adults from pituitary iron deposition + HYPOTHYROIDISM + HYPOPARA + DIABETES from pancreatic iron deposition — endocrine complications affect 30-70%+ adults); skin bronze pigmentation. Splenomegaly; gallstones; bone changes + osteoporosis; infection susceptibility; thrombosis (especially NTDT post-splenectomy). Modern era TDT survival into 50s+. Diagnostics: CBC + smear (microcytic hypochromic + target cells); Hb electrophoresis (decreased HbA + increased HbA2 ± HbF); HBB genotyping; iron studies including ferritin + **LIVER IRON CONCENTRATION (LIC) by T2* MRI gold standard** + cardiac T2* MRI (iron loading <20ms); annual endocrine panel; bone density. Standard of care: **REGULAR TRANSFUSION every 2-5 weeks for TDT + IRON CHELATION ESSENTIAL** (DEFERASIROX [Exjade, Jadenu, oral] + DEFEROXAMINE [Desferal, IV/SC infusion] + DEFERIPRONE [Ferriprox, oral] — often combination therapy). **LUSPATERCEPT (REBLOZYL, Bristol Myers Squibb / Acceleron) = ActRIIB-Fc FUSION RECOMBINANT PROTEIN PEPTIDE-LIKE THERAPY**: **FDA-APPROVED NOVEMBER 2019 for ADULT beta-thal TDT** as transfusion-burden-reducing therapy; **EXPANDED 2023 to LOWER-RISK MDS as first-line**. Mechanism: blocks TGF-β superfamily ligands → improves late-stage erythropoiesis differentiation. Phase 3 BELIEVE trial: ~33% reduction in transfusion burden + effective in ~70% TDT adults. **CASGEVY (EXAGAMGLOGENE AUTOTEMCEL, Vertex/CRISPR Therapeutics) = CRISPR-Cas9 GENE THERAPY**: FDA-approved December 2023 for sickle cell + **JANUARY 2024 for transfusion-dependent beta-thalassemia** — FIRST CRISPR-edited gene therapy approval. **ZYNTEGLO (BETIBEGLOGENE AUTOTEMCEL, Bluebird Bio) = LENTIVIRAL GENE THERAPY** FDA-approved August 2022 for beta-thal TDT — first gene therapy for any beta-globin disorder. **ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)**: curative; HLA-matched sibling 80-90% success in young patients. NTDT: hydroxyurea HbF induction. **Endocrine surveillance**: annual TSH + free T4 + AM testosterone (M) or estradiol/menstrual (F) + LH/FSH + IGF-1 + cortisol + Ca + PO4 + glucose + HbA1c + DEXA + dental + ophthalmologic. **Pregnancy high-risk**: pre-pregnancy cardiac MRI; deferoxamine compatible 3rd trimester only; deferasirox + deferiprone CONTRAINDICATED. Pre-implantation genetic testing for carrier couples. **Thalassemia International Federation (TIF) 2022 guidelines + Cooley's Anemia Foundation + AHA cardiac iron management + Endocrine Society 2024 endocrine complications + regional thalassemia foundations**. **Editorial**: LUSPATERCEPT + CASGEVY + ZYNTEGLO named explicitly as FDA-approved standard-of-care. Community peptides Tier 3: BPC-157 pro-angiogenic concern in iron-overload cardiomyopathy + hepatic fibrosis; NMN iron-NAD+ crosstalk uncharacterized; **GH-axis trio iron-induced hypopituitarism context** — ~25-30% TDT adults have GHD from pituitary iron deposition damaging somatotrophs; upstream-stimulation community peptides assume functional pituitary which iron deposition compromises; somatropin replacement is established. Semaglutide pancreatic iron-overload diabetes context (insulin-deficient mechanism vs T2D insulin resistance). Seventy-second deliberate non-elevation of community peptides.

Autosomal recessive inborn error of metabolism. Biallelic PAH mutations (chromosome 12q23.2) → loss of phenylalanine hydroxylase function → inability to convert PHENYLALANINE (Phe) to TYROSINE → toxic Phe accumulation in blood + brain → severe intellectual disability + neuropsychiatric complications + microcephaly + seizures + eczematous skin + musty body odor if untreated from birth. ~400 PAH mutations identified; incidence ~1/10,000-15,000 live births (higher Turkey + Ireland + Italy). **NEWBORN SCREENING UNIVERSAL since 1960s** (Robert Guthrie blood spot test) — historic public health success transforming PKU from inevitable severe disability to manageable chronic disease. **CLASSIC PKU**: severe PAH deficiency; Phe untreated >20 mg/dL (>1200 µmol/L); strict lifelong dietary restriction. **MODERATE PKU**: Phe 6-20 mg/dL. **MILD HYPERPHENYLALANINEMIA**: <6 mg/dL; may not need treatment. **MATERNAL PKU SYNDROME**: women with untreated PKU during pregnancy → maternal hyperphenylalaninemia → fetal microcephaly + intellectual disability + congenital heart disease + IUGR regardless of fetal genotype; **PRE-PREGNANCY Phe CONTROL CRITICAL**. Diagnostics: newborn screening; confirmed quantitative amino acid analysis; PAH genotyping. Differential: BH4 (tetrahydrobiopterin) deficiency variants (PTPS + DHPR + GTPCH1 mutations affecting BH4 cofactor — present similarly but need different management including neurotransmitter precursors). Standard of care: **LIFELONG PHENYLALANINE-RESTRICTED DIET load-bearing** — strict avoidance high-protein (meat + dairy + eggs + nuts + legumes + grains + ASPARTAME); medical foods (Phe-free protein substitutes + low-protein modified foods + special metabolic formulas); intensive dietitian management; metabolic clinic follow-up; psychosocial burden enormous — dietary restriction lifelong + social/family/educational impact. Targets: pediatric Phe 120-360 µmol/L; adult Phe <600 µmol/L (US/some); UK + some EU jurisdictions historically recommend stricter lifelong treatment. **SAPROPTERIN DIHYDROCHLORIDE (KUVAN, BioMarin) = synthetic BH4 cofactor** FDA-approved 2007 for BH4-RESPONSIVE PKU (~30-50% of patients respond; partial PAH function patients); reduces dietary restriction burden. **PEGVALIASE (PALYNZIQ, BioMarin) = PEGYLATED RECOMBINANT PHENYLALANINE AMMONIA LYASE (PAL) ENZYME = PEPTIDE/PROTEIN THERAPY**: **FDA-APPROVED MAY 2018** for adult PKU patients with Phe >600 µmol/L (10 mg/dL); subcutaneous injection; converts Phe to trans-cinnamic acid + ammonia via PAL enzyme bypassing PAH defect; **REMS PROGRAM** due to anaphylaxis risk (~3-5% of patients); requires careful induction + monitoring; works in patients with even severe PAH mutations (not BH4 responsive). PRISM Phase 3 trials: ~70% of treated patients achieve substantial Phe reduction. AEs: injection site reactions + anaphylaxis + arthralgia + hypersensitivity. **THIS IS THE TRANSFORMATIVE PEPTIDE THERAPY for adult PKU**. Emerging: mRNA therapy + gene therapy in trials. National PKU Alliance (npkua.org) + European Society for Phenylketonuria + Children's PKU Network + International PKU Federation patient advocacy. American College of Medical Genetics + Endocrine Society + European PKU 2017 guidelines. **Editorial**: PEGVALIASE + SAPROPTERIN named explicitly as FDA-approved standard-of-care. Community peptides Tier 3: BPC-157 no PAH engagement + pediatric safety unknowns; NMN no engagement with phenylalanine metabolism + pediatric safety; GH-axis trio (CJC + tesa + ipa) somatropin precedent in confirmed pediatric PKU GHD but community GH-axis peptides not interchangeable + growth concerns usually nutritional not GH-axis. Seventy-third deliberate non-elevation of community peptides.

Autosomal recessive motor neuron disease. Biallelic LOF mutations in SMN1 (survival motor neuron 1, chromosome 5q13.2) → reduced functional SMN protein → progressive degeneration α-motor neurons in spinal cord anterior horn + lower brainstem → progressive muscle weakness + atrophy. SMN2 = paralog producing partially functional SMN protein at low levels; **SMN2 COPY NUMBER (1-5) DETERMINES DISEASE SEVERITY** — more copies milder phenotype. **SUBTYPES** (pre-treatment classification): TYPE 0 (prenatal/birth onset; severe contractures; respiratory failure; death <6mo; 1 SMN2); **TYPE 1 (WERDNIG-HOFFMANN)** — most common; onset before 6mo; never sits independently; floppy + paradoxical breathing + feeding/swallowing difficulty; **HISTORICAL DEATH BY AGE 2 FROM RESPIRATORY FAILURE — WAS LEADING GENETIC CAUSE OF INFANT MORTALITY UNTIL ~2017** (2 SMN2 copies); TYPE 2 (DUBOWITZ): onset 6-18mo; sits but never walks; respiratory + nutritional + orthopedic; survival into adulthood possible with support (3 SMN2); TYPE 3 (KUGELBERG-WELANDER): onset >18mo; walks initially but may lose ambulation; near-normal life expectancy (3-4 SMN2); TYPE 4 adult-onset mild (4+ SMN2). Incidence ~1/10,000 live births; carrier frequency ~1/40-50 — one of MOST COMMON AR genetic disorders. **NEWBORN SCREENING UNIVERSAL US STATES SINCE 2018**; SMA1 added to recommended panel 2018; international jurisdictions expanding. **CRITICAL COMPLICATIONS (untreated)**: progressive proximal muscle weakness; SCOLIOSIS universal non-ambulators; CONTRACTURES; RESPIRATORY FAILURE (intercostal weakness + diaphragmatic sparing → paradoxical breathing infants + restrictive lung + recurrent pneumonia); BULBAR weakness → feeding/swallowing difficulties; growth failure. **INTELLIGENCE NORMAL**. **STANDARD OF CARE TRANSFORMED 2016-2020**: pre-2016 was supportive care only — PT + respiratory + nutrition (G-tube) + orthopedic + palliative for SMA1. **NUSINERSEN (SPINRAZA, Biogen) = ANTISENSE OLIGONUCLEOTIDE** **FDA-APPROVED DECEMBER 2016** for SMA all ages + all types — FIRST SMA-specific therapy; mechanism: ASO binds SMN2 pre-mRNA splice silencer → increases exon 7 inclusion → increases full-length functional SMN from SMN2; **intrathecal via lumbar puncture** (loading then Q4mo lifelong). ENDEAR + CHERISH + NURTURE Phase 3. **ONASEMNOGENE ABEPARVOVEC (ZOLGENSMA, Novartis Gene Therapies/AveXis) = AAV9 GENE THERAPY** **FDA-APPROVED MAY 2019** for SMA <2y (≤21 kg); **SINGLE IV DOSE**; delivers SMN1 gene replacing missing copy. STR1VE + SPR1NT. **~$2.1M per dose**; transformative pre-symptomatic SMA1 detected via newborn screening. **RISDIPLAM (EVRYSDI, Genentech/Roche/PTC Therapeutics) = ORAL SMALL MOLECULE SPLICE MODIFIER** **FDA-APPROVED AUGUST 2020** (≥2mo; expanded <2mo); ORAL DAILY; binds SMN2 pre-mRNA modulating splice → increased exon 7 inclusion + functional SMN. SUNFISH + FIREFISH + JEWELFISH. Excellent CNS + peripheral distribution unlike intrathecal nusinersen. **THESE THREE THERAPIES HAVE TRANSFORMED SMA** — newborn screening + early treatment preserves motor function near normal in pre-symptomatic. Supportive: PT/OT/speech essential; respiratory (cough assist + BiPAP + tracheostomy); nutritional support; orthopedic (scoliosis surgery + contracture prevention); psychosocial. ATS Consensus 2018 pulmonary. **APITEGROMAB (anti-latent-myostatin biologic antibody, Scholar Rock/Roche) PHASE 3 SAPPHIRE READOUTS EMERGING** — potential adjunct for muscle preservation in patients on SMN-restorative therapy. Cure SMA (curesma.org) + SMA Foundation (smafoundation.org) + Muscular Dystrophy Association + International SMA Consortium patient advocacy. American Academy of Neurology + Treat-NMD international consortium guidelines. **Editorial**: NUSINERSEN + ZOLGENSMA + RISDIPLAM = standard-of-care named explicitly in browse; APITEGROMAB Phase 3 emerging future relevance noted. Community peptides Tier 3: BPC-157 no SMA characterization + wrong mechanism (SMA is motor neuron disease, muscle atrophy is secondary to denervation; not 'muscle repair'); NMN no SMA-specific evidence + NAD+ motor neuron work mostly ALS preclinical; GH-axis trio IGF-1 neurotrophic angle has disappointing clinical translation in motor neuron disease + myostatin framing mismatched (SMA is motor neuron not myopathy); APITEGROMAB is the regulated biologic with defined SMA-adjunct hypothesis. Seventy-fourth deliberate non-elevation of community peptides.

X-linked recessive disorders caused by mutations in DMD (Xp21.2-p21.1) — the largest gene in the human genome at ~2.4 Mb across 79 exons. Out-of-frame mutations → absent/severely reduced DYSTROPHIN protein = **DUCHENNE severe form** (incidence ~1/3500-5000 male births); in-frame mutations → partial-function dystrophin = **BECKER milder form** (often diagnosed in adulthood). Dystrophin normally links cytoskeletal actin to dystrophin-associated glycoprotein complex stabilizing sarcolemma during muscle contraction; absence → progressive fiber necrosis + fat/fibrotic replacement + defined clinical trajectory. Females typically carriers; ~5-10% manifesting carriers variable symptoms; subset have cardiomyopathy without overt muscle involvement. **DMD PROGRESSION (pre-treatment)**: delayed motor milestones + Gowers sign at 3-5y; loss of ambulation 10-13y; teen scoliosis + contractures + restrictive lung; late teens/20s dilated cardiomyopathy + respiratory failure; historical death 20s-30s. Modern multidisciplinary care extended median survival 30s-40s+. **CARDIOMYOPATHY = LEADING MORTALITY MODERN ERA**. Diagnostics: clinical + elevated CK (often >10,000 IU/L) + DMD gene analysis + dystrophin IHC if needed. Standard of care transformed continually: **CORTICOSTEROIDS (prednisone, deflazacort) = historical foundation** — slow progression + prolong ambulation + delay cardiac/respiratory + significant side effects. **VAMOROLONE (Agamree, ReveraGen/Catalyst) FDA OCT 2023** ≥2y — dissociative steroid reduced side effects. **EXON-SKIPPING ANTISENSE OLIGONUCLEOTIDES (ASOs)** mutation-specific dystrophin restoration: **ETEPLIRSEN (Exondys 51, Sarepta) FDA SEP 2016** exon 51 (~13% eligible); **GOLODIRSEN (Vyondys 53, Sarepta) FDA DEC 2019** exon 53; **VILTOLARSEN (Viltepso, NS Pharma) FDA AUG 2020** exon 53; **CASIMERSEN (Amondys 45, Sarepta) FDA FEB 2021** exon 45. All weekly IV; modest dystrophin restoration; accelerated approval pathway. **DELANDISTROGENE MOXEPARVOVEC (ELEVIDYS, Sarepta) = AAV-VECTORED MICRO-DYSTROPHIN GENE THERAPY FDA JUNE 2023** initially ambulatory ≥4-5y; **EXPANDED JUNE 2024 all DMD ≥4y** including non-ambulatory; SINGLE IV INFUSION ~$3.2M; EMBARK Phase 3 missed primary endpoint but signals; transformative for community despite controversy. **GIVINOSTAT (Duvyzat, Italfarmaco) HDAC INHIBITOR FDA MARCH 2024** ambulatory ≥6y. ATALUREN (Translarna, PTC) EMA-conditional nonsense mutations; FDA rejected multiple times. **APITEGROMAB (Scholar Rock anti-myostatin biologic antibody) Phase 3 DMD**. Multidisciplinary supportive care structured by 2018 DMD Care Considerations: PT + OT + cough assist + BiPAP + annual cardiac surveillance + ACE/ARB + beta-blocker early + scoliosis surgery + osteoporosis + puberty + speech/swallowing + nutrition + psychosocial. Delivered through **PPMD Certified Duchenne Care Center network**. Parent Project Muscular Dystrophy (PPMD) + Muscular Dystrophy Association + CureDuchenne + Duchenne Foundation + HOPE/Cure Becker patient advocacy. **Editorial**: Community peptide marketing reaches DMD families HEAVILY (vulnerable pediatric population + desperate families); Tier 3 across. BPC-157 'muscle healing' wrong mechanism (sarcomere stability disorder not tendon healing). NMN mitochondrial framing real biology but no DMD-specific evidence + no pediatric safety. GH-axis trio CORRECTION: NOT myostatin inhibitors (community framing wrong) — GHRH analogs/secretagogues raising IGF-1; somatropin is established medicine for confirmed GHD under endocrinology not interchangeable. APITEGROMAB is the regulated anti-myostatin program in Phase 3. Seventy-fifth deliberate non-elevation of community peptides.

Autosomal recessive progressive neurodegenerative disease. **MOST COMMON HEREDITARY ATAXIA**. Biallelic GAA trinucleotide repeat expansions in intron 1 of FXN (frataxin, 9q21.11). Normal 5-33 GAA repeats; pathologic 70-1000+ (typically 600-1200) → reduced FXN transcription → **FRATAXIN PROTEIN DEFICIENCY**. Frataxin = mitochondrial iron-sulfur cluster assembly protein essential for mitochondrial iron metabolism + oxidative phosphorylation + Krebs cycle enzymes. Deficiency → mitochondrial iron accumulation + oxidative stress + dysfunction → progressive neurodegeneration (dorsal root ganglia + spinocerebellar tracts + corticospinal tracts + dentate cerebellum + cardiac muscle + pancreatic β-cells). Incidence ~1/40,000-50,000 European populations; carrier ~1/85. Typical onset 5-25y (mean 10-15); LATE-ONSET (LOFA >25y) + VERY-LATE-ONSET (VLOFA >40y) usually shorter repeats. **CLINICAL FEATURES**: PROGRESSIVE GAIT ATAXIA (cerebellar + sensory ataxia from dorsal column involvement); dysarthria; dysmetria; LOSS OF DEEP TENDON REFLEXES (Achilles especially); EXTENSOR PLANTAR RESPONSES (Babinski); LOSS OF VIBRATION + PROPRIOCEPTION; muscle weakness + atrophy; SCOLIOSIS universal; pes cavus + foot deformity; **HYPERTROPHIC CARDIOMYOPATHY ~60% — concentric LVH progressing to dilated CM + arrhythmias + heart failure = LEADING MORTALITY DRIVER**; **DIABETES ~30%** insulin-deficient (β-cell failure from mitochondrial dysfunction, NOT T2D); optic atrophy + visual loss subset; sensorineural hearing loss; bladder dysfunction; **COGNITION PRESERVED** but executive function affected. **WHEELCHAIR-DEPENDENT BY 25-30** (~10-15y post-onset). Historical median survival ~37y. Diagnostics: clinical neurology + nerve conduction (axonal sensory neuropathy) + brain/spinal MRI (cord atrophy + cerebellar atrophy); ECG + echocardiogram + cardiac MRI for HCM; HbA1c diabetes; **FXN GAA repeat analysis = gold standard**. Standard of care: NO CURE; multidisciplinary — neurology (ataxia + disease-modifying therapy) + cardiology (HCM + arrhythmias + heart failure) + endocrinology (diabetes) + PT/OT/speech + orthopedic (scoliosis) + ophthalmology + audiology + pulmonology (later stages); mobility devices + wheelchair planning. **OMAVELOXOLONE (SKYCLARYS, Reata Pharmaceuticals/Biogen) = Nrf2 ACTIVATOR** **FDA-APPROVED FEBRUARY 2023** for FA patients ≥16 years — **FIRST FDA-APPROVED THERAPY for Friedreich ataxia AFTER 50+ YEARS** of disease description. **EMA-APPROVED FEBRUARY 2024**. Mechanism: activates Nrf2 (nuclear factor erythroid 2-related factor 2) antioxidant pathway → restores mitochondrial function + reduces oxidative stress; doesn't restore frataxin but compensates. MOXIe trial: significant mFARS improvement. Oral daily. AEs: ELEVATED TRANSAMINASES (LFT monitoring) + headache + nausea + abdominal pain + fatigue + decreased appetite. **TRANSFORMATIVE — first disease-modifying option in FA history despite modest effect size**. ~$370k/year list pricing; access issues real. **VATIQUINONE (EPI-743, Reata)** Phase 3 MOVE-FA mitochondrial protectant readouts emerging. **GENE THERAPY** multiple AAV-based frataxin replacement programs in trials. HDAC inhibitors increasing FXN transcription in trials. Antioxidants historically (idebenone + MitoQ + CoQ10) limited evidence. **CARDIAC MANAGEMENT**: ACE inhibitors + beta-blockers + ICDs arrhythmias + heart failure management standard; cardiomyopathy is leading mortality. **DIABETES**: INSULIN therapy; CGM useful; metabolic care. **Friedreich's Ataxia Research Alliance (FARA, curefa.org) + Friedreich's Ataxia Parents Group + Ataxia UK + Euroataxia + National Ataxia Foundation + International Friedreich Ataxia Consortium**. **Editorial**: OMAVELOXOLONE named explicitly as transformative FDA-approved standard-of-care after 50+ years. Community peptides Tier 3: BPC-157 no engagement + pro-angiogenic concern in HCM population; NMN mitochondrial framing more biologically grounded than in most conditions (FA IS mitochondrial disease) but no FA-specific evidence + same category as idebenone/MitoQ/CoQ10 limited clinical benefit; GH-axis trio IGF-1 cardiac hypertrophy concern in HCM population; semaglutide FA diabetes is insulin-deficient β-cell failure mechanism ≠ T2D insulin resistance. Seventy-sixth deliberate non-elevation of community peptides.

Amyloid fibril deposition of misfolded transthyretin (TTR, prealbumin) protein in tissues. **TWO MAIN FORMS**: **HEREDITARY ATTR (hATTR / ATTRv = variant)** autosomal dominant; >130 TTR mutations; geographic clusters — V30M Portuguese/Swedish/Japanese endemic (neuropathy-predominant); V122I African American ~3-4% (cardiac); T60A Irish/Appalachian (mixed); L111M Danish (cardiac); others global. **WILD-TYPE ATTR (wtATTR)** non-mutated TTR misfolds with age; elderly males >70; cardiac-predominant; formerly 'senile systemic amyloidosis'; UNDERDIAGNOSED CAUSE OF HFpEF in elderly. TTR normally synthesized by liver (~99%) + choroid plexus + retina; transports thyroxine + retinol-binding protein/vitamin A. Pathophysiology: mutated/aged TTR tetramer dissociates → monomers misfold → oligomers/protofilaments → amyloid fibril deposition in target tissues. **CLINICAL PHENOTYPES OVERLAP** (classify by predominance): NEUROPATHY-PREDOMINANT ATTRv (formerly FAP) — autonomic + sensorimotor peripheral neuropathy (length-dependent; small + large fiber); CARDIAC-PREDOMINANT ATTRv + wtATTR (formerly FAC) — restrictive cardiomyopathy + heart failure + AF + AV block → pacemaker; MIXED. Other: BILATERAL CARPAL TUNNEL (often decades before — RED FLAG); lumbar spinal stenosis; biceps tendon rupture; vitreous opacity + glaucoma; renal; GI dysmotility. **'RULE OF 4s' RED FLAGS**: bilateral carpal tunnel + lumbar stenosis + biceps rupture + family history → ATTR workup. Natural history untreated: progressive disability + death 5-15 years onset. **DIAGNOSIS**: clinical + TTR sequencing + **99mTc-PYP/DPD/HMDP scintigraphy** REVOLUTIONIZED cardiac ATTR diagnosis (intense myocardial uptake = positive without biopsy if SPEP + UPEP + free light chains exclude AL amyloidosis — CRITICAL differential); echo/cardiac MRI specific patterns; tissue biopsy + Congo red + amyloid typing mass spectrometry. **STANDARD OF CARE TRANSFORMED 2018-2024**: **TAFAMIDIS (Vyndaqel/Vyndamax, Pfizer) = TTR TETRAMER STABILIZER FDA MAY 2019** ATTR cardiomyopathy (ATTRv + wtATTR); ATTR-ACT trial mortality + hospitalization reduction; EMA earlier ATTRv neuropathy. **PATISIRAN (Onpattro, Alnylam) = LIPID NANOPARTICLE siRNA FDA AUG 2018** hATTR neuropathy; APOLLO trial; IV Q3wk; first-in-class siRNA. **INOTERSEN (Tegsedi, Akcea/Ionis) = ASO FDA OCT 2018** hATTR neuropathy; SC weekly; NEURO-TTR; thrombocytopenia + glomerulonephritis side effects. **VUTRISIRAN (Amvuttra, Alnylam) = GalNAc-CONJUGATED siRNA FDA JUNE 2022** hATTR neuropathy; HELIOS-A trial; SC Q3mo; **EXPANDED MARCH 2025 ATTR cardiomyopathy** via HELIOS-B (mortality + CV event reduction). **ACORAMIDIS (Attruby, BridgeBio) = NEXT-GENERATION TTR STABILIZER FDA NOV 2024** ATTR cardiomyopathy; oral BID; ATTRibute-CM trial. **EPLONTERSEN (Wainua, Ionis/AstraZeneca) = GalNAc-CONJUGATED ASO FDA DEC 2023** hATTR neuropathy; SC monthly; NEURO-TTRansform. **NTLA-2001 (Intellia) = CRISPR-Cas9 IN VIVO GENE EDITING** Phase 3 MAGNITUDE readouts emerging; single IV; permanently disables TTR. Liver transplant historical for ATTRv neuropathy largely supplanted by silencers. Cardiac: HF management challenging (diuretics cautious + BB/ACEi + AF anticoagulation + pacemakers conduction disease). Amyloidosis Research Consortium + Amyloidosis Foundation + Hereditary Amyloidosis Foundation + ATTR Amyloidosis Network UK + Mackay-Australian Amyloidosis Foundation + IETN International. ESC 2021 cardiac amyloidosis position paper + AHA 2020 statement + EAA expert consensus. **Editorial**: DISEASE TRANSFORMED 2018-2024 — multiple peptide-class disease-modifying therapies (patisiran + vutrisiran + inotersen + eplontersen siRNAs/ASOs + tafamidis + acoramidis stabilizers + NTLA-2001 CRISPR Phase 3) named explicitly as standard-of-care. Multi-jurisdictional (Andrade's 1952 Portuguese description + global endemic foci). Community peptides Tier 3: BPC-157 pro-angiogenic in restrictive CM + 'rule of 4s' carpal tunnel marketing wrong direction; NMN no TTR engagement + wtATTR sits in elderly NMN demographic; GH-axis trio IGF-1 cardiac hypertrophy in amyloid-thickened ventricle wrong direction + tesamorelin Rule 6 non-propagation; semaglutide STEP-HFpEF signal doesn't propagate to amyloid HFpEF + cachexia/sarcopenia concern. Seventy-seventh deliberate non-elevation of community peptides.

X-linked lysosomal storage disorder. GLA mutations (Xq22.1) encoding α-GALACTOSIDASE A (α-Gal A) → deficient enzyme → accumulation of GLOBOTRIAOSYLCERAMIDE (Gb3) + lyso-Gb3 (toxic metabolite) in lysosomes throughout body → multi-system disease. **X-LINKED INHERITANCE**: males more severely affected (classic Fabry); females NOT traditional carriers — X-inactivation/lyonization produces clinically significant symptoms in many heterozygotes (asymptomatic to nearly as severe as males). Incidence: ~1/40,000 males classic Fabry; broader phenotype incl. late-onset cardiac variant ~1/3,100. **CLASSIC PHENOTYPE** (males <1% enzyme activity): **CHILDHOOD ONSET 3-10y** — **NEUROPATHIC PAIN** (acroparesthesias = burning hands/feet; FABRY PAIN CRISES triggered by exercise/heat/stress/fever; often DISABLING; **frequently MISDIAGNOSED as growing pains + fibromyalgia + somatization for years**); ANGIOKERATOMAS (dark red-purple skin lesions especially 'bathing trunk' distribution); CORNEA VERTICILLATA (whorl-like corneal opacity diagnostic on slit lamp; also amiodarone/chloroquine differential); HYPOHIDROSIS / anhidrosis (heat intolerance + reduced sweating); chronic diarrhea + abdominal pain (GI dysmotility); proteinuria progressing **PROGRESSIVE KIDNEY DISEASE → ESRD 4th DECADE** (LEADING MORTALITY CAUSE HISTORICALLY pre-ERT); **HYPERTROPHIC CARDIOMYOPATHY** → dilated CM + arrhythmias + heart failure (5th decade); **CRYPTOGENIC STROKE YOUNG AGE** (white matter lesions + small vessel disease); ophthalmologic; psychiatric (depression + anxiety pain-related). **LATE-ONSET/VARIANT PHENOTYPE**: residual enzyme >1%; milder; primarily cardiomyopathy or cryptogenic stroke adulthood; recognized increasingly as cause of unexplained LVH or HFpEF + cryptogenic stroke. Diagnostics: clinical suspicion (childhood neuropathic pain + family history) + α-Gal A enzyme activity plasma/leukocytes (males diagnostic; female levels VARIABLE due to lyonization — may be FALSELY NORMAL); **LYSO-GB3 plasma/urine** highly sensitive biomarker; **GLA GENE SEQUENCING gold standard** especially females. **CASCADE FAMILY SCREENING CRITICAL** once index case identified. Standard of care: multidisciplinary (genetics + nephrology + cardiology + neurology + pain + ophthalmology + dermatology + audiology + psychiatry). **ENZYME REPLACEMENT THERAPY (ERT) STANDARD OF CARE SINCE 2001**: **AGALSIDASE BETA (FABRAZYME, Sanofi/Genzyme) FDA 2003**; EMA 2001; IV Q2wk 1mg/kg; full-length recombinant α-Gal A. **AGALSIDASE ALFA (REPLAGAL, Shire/Takeda) EMA-APPROVED 2001 (NEVER FDA-approved**, manufacturing issues); widely used internationally; IV Q2wk 0.2mg/kg. Both reduce Gb3 + lyso-Gb3; modest clinical benefits; **IRRs (infusion reactions) common; ANTI-DRUG ANTIBODIES ~50% classic males may reduce efficacy**. **MIGALASTAT (GALAFOLD, Amicus Therapeutics) = ORAL PHARMACOLOGICAL CHAPERONE FDA AUG 2018** for AMENABLE GLA MUTATIONS (binds α-Gal A stabilizing properly folded enzyme; only works missense mutations producing some residual properly-conformable enzyme; ~30-50% of patients amenable per Galafold Amenability Table); EMA 2016; oral QOD; less burdensome than IV ERT. **PEGUNIGALSIDASE ALFA (ELFABRIO, Chiesi/Protalix) = PEGylated α-Gal A FDA MAY 2023**; IV Q2wk; longer half-life + reduced immunogenicity than Fabrazyme; BRIDGE + BALANCE trials. Emerging: SUBSTRATE REDUCTION THERAPY (venglustat) in trials; **GENE THERAPY** multiple AAV-based α-Gal A delivery (FLT190 + AVR-RD-01 + ST-920) in trials. PAIN MANAGEMENT essential: anticonvulsants (gabapentin + pregabalin + carbamazepine); avoid triggers (heat + exercise + stress); pain crisis management. National Fabry Disease Foundation US + Fabry International Network + Fabry Disease Foundation + Fabry Registry + national patient organizations international. ESC 2024 expert consensus + Amicus Galafold Amenability Table. **Editorial**: ENZYME REPLACEMENT THERAPIES (FABRAZYME + REPLAGAL + ELFABRIO) are TRUE PEPTIDE/PROTEIN THERAPIES = recombinant enzymes administered as biologics; named explicitly as standard-of-care. MIGALASTAT (Galafold) is small-molecule chaperone (not peptide). Multi-jurisdictional disease (Replagal EMA-only + Fabrazyme/Elfabrio global FDA-approved). Community peptides Tier 3: BPC-157 angiogenic concern + pediatric uncharacterized (classic Fabry pediatric onset); NMN no GLA engagement + pediatric safety + ERT/Galafold titration biomarkers confounded; GH-axis trio IGF-1 cardiac hypertrophy in Fabry CM + renal hemodynamic in nephropathy + tesamorelin label HIV-LD only. Seventy-eighth deliberate non-elevation of community peptides.

Autosomal recessive lysosomal storage disorder + GSD type II. Biallelic mutations in GAA (17q25.3) encoding ACID α-GLUCOSIDASE → deficient GAA → glycogen accumulation in lysosomes throughout body especially CARDIAC + SKELETAL MUSCLE + DIAPHRAGM + liver + smooth muscle + CNS. **TWO SUBTYPES**: **INFANTILE-ONSET POMPE DISEASE (IOPD)** — most severe; presents <12 months; NULL GAA mutations (no enzyme activity); generalized hypotonia + SEVERE HYPERTROPHIC CARDIOMYOPATHY (massive cardiomegaly + WPW-like pattern + heart failure) + macroglossia + hepatomegaly + respiratory failure + feeding difficulties; HISTORICAL DEATH BY AGE 1 YEAR from cardiopulmonary failure pre-ERT; transformed by alglucosidase alfa; **CRIM-NEGATIVE IOPD develops anti-drug antibodies → immune tolerance induction protocols (rituximab + methotrexate + IVIG)**. **LATE-ONSET POMPE DISEASE (LOPD)** — partial enzyme activity; presents childhood through adulthood (median 30s-40s); proximal skeletal myopathy + progressive limb-girdle weakness + **DIAPHRAGMATIC WEAKNESS often presenting symptom (dyspnea + orthopnea + sleep-disordered breathing)** + scoliosis + cardiac involvement less severe than IOPD; mortality respiratory failure; many DIAGNOSED LATE from limb-girdle muscular dystrophy workup. Incidence ~1/40,000-100,000 combined varying ethnicity; higher in some populations (~1/14,000 African American; ~1/40,000 Taiwan). **NEWBORN SCREENING UNIVERSAL IN MANY US STATES SINCE 2015** (Taiwan pioneered universal screening); transformed early diagnosis + treatment. Diagnostics: clinical suspicion + CK elevated + **GAA ENZYME ACTIVITY dried blood spot/leukocytes/fibroblasts diagnostic** + GAA gene sequencing + CRIM status for IOPD; cardiac workup IOPD; pulmonary function FVC supine vs upright (diaphragmatic weakness); muscle biopsy if unclear. **STANDARD OF CARE = ENZYME REPLACEMENT THERAPY (ERT) STANDARD SINCE 2006**: **ALGLUCOSIDASE ALFA (MYOZYME/LUMIZYME, Sanofi/Genzyme) FDA APRIL 2006** — recombinant human GAA; IV Q2wk 20mg/kg; first ERT for Pompe; transformed IOPD survival from death by 1 year to long-term survival typically with significant disability. **AVALGLUCOSIDASE ALFA (NEXVIAZYME, Sanofi) FDA AUGUST 2021** late-onset Pompe ≥1y; IV Q2wk 20mg/kg; next-generation with enhanced mannose-6-phosphate residues for improved muscle uptake; COMET trial demonstrated improved FVC + functional outcomes vs alglucosidase alfa. **CIPAGLUCOSIDASE ALFA + MIGLUSTAT (POMBILITI + OPFOLDA, Amicus Therapeutics) FDA SEPTEMBER 2023** late-onset adults; combination — recombinant GAA with enhanced bis-phosphorylated M6P glycan (cipaglucosidase) + ORAL ENZYME STABILIZER (miglustat) just before infusion to prevent enzyme degradation in blood; PROPEL trial demonstrated improved FVC + 6MWT vs alglucosidase alfa. AAV-based gene therapy multiple programs in trials. Supportive: respiratory care (NIV → BiPAP → tracheostomy + ventilator); cardiac care (HF management IOPD); PT; nutrition; speech/swallowing; multidisciplinary Pompe center care. Acid Maltase Deficiency Association (AMDA) + International Pompe Association (IPA) + Pompe Disease Foundation + Muscular Dystrophy Association + Lysosomal Storage Diseases patient organizations international. **Editorial**: THREE FDA-APPROVED ERTs = TRUE PEPTIDE/PROTEIN THERAPIES named explicitly as standard-of-care (alglucosidase alfa 2006 + avalglucosidase alfa 2021 + cipaglucosidase alfa+miglustat combination 2023). Multi-jurisdictional disease (Taiwan pioneer + US/global). Community peptides Tier 3: BPC-157 no Pompe engagement + pediatric IOPD safety; NMN general-aging framing doesn't engage lysosomal storage; GH-axis trio LOPD myostatin framing reaches but COMET + PROPEL trial data are the evidence base; IOPD HCM concerning for IGF-1 mitogenic effects. Seventy-ninth deliberate non-elevation of community peptides.

Autosomal codominant disorder of LDL receptor pathway → extreme LDL-C elevation → markedly accelerated atherosclerotic cardiovascular disease (ASCVD) → premature coronary heart disease + stroke + peripheral vascular disease. **GENETIC CAUSES**: **LDLR mutations 60-90%** (>2,000 variants); **APOB mutations 5-10%** (R3500Q most common); **PCSK9 gain-of-function ~5%**; **LDLRAP1 <1%** autosomal recessive. **HETEROZYGOUS FH (HeFH)**: one defective copy; **PREVALENCE ~1/250 GENERAL POPULATION** — much more common than previously appreciated; **~25 MILLION CASES GLOBALLY; ~80% CURRENTLY UNDIAGNOSED**; LDL-C 190-450 mg/dL untreated; men first coronary event median 40s pre-treatment; women 50s pre-treatment; ~50% men + ~30% women without treatment develop CHD by 50. **HOMOZYGOUS FH (HoFH)**: two defective copies (compound heterozygous or true homozygous); **PREVALENCE ~1/250,000-360,000**; LDL-C 400-1000+ mg/dL untreated; ASCVD ONSET CHILDHOOD/ADOLESCENCE; **CHILDREN CAN HAVE MI**; severe aortic stenosis; tendinous + tuberous xanthomas + xanthelasmas + corneal arcus; **HISTORICAL DEATH 20s-30s** pre-treatment + transplant. Clinical: cholesterol elevations + **TENDINOUS XANTHOMAS** (Achilles + finger extensors HIGHLY SPECIFIC) + xanthelasmas + corneal arcus <45y + premature CHD/stroke/PAD + family history premature CHD CRITICAL. Diagnostics: **DUTCH LIPID CLINIC NETWORK (DLCN) + Simon Broome + MEDPED CRITERIA**; high LDL-C + family history + xanthomas + premature CHD; **GENETIC TESTING** confirms ~80% with NGS panel; **CASCADE FAMILY SCREENING ONCE INDEX CASE IDENTIFIED CRITICAL** (each first-degree relative 50% risk). Standard of care: **HIGH-INTENSITY STATIN = FOUNDATION** atorvastatin 40-80mg or rosuvastatin 20-40mg + ezetimibe added often. Bile acid sequestrants + niacin historical. **LIPID APHERESIS** for HoFH + refractory HeFH. **TARGETS**: LDL-C <100 mg/dL primary prevention HeFH; <70 mg/dL with established ASCVD; <55 mg/dL very high risk. **PCSK9 INHIBITORS — MONOCLONAL ANTIBODIES (TRUE PEPTIDE/PROTEIN THERAPIES)**: **EVOLOCUMAB (REPATHA, Amgen) FDA AUGUST 2015** HeFH + HoFH + established ASCVD; SC Q2wk or monthly; ~60% LDL-C reduction; FOURIER mortality + MI + stroke reduction. **ALIROCUMAB (PRALUENT, Sanofi/Regeneron) FDA JULY 2015** HeFH + established ASCVD; SC Q2wk; ~60% LDL-C reduction; ODYSSEY OUTCOMES CV event reduction. Both bind circulating PCSK9 → blocks LDLR degradation → upregulated LDL clearance. **INCLISIRAN (LEQVIO, Novartis) = siRNA TARGETING HEPATIC PCSK9 mRNA FDA DECEMBER 2021** HeFH + established ASCVD; ~50% LDL-C reduction; SC Q6mo after loading; novel siRNA mechanism. **EVINACUMAB (EVKEEZA, Regeneron) = MONOCLONAL ANTIBODY targeting ANGPTL3 FDA FEBRUARY 2021** HoFH ≥12y (later ≥6mo); **EXPANDED MARCH 2024 ≥6 months**; ANGPTL3 inhibition LDLR-INDEPENDENT pathway crucial for HoFH where LDLR pathway broken; ELIPSE HoFH trial; ~50% LDL-C reduction (unprecedented for genetic LDLR-deficiency); IV Q4wk; transformative for HoFH. LOMITAPIDE (Juxtapid) MTP inhibitor FDA 2012 HoFH (complex hepatic + REMS). MIPOMERSEN (Kynamro) ASO ApoB FDA 2013 HoFH (WITHDRAWN 2019). **BEMPEDOIC ACID (NEXLETOL, Esperion) ATP-CITRATE LYASE INHIBITOR FDA 2020** non-statin oral; CLEAR Outcomes 2023 CV mortality reduction. **VERVE-101 / VERVE-102 (Verve Therapeutics) = IN VIVO CRISPR BASE EDITING of PCSK9** Phase 1; single-dose permanent. **FH FOUNDATION (US, thefhfoundation.org) + International FH Foundation + Heart UK + European Atherosclerosis Society FH Studies Collaboration**. AHA + ACC + ESC + IAS guidelines + Pediatric Lipid Working Group + FH Foundation Care Guideline. **Editorial**: **PCSK9 MONOCLONAL ANTIBODIES (evolocumab + alirocumab) + PCSK9 siRNA (inclisiran) + ANGPTL3 mAb (evinacumab HoFH) = TRUE PEPTIDE-CLASS DISEASE-MODIFYING THERAPIES** named explicitly as standard-of-care alongside statins. Community peptides Tier 3: BPC-157 pro-angiogenic concern in established atherosclerotic plaque; NMN cardiovascular framing doesn't map to LDL receptor pathway; GH-axis trio doesn't engage LDLR/APOB/PCSK9/ANGPTL3; semaglutide SELECT CV benefit COMPLEMENTARY to lipid therapy not substitute. Eightieth deliberate non-elevation of community peptides.

X-linked recessive bleeding disorder caused by deficiency of clotting factors. **HEMOPHILIA A** = factor VIII (FVIII) deficiency from F8 gene mutations (Xq28) — most common (~80% of hemophilia; incidence ~1/5,000-10,000 male births). **HEMOPHILIA B** = factor IX (FIX) deficiency from F9 gene mutations (Xq27.1) — less common (~20%; ~1/25,000-40,000 male births). Severity classified by factor activity: **SEVERE <1%** (spontaneous bleeds; joint bleeds + ICH risk); **MODERATE 1-5%** (bleeding with minor trauma); **MILD 5-40%** (bleeding only with surgery/trauma; often undiagnosed until adulthood). **MANIFESTATIONS** (untreated severe): HEMARTHROSES → hemophilic arthropathy → progressive joint destruction (target joints knees + ankles + elbows); MUSCLE HEMATOMAS (compartment syndrome); **ICH = LEADING MORTALITY CAUSE** (especially infants + after trauma); GI/GU bleeding; oropharyngeal hematoma (airway compromise); post-surgical/dental bleeding. **CARRIER FEMALES**: typically asymptomatic but can have lower FVIII/FIX + bleeding (menorrhagia + postpartum); X-inactivation variable expression; OBLIGATE CARRIERS include daughters of affected males. Diagnostics: aPTT prolonged (corrected by mixing study); FVIII or FIX activity assay; F8/F9 genetic testing; **INHIBITOR TESTING (Bethesda assay)** — ~30% severe HA + ~5% severe HB develop neutralizing antibodies = major treatment-era complication. **STANDARD OF CARE TRANSFORMED 2017-2024**. Historical: factor concentrate replacement (recombinant FVIII/FIX or plasma-derived); prophylaxis standard from 1990s; on-demand for breakthrough; immune tolerance induction (ITI) for inhibitor patients. Extended half-life products (Eloctate/rFVIIIFc + Alprolix/rFIXFc + Adynovate + Idelvion + Rebinyn) extended dosing 2-3x/week to weekly. **EMICIZUMAB (HEMLIBRA, Roche/Genentech) = BISPECIFIC ANTIBODY mimicking FVIIIa** **FDA-APPROVED NOVEMBER 2017** initially HA with inhibitors → **EXPANDED OCT 2018 ALL HEMOPHILIA A regardless of inhibitor status**; mechanism: binds FIX/FIXa + FX/FXa bridging to mimic FVIIIa; SC weekly/Q2wk/Q4wk; HAVEN + HOHOEMI trials; ~96% bleeding reduction; TRANSFORMATIVE for HA; less effective HB. **EFANESOCTOCOG ALFA (ALTUVIIIO/ALTUVOCT, Sanofi/Sobi) = ENHANCED EHL FVIII FDA FEB 2023** hemophilia A; ULTRA HALF-LIFE; once-weekly achieves near-normal hemostasis; XTEND-1 + XTEND-Kids + ELECTIVE-A trials. **FITUSIRAN (QFITLIA, Alnylam/Sanofi) = siRNA TARGETING ANTITHROMBIN FDA MARCH 2025** HA + B with or without inhibitors; mechanism: reduces antithrombin → rebalances coagulation; SC monthly; ATLAS trials; ~70% bleeding reduction. **CONCIZUMAB (ALHEMO, Novo Nordisk) = MONOCLONAL ANTIBODY TARGETING TFPI FDA DEC 2024** HA or B with inhibitors ≥12y; mechanism: blocks TFPI → increases thrombin generation; SC daily; explorer8 trial. **GENE THERAPY ERA**: **VALOCTOCOGENE ROXAPARVOVEC (ROCTAVIAN, BioMarin) = AAV5-FVIII GENE THERAPY FDA JUNE 2023** severe adult HA; single IV; GENEr8-1; ~$2.9M; transformative but expensive. **ETRANACOGENE DEZAPARVOVEC (HEMGENIX, CSL Behring) = AAV5-FIX GENE THERAPY FDA NOV 2022** adult severe HB; HOPE-B; ~$3.5M. **FIDANACOGENE ELAPARVOVEC (BEQVEZ, Pfizer) = AAV-FIX GENE THERAPY FDA APRIL 2024** adult severe HB; BENEGENE-2. Multiple emerging gene therapies in trials. Inhibitor management: bypassing agents (rFVIIa NovoSeven + activated prothrombin complex FEIBA); ITI; emicizumab now standard. **HEMOPHILIA TREATMENT CENTERS (HTCs)** WFH network multidisciplinary. **WORLD FEDERATION OF HEMOPHILIA (WFH, wfh.org)** + National Hemophilia Foundation + Hemophilia Federation of America + Hemophilia Society UK + national societies international. WFH 2020 guidelines + MASAC + EUHASS. Global access disparities (high-income vs LMICs). **CONTAMINATED-PLASMA ERA HIV/HCV TRAUMATIC COMMUNITY MEMORY** from 1980s shapes new biologic reception. **Editorial**: Multiple peptide/protein-class disease-modifying therapies named explicitly as standard-of-care (emicizumab + efanesoctocog alfa + fitusiran + concizumab) + gene therapies (Roctavian + Hemgenix + Beqvez). Community peptides Tier 3: BPC-157 'healing peptide' frame + INJECTION BLEED RISK in severe disease + IM CONTRAINDICATED; NMN aging hemophilia new demographic but no F8/F9 characterization; GH-axis trio injection bleed + GH/IGF-1 coagulation effects uncharacterized; semaglutide rising obesity in aging hemophilia population + coordination-of-care (factor PK shifts + injection timing). Eighty-first deliberate non-elevation of community peptides.

Most common lysosomal storage disorder. Autosomal recessive; biallelic mutations in GBA1 (chromosome 1q21) encoding **β-GLUCOCEREBROSIDASE (GCase / β-glucosidase / lysosomal acid β-glucosidase)** → deficient enzyme → accumulation of GLUCOCEREBROSIDE (GlcCer / glucosylceramide) in macrophages → 'Gaucher cells' (lipid-laden macrophages) infiltrate organs. **3 CLASSICAL TYPES** based on neurologic involvement: **TYPE 1 (NON-NEURONOPATHIC)** — MOST COMMON ~94%; no primary CNS involvement; presents childhood to adulthood; **ASHKENAZI JEWISH HERITAGE high prevalence** (carrier ~1/15-18; disease ~1/450-855 — orders of magnitude higher than general population); HEPATOMEGALY + SPLENOMEGALY (often massive); THROMBOCYTOPENIA (hypersplenism + marrow infiltration); ANEMIA; BONE INVOLVEMENT — pain + bone crises + AVASCULAR NECROSIS (femoral heads especially) + osteopenia + pathologic fractures + Erlenmeyer flask deformity distal femur; growth retardation children; pulmonary hypertension subset; **NEUROLOGIC SPARING defining feature** (though Parkinson's risk increased). **TYPE 2 (ACUTE NEURONOPATHIC)** — RARE; INFANTILE onset; severe neurological deterioration + brainstem involvement + bulbar palsy + spasticity + seizures + opisthotonus + horizontal gaze palsy; RAPIDLY FATAL typically 2-4 years; ERT doesn't cross BBB so doesn't address neurologic features. **TYPE 3 (CHRONIC NEURONOPATHIC)** — JUVENILE/ADOLESCENT onset; intermediate severity; visceral + bone disease similar to Type 1 PLUS slow horizontal saccadic eye movements + cognitive deficits + seizures + spasticity in some; survival to adulthood possible. **GAUCHER-PARKINSONISM ASSOCIATION**: GBA1 mutations (even heterozygous) = MOST COMMON GENETIC RISK FACTOR FOR PARKINSON'S DISEASE + Lewy body dementia; ~5-10% Gaucher Type 1 develop parkinsonism; heterozygous GBA1 carriers ~5x increased PD risk; α-synuclein accumulation mechanism. Incidence: ~1/40,000-1/100,000 general; markedly higher Ashkenazi ~1/450-855; founder mutations N370S (N409S Ashkenazi) + L444P (L483P Type 2/3). Diagnostics: clinical suspicion + β-glucocerebrosidase enzyme activity (leukocytes/fibroblasts; low/absent diagnostic) + GBA1 genetic testing + chitotriosidase + glucosylsphingosine (lyso-Gb1) biomarkers tracking activity; bone imaging (MRI for marrow infiltration + AVN). Standard of care: **TYPE 1 + Type 3 visceral disease = ENZYME REPLACEMENT THERAPY (ERT) STANDARD SINCE 1991**. **IMIGLUCERASE (CEREZYME, Sanofi/Genzyme) FDA MAY 1994** — recombinant β-glucocerebrosidase modified macrophage uptake; IV Q2wk; gold standard (alglucerase/Ceredase 1991 placental-derived predecessor — discontinued). **VELAGLUCERASE ALFA (VPRIV, Shire/Takeda) FDA FEBRUARY 2010** — recombinant β-glucocerebrosidase human fibroblast cell line; IV Q2wk; similar efficacy. **TALIGLUCERASE ALFA (ELELYSO, Pfizer/Protalix) FDA MAY 2012** — recombinant β-glucocerebrosidase carrot cell line (first plant-cell-produced biologic); IV Q2wk. All three transformed Type 1 + visceral Type 3 outcomes — reduced hepatosplenomegaly + improved cytopenias + bone disease + QoL; **do NOT cross BBB** so don't address neurological Type 2/3 features. **SUBSTRATE REDUCTION THERAPY (SRT)** reduces GlcCer synthesis: **MIGLUSTAT (ZAVESCA, Actelion) = small molecule glucosylceramide synthase inhibitor FDA JULY 2003** mild-moderate Type 1 unable receive ERT (rarely first-line; GI + cognitive + peripheral neuropathy); also Niemann-Pick C. **ELIGLUSTAT (CERDELGA, Sanofi/Genzyme) = potent + selective glucosylceramide synthase inhibitor FDA AUGUST 2014** Type 1 adults; ORAL — no IV infusion; effective alternative to ERT; CYP2D6 genotype-dependent dosing; ENCORE + EDGE trials comparable efficacy ERT in stable. Both SRTs cross BBB but don't reverse established neurologic damage Type 2/3. AMBROXOL (small-molecule chaperone) trials for neuronopathic; GENE THERAPY multiple AAV programs (PR001/LY-3884961 for PD + Gaucher; Avrobio AVR-RD-02 LV ex-vivo); CRISPR preclinical. Multidisciplinary care: hematology (cytopenias) + hepatology (organomegaly + HCC surveillance) + orthopedic (bone disease + AVN) + pulmonology (pulmonary HTN) + neurology (Type 3 + Parkinson watch) + genetics (cascade screening Ashkenazi families) + pain + bone density. National Gaucher Foundation (US, gaucherdisease.org) + Gaucher Community Alliance + European Gaucher Alliance + International Collaborative Gaucher Group (ICGG) Gaucher Registry largest patient registry + European Working Group on Gaucher Disease (EWGGD). **Editorial**: Multiple FDA-approved ERTs + SRTs named explicitly as standard-of-care peptide/protein therapies + emerging gene therapy. Multi-jurisdictional (Ashkenazi founder mutations + global). Community peptides Tier 3: BPC-157 pro-angiogenic concern in elevated HCC + multiple myeloma + malignancy risk; NMN GBA1-Parkinson's extrapolation; GH-axis trio pediatric growth retardation context but somatropin is supervised standard not community peptides. Eighty-second deliberate non-elevation of community peptides.

Acquired clonal hematopoietic stem cell disorder — somatic PIGA mutations cause loss of GPI-anchored complement regulators CD55 and CD59, driving uncontrolled complement-mediated intravascular hemolysis, life-threatening thrombosis (characteristically hepatic vein / Budd-Chiari and cerebral venous sinus), and bone marrow failure with frequent aplastic anemia overlap. Standard-of-care transformed by complement-pathway inhibitors: eculizumab (Soliris, FDA March 2007 — first complement inhibitor ever), ravulizumab (Ultomiris, FDA December 2018), pegcetacoplan (Empaveli/Aspaveli, FDA May 2021), iptacopan (Fabhalta, FDA December 2023 — first oral), danicopan (Voydeya, FDA March 2024), crovalimab (PiaSky, FDA June 2024). Meningococcal vaccination is load-bearing precondition. Allogeneic HSCT remains the only curative option. Eighty-third deliberate non-elevation of community peptides.

Family of autosomal recessive lysosomal storage disorders (MPS II is X-linked) caused by deficiency of specific enzymes that degrade glycosaminoglycans (GAGs/mucopolysaccharides) — GAG accumulation in lysosomes throughout the body produces multi-system disease. Pediatric onset is typical; identity-affirming community within rare-disease and disability advocacy. Multi-system: skeletal dysplasia (dysostosis multiplex), short stature, joint stiffness, hepatosplenomegaly, progressive cardiac valve disease, airway obstruction (anesthesia high-risk), corneal clouding, hearing loss, cognitive impairment in CNS-involving forms. Disease-modifying ERTs: LARONIDASE (Aldurazyme, FDA April 2003) MPS I; IDURSULFASE (Elaprase, FDA July 2006) MPS II; PABINAFUSP ALFA (Izcargo) approved Japan March 2021 for neuronopathic MPS II via BBB-crossing transferrin-receptor fusion; ELOSULFASE ALFA (Vimizim, FDA February 2014) MPS IVA; GALSULFASE (Naglazyme, FDA May 2005) MPS VI; VESTRONIDASE ALFA (Mepsevii, FDA November 2017) MPS VII. MPS III (Sanfilippo) has NO approved ERT — gene therapy trials (Lysogene, Abeona, Ultragenyx UX111) are the load-bearing hope. HSCT for severe MPS I Hurler in infancy <2y is standard-of-care. Eighty-fourth deliberate non-elevation of community peptides.

Rare lymphoproliferative disorder family. Unicentric Castleman disease (UCD) involves a single lymph-node region and is often curable with surgical resection. Multicentric Castleman disease (MCD) involves multiple lymph-node regions with systemic inflammatory disease driven by cytokine storm, IL-6 dominant. MCD subtypes: HHV-8-associated MCD (KSHV-related; standard-of-care RITUXIMAB (Rituxan, Roche/Genentech) plus antiretrovirals in HIV-positive patients); HHV-8-negative idiopathic multicentric Castleman disease (iMCD), subdivided into iMCD-TAFRO (thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly), iMCD-NOS, and iMCD-IPL; POEMS-associated MCD. Standard-of-care peptide/protein therapies: SILTUXIMAB (Sylvant, EUSA Pharma/Recordati) chimeric anti-IL-6 mAb FDA April 2014 for HHV-8-negative iMCD — first and only FDA-approved iMCD therapy; IV every 3 weeks. TOCILIZUMAB (Actemra, Roche/Chugai) anti-IL-6 receptor mAb approved in JAPAN for iMCD since 2005 — multi-jurisdictional reality preceding the US approval by nearly a decade; off-label in the US. iMCD is fatal without treatment in severe flares. Castleman Disease Collaborative Network (CDCN, castlemannetwork.org) is the international research and patient-advocacy consortium. Eighty-fifth deliberate non-elevation of community peptides.

Most common monogenic autoinflammatory disease — autosomal recessive MEFV gene mutations (chromosome 16p13.3) encoding pyrin. Classic recurrent self-limited attacks of 12-72 hours: fever, serositis (peritonitis, pleuritis, synovitis, scrotal pain), erysipelas-like erythema. Subclinical inflammation between attacks with elevated CRP and serum amyloid A. AA amyloidosis is the leading long-term complication if untreated, leading historically to renal failure. Standard-of-care: COLCHICINE (since Goldfinger 1972, first-line lifelong, prevents both flares and amyloidosis). For ~5-10% colchicine-resistant FMF: IL-1 blockade — CANAKINUMAB (Ilaris, Novartis, anti-IL-1β mAb, FDA-approved 2016 for colchicine-resistant FMF + HIDS + TRAPS + CAPS, SC every 4-8 weeks), ANAKINRA (Kineret, Swedish Orphan Biovitrum, IL-1 receptor antagonist, SC daily widely used off-label), RILONACEPT (Arcalyst, Regeneron, IL-1 trap, SC weekly, FDA-approved for CAPS). Related periodic fever syndromes share IL-1β biology: CAPS (NLRP3 — FCAS + Muckle-Wells + NOMID/CINCA spectrum), TRAPS (TNFRSF1A), HIDS / mevalonate kinase deficiency (MVK), PFAPA (most common pediatric periodic fever, polygenic). Multi-jurisdictional reality: FMF concentrates in populations of Mediterranean ancestry — Sephardic Jewish (carrier rate ~1/5-7), Armenian (~1/7), Turkish, Arab, Italian — with largest clinical cohorts in Turkey, Israel, and Armenia. Eighty-sixth deliberate non-elevation of community peptides.

Ultra-rare autosomal recessive disorder of triglyceride metabolism — biallelic loss-of-function mutations in LPL (most common; lipoprotein lipase deficiency), APOC2, APOA5, GPIHBP1, or LMF1 → impaired chylomicron clearance → severe persistent hypertriglyceridemia (>880 mg/dL, often >2000 mg/dL) → recurrent acute pancreatitis from childhood as #1 mortality and chronic morbidity driver. Eruptive xanthomas + lipemia retinalis + hepatosplenomegaly + chronic abdominal pain + fatigue + documented cognitive and psychological burden. Standard-of-care framework: EXTREME LIFELONG FAT-RESTRICTED DIET (<10-15% calories from fat, sometimes <20g/day, medium-chain triglycerides for caloric density) — the foundation, quality-of-life-defining; OLEZARSEN (Tryngolza, Ionis, GalNAc-conjugated APOC3 antisense oligonucleotide FDA-approved December 2024 — the first FDA-approved FCS therapy, SC monthly); VOLANESORSEN (Waylivra, Akcea/Ionis, APOC3 antisense EMA-approved May 2019 — multi-jurisdictional reality where APOC3 antisense was first approved in Europe; SC weekly with mandatory thrombocytopenia monitoring; NOT FDA-approved due to platelet safety signal); plasmapheresis for acute hypertriglyceridemic pancreatitis. Statins and fibrates ineffective for monogenic FCS. FCS Foundation (fcsfoundation.org) + ACTION FCS registry + IDEAL FCS multi-jurisdictional studies. Eighty-seventh deliberate non-elevation of community peptides.

The family of hereditary motor and sensory neuropathies (HMSN) — the most common inherited neurologic disorder at roughly 1 in 2,500, with progressive distal weakness, the characteristic 'inverted champagne bottle' lower-limb atrophy, sensory loss, pes cavus, and hammer toes. Genetic testing across the 100+ causative genes drives subtype confirmation: CMT1A (PMP22 duplication, ~50% of cases, demyelinating), CMT1B (MPZ), CMT2 (axonal subtypes), CMT4 (recessive demyelinating), CMTX1 (X-linked, GJB1), HNPP (PMP22 deletion — the opposite-direction relative). NEUROMUSCULAR SPECIALIST COORDINATION and the CMTA WALLET CARD (vincristine ABSOLUTELY CONTRAINDICATED, plus paclitaxel, cisplatin, isoniazid, nitrofurantoin, amiodarone, and gold compounds with caution) anchor safety. PXT3003 (Pharnext combination of low-dose baclofen + naltrexone + sorbitol) EMA marketing authorization application in CMT1A and AAV gene-therapy pipeline (Sarepta CMT1A and others) carry the disease-modifying conversation. NO disease-modifying therapy currently FDA-approved. Standard-of-care mainstay is symptomatic: physical therapy, AFO orthotics, occupational therapy, gabapentinoids and amitriptyline for neuropathic pain, foot-deformity surgery, mobility aids. CMTA (cmtausa.org) + HNF + Inherited Neuropathy Consortium (INC, NIH-funded). Eighty-eighth deliberate non-elevation of community peptides.

Bone marrow failure syndrome — pancytopenia with hypocellular marrow. Acquired AA is immune-mediated T-cell-driven destruction of hematopoietic stem cells (idiopathic majority, drug/toxin minority). Inherited bone marrow failure syndromes (IBMFS) overlap and are often pediatric onset: Fanconi anemia (FA, FANC genes, MMC chromosomal breakage), Dyskeratosis congenita (DC, TERT/TERC/DKC1 telomere genes), Diamond-Blackfan anemia (DBA, ribosomal gene mutations), Shwachman-Diamond syndrome (SBDS). AA-PNH is a recognized bidirectional overlap entity. Severe AA (SAA) by Camitta criteria: hypocellular marrow + ≥2 of (ANC <500, platelets <20K, retic <60K). Very Severe AA (VSAA): ANC <200. Standard-of-care peptide/protein therapies: allogeneic HSCT (curative — first-line for SAA <50y with matched sibling donor); immunosuppressive therapy (IST) with horse ATG (hATG) + cyclosporine A; ELTROMBOPAG (Promacta US / Revolade ex-US, Novartis) — TPO receptor agonist FDA-approved November 2014 for refractory SAA, expanded January 2018 to front-line SAA in combination with hATG + CsA (NIH Clinical Center RACE trial; combined response rate ~85% vs ~60% for IST alone). Romiplostim (Nplate, Amgen) emerging role. Inherited BMF-specific therapies and gene therapy programs (Rocket Pharmaceuticals RP-L102/RP-L201 for Fanconi) are the load-bearing hope. Eighty-ninth deliberate non-elevation of community peptides.

Most common inherited hemolytic anemia in Northern European populations (~1/2,000-5,000), with documented prevalence in African, Middle Eastern, and Asian heritage cohorts. Autosomal dominant majority and autosomal recessive minority — mutations in ANK1 (ankyrin), SPTB (β-spectrin), SPTA1 (α-spectrin), SLC4A1 (band 3), or EPB42 (protein 4.2) disrupt membrane-skeleton vertical interactions, producing spherocytes destroyed in the spleen. Hemolytic anemia, jaundice (often neonatal — a leading cause of neonatal jaundice requiring exchange transfusion in some populations), splenomegaly, pigment gallstones, parvovirus B19-triggered aplastic crises, and folate-deficiency-driven megaloblastic crises define the clinical picture. Diagnosis: family history + peripheral blood smear (spherocytes) + EMA BINDING TEST BY FLOW CYTOMETRY (modern preferred, displacing the older osmotic fragility test) + cryohemolysis + genetic testing for severe / atypical cases. Standard-of-care: SPLENECTOMY (historically curative for moderate-severe HS) with modern shift toward PARTIAL SPLENECTOMY IN CHILDREN and reluctance to splenectomize under 5 years given sepsis risk — pre-splenectomy pneumococcal + meningococcal + Hib vaccination and post-splenectomy antibiotic prophylaxis non-negotiable; FOLIC ACID supplementation; transfusions for severe HS or aplastic crisis; cholecystectomy for symptomatic pigment stones; parvovirus B19 monitoring. MITAPIVAT (Pyrukynd, Agios Pharmaceuticals), the pyruvate kinase activator FDA-approved February 2022 for pyruvate kinase (PK) deficiency, is under Phase 3 evaluation for expanded indication in HS and thalassemia. Related red cell membrane disorders: hereditary elliptocytosis (HE), hereditary pyropoikilocytosis (HPP), hereditary stomatocytosis (overhydrated and dehydrated subtypes). Related hereditary enzyme disorders adjacent: G6PD deficiency (~400M worldwide, X-linked, Mediterranean / African / Asian heritage), PK deficiency, glucose-phosphate isomerase deficiency. Hereditary Spherocytosis Foundation + Hereditary Hemolytic Anemia Foundation + Rare Anemias Foundation. Ninetieth deliberate non-elevation of community peptides.

Inborn errors of immunity — over 450 recognized syndromes (IUIS 2022 + 2024 update). Major patient-community-organized families covered: SEVERE COMBINED IMMUNODEFICIENCY (SCID, 'bubble baby disease') with multiple genetic etiologies (IL2RG X-linked ~50%, JAK3, IL7R, ADA, RAG1/RAG2, DCLRE1C/Artemis, CD3D); X-LINKED AGAMMAGLOBULINEMIA (XLA, Bruton agammaglobulinemia, BTK mutations); COMMON VARIABLE IMMUNODEFICIENCY (CVID, the most common symptomatic PID, heterogeneous with ~25% monogenic — TACI, ICOS, NFKB, CTLA4, LRBA); CHRONIC GRANULOMATOUS DISEASE (CGD, NADPH oxidase complex defect — CYBB X-linked + NCF1/2/4 + CYBA, impaired neutrophil oxidative burst → catalase-positive infections including Aspergillus, Staph aureus, Burkholderia). The diagnostic landscape was transformed by the addition of TREC (T-cell receptor excision circles) NEWBORN SCREENING to the US Recommended Uniform Screening Panel in 2010 (universal across all US states by 2018). Standard-of-care by syndrome: SCID — allogeneic HSCT, STRIMVELIS (GSK) EMA-approved 2016 ex vivo gene therapy for ADA-SCID (first ex vivo gene therapy for any disease in the EU), ELAPEGADEMASE (Revcovi, Leadiant) pegylated recombinant ADA enzyme replacement FDA-approved October 2018 SC weekly, X-SCID gene therapy programs advancing; XLA — IVIG monthly or SCIg weekly LIFELONG; CVID — IgG replacement lifelong, ABATACEPT (Orencia, BMS) for CTLA4 deficiency, rapamycin for LRBA, HSCT for severe cases; CGD — prophylactic TMP-SMX + itraconazole + IFN-gamma (Actimmune, FDA-approved 1990), allogeneic HSCT curative, Orchard Therapeutics OTL-102 gene therapy investigational. Other PIDs covered editorially: Wiskott-Aldrich syndrome (WAS), Ataxia-telangiectasia (A-T), DiGeorge syndrome (22q11), Hyper-IgM, IPEX syndrome, XLP, STAT/JAK signaling defects. Immune Deficiency Foundation (IDF, primaryimmune.org) US + Jeffrey Modell Foundation (JMF, info4pi.org) international + ESID European + USIDNET US registry. Ninety-first deliberate non-elevation of community peptides.

The family of clonal and inflammatory histiocytic proliferations transformed by the Badalian-Very 2010 Blood discovery of BRAF-V600E in Langerhans Cell Histiocytosis — the landmark that moved this field from 'mysterious' rare disease into precision medicine. Langerhans Cell Histiocytosis (LCH) — clonal proliferation of CD1a+/CD207+ Langerhans cells with BRAF-V600E in ~55% of cases; spectrum from single-system (bone, skin) to multi-system disease with risk-organ involvement (liver, spleen, hematopoietic); pediatric and adult disease; LCH-associated neurodegeneration is a late complication. Erdheim-Chester Disease (ECD) — rare adult-onset non-Langerhans histiocytosis; foamy CD68+/CD1a-/S100- histiocytes with MAPK pathway mutations (BRAF-V600E ~50%, MAP2K1, NRAS, KRAS); multi-system with long-bone osteosclerosis, 'hairy kidney' perinephric fibrosis, cardiac mass, retroperitoneal fibrosis, CNS involvement. Rosai-Dorfman Disease (RDD) — sinus histiocytosis with massive lymphadenopathy; S100+/CD68+/CD1a- histiocytes with emperipolesis; self-limited in many, aggressive in a subset; MAPK and KIF5B mutations. Hemophagocytic Lymphohistiocytosis (HLH) — life-threatening cytokine storm; primary (familial, FHL) PRF1 / UNC13D / STX11 / STXBP2 mutations with infantile onset, or secondary (EBV-triggered, autoimmune-associated, lymphoma-associated); cardinal criteria fever + cytopenias + hepatosplenomegaly + hyperferritinemia + hypertriglyceridemia + hypofibrinogenemia. Standard-of-care frameworks: LCH-III vinblastine + prednisone backbone, BRAF/MEK inhibition (VEMURAFENIB / Zelboraf, Roche/Genentech, and DABRAFENIB + TRAMETINIB / Tafinlar + Mekinist, Novartis) for BRAF-V600E disease, cladribine, allogeneic HSCT for refractory; ECD VEMURAFENIB (Zelboraf) FDA-APPROVED NOVEMBER 2017 — landmark precision-medicine approval — plus COBIMETINIB (Cotellic) combinations; RDD cobimetinib / MEK inhibition for refractory, sirolimus, cladribine, methotrexate; HLH-94 and HLH-2004 international protocols (etoposide + dexamethasone + cyclosporine), EMAPALUMAB (Gamifant, Sobi) anti-IFN-gamma mAb FDA-APPROVED NOVEMBER 2018 for primary HLH, RUXOLITINIB (Jakafi, Incyte) JAK1/2 for refractory, allogeneic HSCT curative for FHL. Histiocytosis Association (histio.org) + Erdheim-Chester Disease Global Alliance + Rosai-Dorfman Disease Foundation + Histiocyte Society international research consortium + HLH-94/2004 trial cohorts. Ninety-second deliberate non-elevation of community peptides.

Autosomal recessive lysosomal storage disorder caused by CTNS gene mutations encoding CYSTINOSIN — the lysosomal cystine transporter. Loss of function produces cystine accumulation in lysosomes throughout the body and multi-organ damage. Three clinical forms: NEPHROPATHIC INFANTILE (~95%, most severe, Fanconi syndrome by 6-12 months); JUVENILE (intermediate); OCULAR non-nephropathic (adult-onset, corneal crystals only). Manifestations of nephropathic cystinosis: Fanconi syndrome (proximal renal tubular dysfunction → glycosuria + aminoaciduria + phosphaturia + bicarbonate wasting + polyuria + polydipsia + dehydration + failure to thrive), growth failure, hypothyroidism, hypogonadism, diabetes, muscle wasting, swallowing problems, CNS involvement, corneal crystals (universal), ESRD typically by 10-12 years without treatment. Standard-of-care is CYSTEAMINE LIFELONG: cysteamine bitartrate (CYSTAGON, Mylan/Viatris) FDA-approved 1994 with Q6h dosing; delayed-release cysteamine bitartrate (PROCYSBI, Horizon Therapeutics / Amgen) FDA-approved April 2013 with Q12h dosing transformed adherence; topical cysteamine eye drops (CYSTADROPS, Recordati Rare Diseases) FDA-approved August 2020 for corneal crystals. RENAL TRANSPLANTATION for ESRD does NOT recur in the transplanted kidney (defect is in the patient's lysosomes, not the kidneys) but does NOT cure systemic cystinosis — cysteamine must continue lifelong post-transplant. Growth hormone (somatropin) for cystinosis-related growth retardation under pediatric endocrinology supervision in selected cases. Carnitine + electrolyte replacement + bicarbonate + phosphate + vitamin D for Fanconi syndrome management. Investigational gene therapy: Avrobio AVR-RD-04 lentiviral HSC ex-vivo program advancing. Cystinosis Research Foundation (cystinosisresearch.org) US + Cystinosis Foundation Ireland + European Cystinosis Network + Cystinose Network Deutschland. Ninety-third deliberate non-elevation of community peptides.

Autosomal recessive inborn error of tyrosine catabolism. **ALKAPTONURIA (AKU)**: biallelic HGD mutations (chromosome 3q13.33) → loss of homogentisate 1,2-dioxygenase activity → homogentisic acid (HGA) accumulation → oxidation to benzoquinone acetate → ochronotic pigment deposition in connective tissue. **Archibald Garrod 1902** described AKU as the founding example of 'inborn error of metabolism' — Mendelian inheritance applied to humans for the first time. CHILDHOOD: black-staining urine on exposure to air. ADULTHOOD: ochronosis (slate-blue/black pigmentation of cartilage, sclera, ear cartilage, skin) and ochronotic arthropathy (severe destructive arthritis typically affecting lumbar/cervical spine first, then large joints; multiple joint replacements common); aortic and mitral valve calcification and ochronotic coronary artery disease (~80% cardiac involvement by age 60); kidney stones from HGA crystallization. **AKU diagnosis is often delayed into adulthood when ochronotic arthropathy finally presents**. **SLOVAK REPUBLIC and DOMINICAN REPUBLIC founder populations** carry the highest known AKU prevalence. **HEREDITARY TYROSINEMIA TYPE I (HT-1)**: FAH gene mutations; pre-treatment fatal pediatric liver and kidney disease; **QUEBEC SAGUENAY-LAC-SAINT-JEAN founder population** has the highest known global prevalence. **HT-2 (Richner-Hanhart syndrome)**: TAT gene; oculocutaneous presentation. **HT-3**: HPD gene; rare. **NITISINONE (Orfadyn, Sobi) is the disease-modifying therapy** — HPPD inhibitor acting upstream of the metabolic block. **FDA-approved 2002 for HT-1**, transforming what had been a fatal pediatric disease, and **FDA-approved October 2020 for ALKAPTONURIA** after the SONIA-2 European DevelopAKUre trial — 118 years after Garrod's founding description. **DIETARY TYROSINE and PHENYLALANINE RESTRICTION** is the load-bearing adjunct to nitisinone. Joint replacement and cardiac valve surgery common in advanced AKU. AKU Society (UK, akusociety.org) + Genetic Alkaptonuria Network + DevelopAKUre European consortium (Cardiff-coordinated) + UK Royal Liverpool National AKU Centre. Ninety-fourth deliberate non-elevation of community peptides.

Autosomal recessive disorder of branched-chain amino acid (BCAA) catabolism caused by deficiency of the BRANCHED-CHAIN α-KETOACID DEHYDROGENASE COMPLEX (BCKDC) required to catabolize leucine, isoleucine, and valine. Multiple genetic etiologies: BCKDHA (E1α subunit), BCKDHB (E1β subunit), DBT (E2 subunit), DLD (E3 subunit, shared with PDH and αKGDH), PPM1K (phosphatase), BCKDK (kinase). CLASSIC MSUD (~85% of cases, severe) presents in the first days/weeks of life with poor feeding, lethargy, encephalopathy, opisthotonus, and characteristic maple-syrup-smelling urine; untreated progresses to coma, cerebral edema, and death. MENNONITE and AMISH FOUNDER POPULATIONS (Lancaster County PA, Old Order Amish) carry the highest known prevalence (~1 in 175 births) via a distinct BCKDHA founder mutation. MSUD is on the US Recommended Uniform Screening Panel — universal NEWBORN SCREENING detects elevated leucine in the first days of life across all US states. Standard-of-care: LIFELONG STRICT LEUCINE-RESTRICTED DIET — limited natural protein plus BCAA-FREE MEDICAL FORMULA (Mead Johnson BCAD 1/2; Nutricia MSUD Anamix); PLASMA LEUCINE MONITORING with age-specific target ranges and the pathognomonic alloisoleucine marker; THIAMINE for thiamine-responsive MSUD subtypes; CRISIS MANAGEMENT with HEMODIALYSIS/CRRT plus intralipid + dextrose for protein anabolism in acute decompensation; LIVER TRANSPLANTATION as a GENUINELY CURATIVE pathway since the 2004 Strauss/Morton Clinic for Special Children pediatric cohort — restores enough BCKDC activity in the liver to remove the lifelong dietary restriction (DOMINO LIVER TRANSPLANT: MSUD donor livers can be used for non-MSUD recipients because the MSUD liver functions normally for non-BCAA metabolism). MSUD Family Support Group (msudfamilysupportgroup.org) US + MSUD Research Foundation + Clinic for Special Children Strasburg PA (Strauss/Morton lab, world-leading MSUD center) + European MSUD network. Ninety-fifth deliberate non-elevation of community peptides.

Homocystinuria is an autosomal recessive inborn error of methionine/homocysteine metabolism. Classical homocystinuria is cystathionine β-synthase (CBS) deficiency; non-classical forms include MTHFR (methylenetetrahydrofolate reductase) deficiency and cobalamin metabolism defects (CblC, CblD, CblE, CblF, CblG, CblJ). CBS deficiency phenotype spans (a) vascular/thrombotic disease — DVT, pulmonary embolism, stroke, often in children and young adults, with aortic disease; (b) ocular — ECTOPIA LENTIS (lens dislocation, pathognomonic) plus myopia, glaucoma, and retinal detachment; (c) skeletal — marfanoid habitus (tall, thin, arachnodactyly), pectus deformity, genu valgum, overlapping Marfan syndrome body morphology but with OSTEOPOROSIS instead of aortic root dilation; (d) CNS — intellectual disability, psychiatric disease, seizures; (e) hair/skin — fair complexion, fine hair. Hyperhomocysteinemia is the load-bearing biomarker and the proximate mechanism for vascular events. Newborn screening for elevated methionine is on the US RUSP; Ireland has the highest known prevalence (~1/65,000) and mandatory NBS; Qatari, Saudi, UAE, and Irish founder populations are well-characterized. Standard of care: PYRIDOXINE (Vitamin B6) RESPONSIVENESS in ~50% of CBS cases — high-dose pyridoxine 200–500 mg/day lowers homocysteine dramatically; B6-non-responsive cases require METHIONINE-RESTRICTED DIET + CYSTEINE SUPPLEMENTATION lifelong (Nutricia HCU Anamix, Mead Johnson Phenex-2 and similar medical foods); BETAINE (Cystadane, Recordati / Orphan Europe) FDA-approved 1996 — methyl donor for remethylation; FOLATE + B12 adjunct; aspirin or anticoagulation for thrombotic prophylaxis in select cases. PEGTIBATINASE (Travere Therapeutics) — recombinant CBS enzyme replacement in Phase 3 HARMONY trial — is the disease-modifying frontier. HCU Network America (hcunetworkamerica.org), European HCU Network, and SSIEM are the patient and professional organization anchors. Marfanoid habitus + ectopia lentis can drive misdiagnosis as Marfan syndrome — the differential is editorially load-bearing. Ninety-sixth deliberate non-elevation.

Autosomal recessive disorders of amino acid catabolism — methylmalonic acidemia (MUT, CblA/B/D), propionic acidemia (PCCA/PCCB), isovaleric acidemia (IVD), and glutaric aciduria type 1 (GCDH) — where toxic organic acids accumulate when protein catabolism outpaces the residual enzyme. Classical forms present neonatally with hyperammonemia, acidosis, and ketosis. Lifelong management leans on protein-restricted diet plus precursor-free medical food (Mead Johnson Propimex, Nutricia MMA/PA Anamix, Nutricia OA1, MJN XLeu Maxamum for IVA), L-carnitine for organic-acid esterification and renal excretion, glycine for IVA, hydroxocobalamin IM for cobalamin-responsive MMA, biotin for PA variants, and ammonia scavengers (sodium benzoate, sodium phenylbutyrate, Ravicti glycerol phenylbutyrate from Horizon/Amgen FDA 2013, Carbaglu carbamylglutamate from Recordati FDA 2010) during decompensation. Combined liver-kidney transplant is increasingly curative for severe MUT mut0 MMA with nephropathy; heart transplant rescues refractory PA cardiomyopathy. The editorial frontier is Moderna's mRNA-3705 (MMA) and mRNA-3927 (PA) Phase 1/2 programs delivering mRNA encoding the missing enzymes. Patient infrastructure: Organic Acidemia Association (OAA, oaanews.org), PA Foundation, MMA Foundation, Clinic for Special Children Strasburg PA (Amish GA1 cohort), European E-IMD registry. Ninety-seventh deliberate non-elevation of community peptides.

Group of inborn errors of nitrogen handling caused by deficiencies of the enzymes and transporters of the urea cycle, with HYPERAMMONEMIC ENCEPHALOPATHY as the primary morbidity-mortality driver. Classical defects: N-acetylglutamate synthase (NAGS) deficiency, carbamoyl phosphate synthetase 1 (CPS1) deficiency, ORNITHINE TRANSCARBAMYLASE (OTC) deficiency — X-linked and the most common UCD (~50% of all UCDs) with males presenting severely in the neonatal period and females presenting variably depending on X-inactivation skew, argininosuccinate synthetase 1 (ASS1) deficiency / CITRULLINEMIA TYPE 1, argininosuccinate lyase (ASL) deficiency / ARGININOSUCCINIC ACIDURIA, arginase 1 (ARG1) deficiency / ARGININEMIA (progressive spastic diplegia distinguishes the late-presenting form). Transporter forms: HHH syndrome (SLC25A15/ORC1) and CITRULLINEMIA TYPE II (CTLN2, SLC25A13/citrin — adult-onset with Japanese predominance and hepatocellular carcinoma risk on chronic liver involvement). Classic neonatal presentation is lethargy + vomiting + hyperventilation (respiratory alkalosis) progressing to coma and cerebral edema; later-onset and partial forms present with episodic encephalopathy triggered by catabolic stress. NEWBORN SCREENING (US RUSP) detects citrullinemia, argininosuccinic aciduria, and arginase deficiency; **OTC and CPS1 are NOT detected by newborn screening** — diagnostic delay until the first hyperammonemic crisis is the load-bearing editorial fact for those two forms. Standard of care: emergency management of hyperammonemic crisis with IV ammonia scavengers + HEMODIALYSIS if NH3 >500 µmol/L; SODIUM PHENYLACETATE + SODIUM BENZOATE (AMMONUL, Ucyclyd/Horizon, FDA-approved 2005) IV scavenger for acute crisis; SODIUM PHENYLBUTYRATE (BUPHENYL, Horizon, FDA-approved 1996) oral chronic scavenger; GLYCEROL PHENYLBUTYRATE (RAVICTI, Horizon/Amgen, FDA-approved February 2013) — improved-palatability liquid form transformative for chronic adherence; CARBAMYLGLUTAMATE (CARBAGLU, Recordati Rare Diseases, FDA-approved 2010) NAG analog; CITRULLINE supplementation for CPS1 and OTC; ARGININE supplementation for ASS1 and ASL; LIFELONG PROTEIN-RESTRICTED DIET + essential amino acid medical foods (Cyclinex, MJN ProPhree, Nutricia equivalents); LIVER TRANSPLANTATION as definitive treatment for severe forms. AAV and mRNA gene therapy frontier: DTX301 (Ultragenyx) AAV8-OTC in the Phase 3 ASCEND trial for OTC deficiency, ARCT-810 (Arcturus Therapeutics) mRNA-OTC Phase 2, and AAV programs for CPS1, ASS1, and ASL in trials. Patient infrastructure: NATIONAL UREA CYCLE DISORDERS FOUNDATION (NUCDF, nucdf.org) + EUROPEAN E-IMD REGISTRY + UCD CONSORTIUM + Japanese CTLN2 adult-onset cohort network. Ninety-eighth deliberate non-elevation of community peptides.

Niemann-Pick disease is a group of lysosomal storage disorders historically grouped under one name but representing distinct underlying biology. NPD-A (SMPD1 mutations causing acid sphingomyelinase deficiency) is the severe infantile neuronopathic form — hepatosplenomegaly, cherry-red macular spot, progressive neurodegeneration, and death by 2-3 years of age; the Ashkenazi Jewish founder population carries an overrepresentation. NPD-B (SMPD1 mutations with residual enzyme activity) is the visceral non-neuronopathic form — hepatosplenomegaly, interstitial lung disease, dyslipidemia, thrombocytopenia, variable cherry-red spot, and adult survival possible. NPD-C (NPC1 or NPC2 mutations causing impaired CHOLESTEROL TRAFFICKING — NOT a sphingomyelin enzyme defect) is a lysosomal cholesterol storage disease despite the shared name, with hepatosplenomegaly, progressive neurodegeneration, vertical supranuclear gaze palsy as a pathognomonic finding, cataplexy, dystonia, ataxia, cognitive decline, and adult-onset psychiatric presentation possible. Standard of care transformed 2022-2024: OLIPUDASE ALFA (XENPOZYME, Sanofi Genzyme) FDA-APPROVED AUGUST 2022 for NPD-A and NPD-B non-CNS manifestations — recombinant acid sphingomyelinase, IV every 2 weeks, via ASCEND and ASCEND-Peds; MIGLUSTAT (ZAVESCA, Actelion/J&J) EMA-APPROVED 2009 for NPD-C — glucosylceramide synthase inhibitor substrate reduction therapy; NOT FDA-approved for NPD-C, off-label in US; September 2024 brought landmark same-day FDA approval pair for NPD-C: MIPLYFFA (arimoclomol, Zevra Therapeutics) — heat shock protein co-inducer combination with miglustat — and AQNEURSA (N-acetyl-L-leucine, IntraBio). HP-β-CD investigational. AAV gene therapy programs (Lysogene and others) in trials. Patient infrastructure: NATIONAL NIEMANN-PICK DISEASE FOUNDATION (NNPDF, nnpdf.org) US, NIEMANN-PICK UK, INTERNATIONAL NIEMANN-PICK DISEASE ALLIANCE (INPDA), and the ARA PARSEGHIAN MEDICAL RESEARCH FOUNDATION (Notre Dame coach's pediatric NPD-C legacy). Ninety-ninth deliberate non-elevation.

Large heterogeneous family of disorders of oxidative phosphorylation caused by mutations in mtDNA or nuclear DNA encoding the >1500 nuclear-encoded mitochondrial proteins or the 13 mtDNA-encoded proteins. Major syndromes: MELAS (Mitochondrial Encephalopathy with Lactic Acidosis and Stroke-like episodes — mtDNA m.3243A>G in MT-TL1; stroke-like episodes + cardiomyopathy + diabetes + sensorineural hearing loss); MERRF (m.8344A>G in MT-TK); LEIGH SYNDROME (subacute necrotizing encephalomyelopathy — multiple mtDNA + nuclear etiologies; infantile/childhood; often fatal); NARP (m.8993T>G in MT-ATP6); KEARNS-SAYRE SYNDROME (large mtDNA deletion; PEO + pigmentary retinopathy + cardiac conduction defects); CPEO; LHON (m.11778G>A in MT-ND4 most common; bilateral subacute vision loss in young adult males); PEARSON SYNDROME; MNGIE (TYMP); primary CoQ10 DEFICIENCY; TANGO2 deficiency; BARTH SYNDROME (TAFAZZIN/TAZ X-linked). HETEROPLASMY (% mutant mtDNA varies by tissue) is load-bearing for mtDNA disorders; maternal inheritance for mtDNA, Mendelian for nuclear. Standard of care: COENZYME Q10 supplementation (clinical use established); L-CARNITINE + B-VITAMINS (riboflavin B2, biotin) + CREATINE + antioxidants; ARGININE + CITRULLINE for MELAS stroke-like episodes; TAURINE for MELAS (Japan-approved). DISEASE-SPECIFIC APPROVALS: IDEBENONE (Raxone/Catena, Santhera Pharmaceuticals) EMA-approved 2015 for LHON; LUMEVOQ (lenadogene nolparvovec, GenSight Biologics) AAV gene therapy for LHON EMA pending; ELAMIPRETIDE (Forzinity, Stealth BioTherapeutics) FDA-APPROVED DECEMBER 2024 for BARTH SYNDROME — cardiolipin remodeling, first disease-modifier in Barth; TANGO2 B-vitamin cocktail (especially riboflavin) Lupski-lab landmark; MNGIE allogeneic HSCT. MEDICATIONS TO AVOID: VALPROATE (mitochondrial toxin, Alpers/POLG contraindication), AMINOGLYCOSIDES (mtDNA hearing-loss susceptibility), STATINS (variable), METFORMIN (lactate elevation in MELAS). Patient infrastructure: UMDF (umdf.org) + MitoAction + MitoCanada Foundation + Mito-Patients UK + AMMi + MitoExchange + NAMDC + Mitochondrial Medicine Society. **Hundredth deliberate non-elevation of community peptides — editorial centennial milestone.**

Posterior-pituitary peptide-hormone deficiency: loss of arginine vasopressin (AVP, antidiuretic hormone) production from hypothalamic magnocellular neurons and posterior pituitary release, producing inability to concentrate urine and consequent polyuria (often 5-15 L/day), polydipsia, nocturia, and hypernatremia if water access is restricted. In 2022 the international consensus (American Society of Neuroendocrinology, Endocrine Society, European Society of Endocrinology, AACE, Pediatric Endocrine Society, Society for Endocrinology) formally RENAMED central diabetes insipidus to ARGININE VASOPRESSIN DEFICIENCY (AVP-D), and renamed nephrogenic DI to ARGININE VASOPRESSIN RESISTANCE (AVP-R), to reduce the historical confusion with diabetes mellitus that has caused documented medication errors and inappropriate fluid-management decisions in hospital settings. Etiologies: post-pituitary-surgery (most common iatrogenic — transient, permanent, or triphasic-pattern), traumatic brain injury with pituitary stalk transection, pituitary or hypothalamic tumors (craniopharyngioma, germinoma, metastases, lymphocytic infundibuloneurohypophysitis), infiltrative diseases (Langerhans cell histiocytosis, sarcoidosis, IgG4-related hypophysitis, ROHHAD), congenital / familial (AVP gene mutations), idiopathic (~30%), post-radiation, and post-Sheehan syndrome (rare). Diagnostics: 24h urine output + urine osmolality (<300 mOsm/kg), plasma sodium + serum osmolality, MRI of the pituitary and hypothalamus (looking for stalk thickening, mass, or absence of the posterior-pituitary T1 'bright spot' — characteristic AVP-D finding), copeptin testing (modern preferred stimulation test, more reliable than the historical water deprivation test), and genetic testing where familial pattern is present. **STANDARD-OF-CARE IS DESMOPRESSIN (DDAVP, dDAVP, MINIRIN)** — a synthetic V2-receptor-selective AVP analog FDA-approved since 1978; available as oral tablets (0.1-0.4 mg BID-TID), oral disintegrating tablet, nasal spray, and subcutaneous / IV formulations. **This is itself a peptide therapy — the load-bearing one in this disease, distinct from community peptide framing.** Juno covers desmopressin as standard-of-care framing; community peptide candidates are not adjuncts. Critical management: hyponatremia risk from over-replacement or impaired free water clearance requires sodium monitoring and the 'drink to thirst' rule; adipsic AVP-D (loss of thirst sensation from hypothalamic damage) is a particularly dangerous subset requiring scheduled fluid intake and close electrolyte monitoring. Pregnancy AVP-D: physiologic AVP-D of pregnancy arises from placental vasopressinase clearing endogenous AVP — desmopressin (vasopressinase-resistant) is standard. Pediatric AVP-D: dosing adjusted; close growth/development monitoring if pituitary mass involved. AMEND Australia + Diabetes Insipidus Foundation patient resources; Endocrine Society + ESE 2024 guidelines + 2022 multi-society consensus nomenclature paper. **Editorial**: BPC-157 no posterior pituitary characterization + pro-angiogenic near recently-operated sella in the most-common AVP-D etiology (post-pituitary-surgery); NMN no osmoregulation engagement; GH-axis trio (CJC-1295 + tesamorelin + ipamorelin) inherits etiology-overlap contraindication — most AVP-D came from pituitary surgery / tumor history, and tesamorelin FDA label contraindicates pituitary tumor history. Fifty-seventh deliberate non-elevation of community peptides.

Partial or complete failure of one or more anterior pituitary hormones — ACTH (→cortisol), TSH (→thyroid hormone), GH (→IGF-1), LH and FSH (→gonadal steroidogenesis and gametogenesis), and prolactin (often preserved or paradoxically elevated from stalk effect); panhypopituitarism = all axes deficient. Posterior pituitary involvement (AVP-D, oxytocin) commonly coexists when pathology is structural. Causes: pituitary adenoma with mass effect or post-resection iatrogenic; traumatic brain injury (underrecognized — ~25-50% TBI patients show pituitary dysfunction at 6-12 months); PITUITARY APOPLEXY (hemorrhage or infarction — neurosurgical emergency with acute adrenal crisis from sudden ACTH loss); SHEEHAN SYNDROME (postpartum pituitary necrosis from severe peripartum hemorrhage); craniopharyngioma and other suprasellar tumors; cranial radiation (latent — manifests years after treatment); infiltrative disease (sarcoidosis, hemochromatosis, Langerhans cell histiocytosis, IgG4-related and lymphocytic hypophysitis); autoimmune hypophysitis including immune checkpoint inhibitor-induced (ipilimumab, nivolumab, pembrolizumab); infections (TB, syphilis, fungal); genetic / congenital combined pituitary hormone deficiency syndromes (PROP1, POU1F1/PIT1, HESX1, LHX3, LHX4, Kallmann syndrome). **ADRENAL CRISIS IS THE LOAD-BEARING EMERGENCY** — patients with ACTH deficiency require stress-dose hydrocortisone for illness, surgery, trauma; emergency injection kit + medical alert non-negotiable. Diagnostics: morning cortisol + ACTH ± cosyntropin stim; free T4 + TSH (free T4 over TSH because TSH is unreliable in secondary hypothyroidism); IGF-1 + GH stimulation testing (insulin tolerance, GHRH-arginine, glucagon — gates somatropin replacement); LH + FSH + testosterone (men) or estradiol + cycle (women); prolactin; pituitary MRI + visual fields where mass effect in play. Management = hormone replacement BY DEFICIENT AXIS: hydrocortisone 15-25 mg/day divided with stress-dose protocols; levothyroxine titrated by free T4; recombinant human GH (somatropin) for confirmed adult GHD; sex hormones (testosterone or estradiol + progesterone); desmopressin if posterior involvement; gonadotropin therapy or pulsatile GnRH for fertility induction (SEPARATE protocol from replacement). Endocrine Society + ESE 2016 + AACE + Pituitary Network Association + Hormone Health Network patient resources. **Editorial**: GH-axis peptides (CJC-1295, tesamorelin, ipamorelin, sermorelin, MK-677) are MECHANISTICALLY WRONG-DIRECTION — they act on the PITUITARY which is the failed organ. Upstream stimulation cannot recruit somatotrophs that are damaged, absent, or non-responsive. SOMATROPIN is the established replacement. Same archetypal error as kisspeptin × Klinefelter (primary hypogonadism). Tier 2 elevation. Fifty-eighth deliberate non-elevation.